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1. Introduction  
Siddha system of medicines prevails in the India since centuries back. The basic 
and fundamental literature of the system has been documented and structured by siddhars 
also known as holy traditional healers. Even several thousand years back the siddhars has 
categorized the disease of mankind based on the five elemental systems. As a 
consequence of their constant research Indian system of traditional medicine have several 
noble formulations that has tendency to prevent, heal, regenerate and rejuvenate 1. 
Because of constant change in the modern lifestyle people have been exposed to 
high lipid and carbohydrate diets with chemicals and pesticides which in turn have ability 
to cause several dreadful diseases includes cancer, degenerative and metabolic disorders 
2. There are numerous diseases which threat the human civilization since years one such 
metabolic disorder is kidney stone also known as urolithiasis disease (Kalladaippu). As 
per the recent demography urolithiasis is one considered to be world third largest 
prevailing metabolic disorder affecting millions of people of several age groups in both 
western and Indian population 3. 
The exact etiology and cause of this disease is still mystery but several hypotheses 
have been documented on its pathological aspect. Long-term use of allopathic drugs in 
the clinical management of urolithiasis leads to increase tissue oxidative stress, 
electrolyte imbalance and metabolic disorders 4. 
Hence society is in constant need of complementary and alternative therapy for 
treating urolithiasis. Siddha system of medicines has several novel formulations which 
act by multiple mechanisms in treating kidney stone like metabolic disorders with no side 
effect. 
Researchers strives their constant effort in bringing up some new drug to the 
market for treating urolithiasis but most of the drug fails at preliminary toxicity 
screening. Hence it also becomes mandatory for a drug to act smart with no side effects. 
Super saturation of urine with calcium oxalate crystals triggers the event of salt 
deposition in the sub endothelial space of renal papillae. Deposition of salt stimulates the 
process of inflammation and there by stimulated abnormal pain and irritation. It is also 
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proven recently that this inflammatory mechanism generate active free radicals that 
damage the nearby basement membrane of the kidney which leads to nephritic syndrome. 
Modern allopathic medicine act by reducing the pain causes vasoconstriction of renal 
capillaries, thus long-term usage of such medicines causes tubular damage and 
degeneration. Most of the siddha formulation are considered as excellent anti-oxidants 
this property of the formulation synergies its potency of reducing the active radicals and 
there by alleviate the symptoms of inflammation associated with urolithiasis 5. 
Urinary obstruction caused due to crystal deposition greatly reduces the volume 
of urine excretion. This obstruction causes hypertension and associated issue and 
presently most of the physicians recommend the usage of diuretics. Greater advantages of 
using diuretics are it increases the urine output and reduces the hypertension. But the 
major concern preventing the usage of diuretics is the development of hypokalemia, 
hyperglycemia, hyponatremia, hyperlipidemia and metabolic imbalance 6.  
Numerous siddha formulation act as a potent diuretics are no emerged among the 
public awareness the advantages of using siddha formulations are cost effective, high 
potency, prolong duration of action, multiple mechanism with no side effects. Now there 
is a tremendous hike in the usages of siddha medicines among public for various ailments 
due to its endless advantage and its non-toxic nature at long-term usage 7. 
The mystery behind the mechanism of most of the siddha preparation are still 
under evaluated and hence AYUSH research portal now brought to the notice of the 
scientist who can develop the protocol and schematically derive the mechanism of drug 
action. The important hurdle behind the development of such protocol with respect to 
siddha drugs are their multi componential nature. Generally siddha drugs belong to 
herbal, poly herbal, minerals or herbo mineral preparations. It is quite tedious and time 
consuming process in deriving the mechanism behind each component. But now a day 
with the help of technology advancement the schematic derivatization of the mechanism 
behind each siddha preparation is achievable. 
Proper diagnosis is highly essential for treating disease on time in siddha a 
specialized branch dealt with such diagnosis is noi nadal. The ultimate aim is to identify 
the correct root cause and potentiate the revealing’s of etiology. This is referred as noi 
mudhal nadal. Identification of cause to the ailment is derived by the examination of 
eight vital parameters namely nature of pulse, urine, changes in eyes, voice texture, 
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colour of body, tongue, and sense of touch and nature of stools. This is referred as 
envagai thervu in this system. This system has channelized a detailed procedure of urine 
examination called as neer kuri which analyses the colour, volume, density, smell etc of 
urine. There are specifications of oil spreading pattern in urine which is referred as nei 
kuri. Siddha approaches a person’s ailment in a holistic way i.e. considering the person as 
a whole, his body constitution etc in treating him. The treatment pattern in each 
individual is different. Many internal and external factors are taken in to account in the 
diagnosis and treatment aspects. 
Ancient siddhars in their text has clearly indicated the symptoms and treatment 
for urolithiasis and as per the prescribed procedures there are number of formulations 
used clinically in humans for the management of kidney stone since centuries. Still the 
reported level of adverse event of such drug is negligible and hence this proves the wide 
safety of margin of the siddha preparation in clinical use. 
Siddhars have categorized diseases numbering 4448 and it is mentioned in Agasthiar 
rathina churukka naadi nool. In Siddha system of medicine the urinary tract diseases are 
broadly ordered in to two types namely, 
1. Diseases which lowers the normal urinary output (Neerarugal noigal) 
2. Diseases which upsurge the normal urinary output (Neer perugal noigal) 
Among them they categorize kalladaippu noi and other disruptive uropathies 
come under neerinai arukkal noigal. They describe that dietary factors play an 
important role in the formation of calculi. Imbalance in the pitha humor results in highly 
concentrated urine and accumulation of salts in the urinary tract 8. 
The basic quality of successful drug candidate for treating urolithiasis should 
possess the following properties (i) It should halt the accumulation of crystals (ii) An 
ideal analgesic with anti-inflammatory property (iii) Potential antioxidant (iv) diuretic 
property (v) Maintain adequate metabolism of essential salts and (vi) anti-microbial 
potency. Combinations of drug present in the siddha preparation are mostly act 
synergistically and hence multiple mechanism of such formulation is possible. Need of 
pharmacotherapy of urolithiasis is greatly matched by the siddha preparation hence usage 
of siddha drug for urolithiasis renders greater advantage and beneficial effects to the 
patient in near future.  
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2. AIM AND OBJECTIVES 
AIM: 
The main aim of the present research work is to systematically standardize the siddha 
formulation Seenaakara parpam and to evaluate its safety and efficacy for the clinical 
management of Kalladaippu noi/ Urolithiasis in standard experimental animal models. 
OBJECTIVES 
I. Standardization of the study drug  
To ascertain the standards and genuienity of the prepared formulations the 
following analysis will be carried out. 
 Identification and authentication of the raw materials  
 Preparation of the drug in three different batches and analyze them 
systematically 
 Analyzing the drug as per the protocol given by PLIM, for analyzing 
parpam 
 Elemental analysis of study drug by AAS technique 
 Evaluation of purity of the drug by microbial load analysis 
 Characterization of functional group by FT-IR analysis. 
 Estimating the particle size distribution in study drug using SEM/EDX 
technique 
 Analyzing the nature of the drug by XRD 
II. In vitro Evaluation of study drug 
 In-vitro antioxidant evaluation of the study drug by DPPH, Hydrogen 
peroxide and Nitric oxide radical scavenging assays. 
 In vitro struvite crystal growth evaluation by single diffusion gel growth  
III. In vivo Evaluation of study drug  
A. Toxicological Profiling 
To establish the safety of the study drug toxicological evaluation will be 
carried out in three phases. 
 Phase I: Short term acute toxicity study in rodents 
 Phase II : Mid term sub-acute toxicity study in rodents 
 Phase III: Long term sub-chronic toxicity study in rodents 
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B. Pharmacological Screening 
To establish the efficacy of the study drug pharmacological screening will 
be carried out in three different experimental animal models. 
 Evaluation of anti urolithiatic activity by Ethylene glycol induced 
urolithiasis in rats 
 Evaluation of anti urolithiatic activity by Zinc disc implantation model 
in rats 
 Evaluation of Diuretic potential of the drug in rats 
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3. PLAN OF WORK 
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4. REVIEW OF LITERATURE 
4.1. Basic Fundamental Principles of Siddha 
According to Siddha the universe is made of five bhoothas (elements). They form 
the elements of macrocosm and microcosm. Hence Siddha strongly believes that 
“Andathil ullathey pindam” which infers that the elements of macrocosm and 
microcosm are the same. The five bhoothas are as follows: 
1. Prithuvi 
2. Appu  
3. Theyu, 
4. Vayu  
5. Aakayam  
“Nilam neer thee vali visumbhodainthum kalantha mayakkam ulagam aathalin” 9 
4.2. KALLADAIPPU NOI 
Kalladaippu noi, also called as Achmari is characterized by sudden retardation in 
the urine output. Onset of pain in the tip of the genitalia, burning sensation over the 
urethral orifice occurs while urination.  Further the symptoms also emerge by 
radiating pain on either side of the vertebral column. 
4.3. Epidemiology 10 
 More common in men and the age of onset is third to fourth decade 
 Elavenil, muthuvenil ( early and late summer) aggravate the disease 
 Palai (arid tract), neithal(coastal tract) and mullai (sylvian tract) 
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Figure 1A: Diagrammatic representation on pathogenesis of urolithiasis 
 
 
4.3.1.Aetiology of disease 11 
 Less water intake  
 Water contaminated by dry leaves 
 Intake of foods that increase pitha and vatha humors 
 Obstacle in outflow  of Semen 
 Intake of food contaminated with stones and sand and increased intake of curd 
and bones 
There are 4 types mentioned by in Yugi Chindhamani 
1. Vali Kalladaippu 
2. Azhal Kalladaippu 
3. Iyya Kalladaippu 
4. Mukkutra Kalladaippu 
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4.3.2 General symptoms 
 Increase in  frequency of urine 
 Partial voiding and obstruction of urine  
 Abnormal pain in the edge of genital orifice with inflammation 
 Irregular shaped stones with sharp edges produces pain in the lower abdomen, 
irritation and pain in the urethra and leads to haematuria 
4.3.3. Changes in humours 
 Increase in Vatha humor 
 Increase in Pitha humor 
 Affected Kizh nokkung kal Vali kalladaippu 
 Pain below the umbilicus 
 Obstruction in the urinary flow 
 Unbearable pain 
 Flatulence 
 Discharge of urethral tissues in urine 
4.3.4. Azhal kalladaippu 
 Extreme burning sensation in the urethral orifice as that of fire 
 Hyperthermia 
 Haematuria 
 Pain in the urethral orifice 
 Discharge of reddish stones in the urine 
4.3.5.Iyya kalladaippu 
  Pain in the umbilicus 
 Radiating pain to the hip and thighs 
 Discharge of white coloured stones in the urine 
4.3.6.Mukkuttra kalladaippu 
 Pain in the urethral orifice 
 Obstruction during urination 
 Discharge of handful of stones similar to sand in urine 
 Discharge of semen along with urine 
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4.3.7.Diagnostic signs  
 Naa / Tongue: Coated, increased salivation, bitter or sour taste 
 Niram / Colour: Pale 
 Mozhi / Speech: Depressive speech due to pain 
 Vizhi / Eye: Normal colour, dry, burning sensation 
 Malam / Stool: Normal 
 Moothiram / Urine 
4.3.8.Neerkuri 
1. Niram (Colour) – Turbid/ Milky 
2. Adarthi (Density) – Increased 
3. Manam ( Odour) – Obnoxious 
4. Nurai ( Froth) – Decreased 
5. Enjal ( Deposits) – Presence of small stones 
Neikuri: Ring, Ring with pearl, Sieve formation 
 Sparisam / Touch: Cold, abdominal tenderness 
 Naadi / Pulse: Rapid in character 
 Azhal naadi, Vali azhal naadi 
 
4.3.9.Differential diagnosis 12 
 Naangoozh thabitham ( Appendicitis) 
 Karuppai kattigal ( Tumour of uterus) 
 Neerkiricharam ( Urinary tract infection) 
4.3.10.Prognosis of the disease 
 Vali, Azhal, Iyam types are curable 
 Mukkuttra kalladaippu cannot be cured 
4.4. Importance of Siddha Medicines 
Siddha system of medicine attains greater importance in recent days as most of 
the novel siddha preparation considered to be a valuable lead for the treatment of various 
infectious, non-infectious and other metabolic disorders in mankind. Gaining popularity 
mandate the drug to be standardized to compete in the global market 13. 
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   4.5. Significance of drug Standardization 
Standardization is a process of elucidating the nature and class of formulation to 
ensure its purity and genuinity through standard guideline as established by AYUSH. 
Central council for research in siddha under ministry of AYUSH has made a detailed 
guideline in systematic standardization of formulation which meant for in humans. 
Standardization renders some valuable information to the researcher about the followings 
• Class and Nature of individual components present with in the formulation 
• Limit of elements including heavy metals 
• Knowledge about genuinity of the raw materials used. 
• Physicochemical property of the finished product. 
• Sterility of the products 
• Detail on trace of pesticides and toxins if any 
• Particle size determination and stability of the product. 
• Structure of the individual compounds 
• Detail on functional group, nature of ring and active side chain. 
• Toxicity nature of the drug 
Preliminary qualitative and quantitative analysis of test drug will reveal the 
information pertains to category of phytocomponents and quantity of each 
components present in fixed quantity of drug. It is evident that each compound exerts 
specific mechanism and sometimes combination of this compounds attribute to 
synergistic action. 
4.6. AYUSH Regulations 
AYUSH and WHO has setup the permissible threshold limit for each category of 
elements. Exceeding limit of certain heavy metals leads to undesirable effects to humans. 
Eg For lead the allowed limit is 10 ppm, arsenic 3 ppm, cadmium 0.3 ppm and for 
mercury it is 1 ppm. Long time exposure of increasing concentration of arsenic leads to 
cardiac depression, cerebral edema, excessive darkening of skin, liver injury and 
peripheral neuropathy. Similarly high level of lead causes anemia, renal injury, 
convulsion, hypertension and encephalopathy 14.  
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4.7. Heavy Metal Poisoning 
Further mercury poisoning causes bronchial irritation, gastroenteritis, urticarial, 
kidney inflammation and high level of cadmium leads to respiratory 
tract and kidney problems. With the recent advancement emerging in the field of 
biotechnology 15. Possible adulteration of spurious drugs in poly herbal formulations is 
better identified by DNA finger printing analysis and gene manipulation studies. 
4.8. Physicochemical evaluation  
Physicochemical evaluation such as ash value, extractive value, pH, loss on 
drying offers information related to purity and genuinity of the drug, since each of the 
above values are unique for each formulation as well as for the raw drug. Pesticide 
residues are un-avoidable in some raw material as it becomes a part of the polluted 
environment and traces absorbed from the field water and soil 16.  
Thus proper purification of the entire crude and raw drug is mandatory before 
subjecting them to the finished product. It is necessary for a drug to be free from toxin, 
since most of the toxin causes life threatening issue of causing vital organ dysfunction    
FT-IR dealt with identification of active functional group responsible for 
biological activity of the compound. Structural activity relationship datas of the 
compounds better substantiate the detail on side chain and group that accounts for 
receptor binding and affinity. These details advance the researcher in predicting the 
pharmacology and mechanism by which the drug acts on living biological system 17.  
Standardization paves a way for sorting out the possible adulteration in 
formulation since most of the time for enhancing the efficacy allopathic drug often 
adulterated with siddha preparation and in turn leads to potential adverse events upon 
long time exposure 18. According to research estimation if a drug seems to be toxic in 
rodents and non- rodents the chance of the toxicity in humans is about 80%. Hence forth 
it is essential for a drug to prove its safety before render its clinical application in 
humans. 
4.9.Focus of research in Urolithiasis 
Current research focus towards urolithiasis attains greater importance as the 
consequence of mortality and morbidity seems very higher in south Asian countries. The 
exact mechanism of urolithiasis is still unrevealed. Some hypothesis has been suggested 
based on the previous pharmacological studies carried out at pre-clinical and clinical 
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level includes the generation of calcium oxalate crystal seems to be the major hallmark 
etiology of causative factor for urolithiasis since 70% of the patient suffering with 
urolithiasis reported with similar clinical condition. Other factor which contributes to this 
condition includes frequent urinary tract infection, diabetes, sedentary life style, obesity 
and hypertension. Certain promoters include uric acid and calcium phosphates aids in 
promotion of crystal formation 19. 
4.9.1. Randall’s plaque theory 
Randall’s plaque theory suggests that deposition of calcium oxalate crystal on the 
basement membrane of the loop of henle of kidney was found to the important 
pathological steps involved in the urolithiasis 20. Most of the patients with urolithiasis 
have been manifested with increased uric acid formation and low urine pH which is 
majorly due to increased formation of hydrogen ions and low excretion of ammonia level 
in renal tubules 21. 
Mismatching balance between calcium and sodium ions worsen the condition of 
kidney it was evident from the research that increased sodium intake aggravates the 
calcium crystal formation. Imbalance in calcium ions could either be due to increased 
absorption from intestine or due to raised bone resorption associated osteoporosis. 
Hyperoxalouria promotes saturation of urinary calcium oxalate crystals 22,23. 
As of now there is no common genetic predisposition was observed for the 
occurrence of urolithiasis but genetically determined insulin resistance emerging with 
metabolic disorders may leads to pathogenesis of stone formation 24,25,26. 
Kidney stone formation is a composite process and it results as a cascade of 
events, including crystal nucleation, growth and accumulation, crystal retention within 
the renal tubules 27. Usually kidney grits are yellow or brown color with a smooth or 
gagged structure. Some common type of kidney stones are calcium oxalate, calcium 
phosphate, uric acid and cysteine, among of which calcium stones are the most common 
form of kidney stones in together humans and rats 28. Urolithiasis, also called calculi or 
uroliths, is a condition which involves the process of stone formation in the kidney. Renal 
calculi are a common cause of blood in the urine and pain in the abdomen, with a 
reported incidence about 12% in the general population 29 
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Figure 1B: Crystals formed in distal limb of Henle (DLH) 30 
 
4.9.2. Therapeutic Strategy  
In recent time most of the researchers aims at several pathway of inhibiting the 
formation and growth of calcium crystal and as per literature it was evidence that certain 
components like Citrate, pyrophosphate and chondroitin sulphate (glycosaminoglycans, 
GAGS) have been identified has potential inhibitors of calcium oxalate. These inhibitors 
mainly acts by surface adsorption techniques over the oxalate crystal there by hinders its 
growth and progression. Use of urinary solubilizes accomplish one of the treatment 
strategy of urolithiasis these agent mainly acts by dissolving the crystal that obstruct the 
flow of urine.  
Endocrine society of India strongly believes that prevention is better than cure. 
The important goal of treatment is to identify the root cause of the disease and hence 
through proper patient counseling the right factor could be identifies. Hence forth 
identified factors may either be corrected by primary care of physician for eg: correcting 
the dietary plan of the patients, suggesting proper medication plan and weight reduction 
programs all will alleviate the clinical symptoms. Hence now treating patients with 
natural phytocomponents like anti-oxidant rich fruits and citrates have been considerable 
increasing the care and wellness of the patients with urolithiatic disorders 31. 
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4.9.3. Mechanism of Siddha drug action 
Siddha system of traditional medicine has several formulations with the potential 
of curing several dreadful diseases. Unlike allopathic drug siddha system of medicine 
acts by multiple mechanism. Siddha practitioners are using traditional medicine made of 
herbs and organic minerals that counteracts the crystal growth formation and also 
increases the urine output and also restores the calcium ion hemostasis in living 
biological system. One such noble formulation is Seenakara parpam (SKP) derived from 
Purified Seenakaaram (Alum / Alumen) ,  Vediuppu Potassium nitrate / salt petre ) and 
Karchunna Neer (Quick Lime solution). 
Traditional practitioners of south India have versatile practice of healing most 
dreadful communicable as well as non-communicable disease through their noble 
preparation. There is a wider belief among the public that most of the siddha formulation 
are prepared from combination of herbs and other minerals includes metallic salts might 
cause metabolic organ dysfunction. Due to this reason siddha system of medicine has a 
broad principle of drug purification. During the process of purification the metals in the 
preparation undergo super transitional elemental state and this metal seems to be 
compatible with living biological system and will not have lodging effect in the 
metabolic organs ,thus proved to be safe for human even after long time exposure. 
Figure 1C: Schematic representation of Mechanism of Action of siddha drugs 
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4.9.4. Toxicity Study Guidelines  
Central Council for Research in Ayurveda & Siddha (CCRAS) had come up with 
a clear guideline on short and long term toxicity studies of Ayurveda and siddha drugs in 
rodents and non-rodents .Economic Co-operation and Development (OECD).As per these 
guidelines dose for short term acute toxicity will be at least ten times higher than the 
normal clinical dose and further based on the results of the acute toxicity study dose may 
be selected for sub-acute and sub-chronic toxicity study which should carried out with 
minimum two to three dose level 32. 
Toxicological profiling of siddha preparation becomes an integrated part of drug 
standardization process. Since most of the formulations are yet to be systematically 
standardized and has to be documented for future research. Toxicity studies reveals most 
important evidence based data with respect to clear toxico kinetic profiling of the drug 
and its effects on C.N.S, A.N.S, C.V.S and behavioral pattern. Rodents are found to be 
most ideal model for toxicity evaluation of siddha drugs as it genetically and biologically 
resembles to that of the humans. Thus emerging toxicity in rodents will definitely imparts 
toxicity in humans 33. 
4.9.5. Detection of Drug induced Toxicity  
Presently advances sophisticated techniques have been used in identifying the 
drug toxicity. Fully automated hematology analyzer is highly useful in evaluating the 
hematopoietic toxicity. If drug adversely causes hemolysis and bone marrow depression 
will be reflected by low level of RBC and hemoglobin level. Similarly emergence of drug 
induced inflammation will be encountered by change in WBC and DLC level. Allergic 
response of drug in rodents will be measured by change in level of eosinophils. Similarly 
immune modulatory effect of the drug was measured as an index of change in basophils, 
lymphocytes and monocytes 34. 
The National Institutes of Health defined biomarker is a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes. 
Alteration in the level of serum markers is a good biological indicator for analysis the 
physiological functioning of the major organs. 
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Figure 1 D: Systematic Approach to characterise toxicity 
 
Hence at the end of the toxicity studies blood will be collected from the animals 
of different drug treated group from which serum will be separated and was subjected to 
estimation of biomarkers such as enzymes, proteins, lipids and other ions 35. 
4.9.6. Techniques involved in New Drug Discovery 
In recent days In-vitro analytical techniques renders a significant contribution 
towards the process of new drug discovery. Every year thousands of new molecules have 
been identified but only few are reaching the market. Most of the drug attains failure in 
the preclinical and clinical phases because of this tendency of causing potential adverse 
effects. These conventional screening methods are extremely expensive and time 
consuming 36.  
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Figure 1 E: Process involved in New Drug discovery 37 
 
Due to considerable advancement in the field of biotechnology researchers of 
modern era is now utilizing in-vitro techniques for the purpose of lead identification and 
optimization. The principle behind most of the in-vitro techniques relies of enzyme 
inhibition. Out of thousands of compound now potential one can be easily identify the 
potential lead with low cost in lesser period of time 38. 
Lead drug with lowest inhibitory concentration (IC50) value has highest potency 
of enzyme inhibition. Thus with in-vitro technique one can refine and optimize the newly 
discovered compounds and the best lead will be choosing for preclinical evaluation. 
Hence the effort of scientist in screening the low potency and high toxic compounds is 
now greatly reduced 39. 
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Figure 1F : Schematic representation of various cellular and extracellular events 
due to oxidative stress 40  
 
 
Oxidative stress is the main etiological reason behind most of the metabolic, 
degenerative and inflammatory disorders of human being. Most of the drugs in siddha 
system of medicine have combination of herbs and minerals and because of this known 
reason nearly 80% of the siddha formulation act as anti-oxidant too. Inbuilt antioxidant 
property is an additional quality for a dug to act as a therapeutic in treating metabolic 
disorders like urolithiasis 41. 
4.9.7.Oxidative stress (OS) in hyperoxaluria 42,43  
 Over production of ROS with down regulation of the expression of anti-oxidant 
enzymes results in reduction of cellular anti-oxidant capacity and hence oxidative 
stress is produced. 
 The life span of ROS is short and they do not travel long distances. 
 Oxidative stress is produced when reaction occurs between the by-products of 
reactive oxygen species and the cell content. 
 Malondialdehyde and isoprostanes are the most common by-products of reactive 
oxygen species induced oxidative stress 
4.9.8 Clinical presentation 
 Many stones are silent and do not produce any symptoms. 
 Patients mostly diagnosed for urolithiasis when undergoing investigations for 
some other condition. 
 The classical feature is sudden severe pain both in renal and ureteric calculi. 
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 Typical renal calculi pain starts in the loin about the level of the costo- vertebral 
angle and moves to the groin 
 Tenderness felt in the loin and in the renal angle 
 A movable stone is more painful. 
 Radiation of pain is felt even in testis and scrotum in males and in the labia in 
female and ends in the anterior thigh portion. 
Other symptoms which may be present include: 
 Fever with rigor 
 Dysuria 
 Haematuria 
 Urinary retention 
 Nausea and vomiting 
4.9.11 Investigation of suspected urinary stone disease35 
 Radiography 
 Excretion urography 
 Ultrasound scanning 
4.9.12 Management of stone disease 44 
Conservative management 
 Most small stones (< 5mm) will pass spontaneously and can be treated 
conservatively 
Non-surgical therapies 45 
Fluid therapy 
 Intake of more amounts of fluids prevents supersaturation of urine. 
This method has scientifically proved to prevent the occurrence of kidney stones. 
Diuretic therapy 46,47  
 Increased renal fluid output facilitates stone passage due to increased hydrostatic 
pressure within the ureter3 
 Diuretic therapy is not recommended in acute ureteric stones39 
Expulsive therapy 48,49 
 Expulsive therapy aims in the spontaneous passage of ureteric calculi with the 
help of drugs40. Calcium channel blockers, alpha-1 adrenergic receptor antagonist 
are some good examples for drugs used in expulsive therapy. 
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 Herbal therapy 
 Medicinal plants used in urolithiasis act as antilithiatic by decreasing the calcium 
ion in the urine, thus altering the ionic composition of urine 
 Some of the herbs act as diuretics 
 Some medicinal plants act by inhibiting the mineralization of calcium phosphate 
and calcium oxalate crystals. 
4.10. Drug Profile 50 
4.10.1.Seenakaram (Alumen, Alum) 
Seenakaram otherwise known as Padikaaram, Cheenam and Padigi. This is 
available in nature and found in combination with certain special form of clay in places 
such as Nepal, kathiyawar, Punjab and bihar. The alum is separated from the clay. This 
appears like crystals and is white in colour. It has sweet, sour and also astringent taste. 
Purification and detoxification: 
The alum is dissolved in water; filtered, boiled when it attains consistency of jelly. It is 
cooled to get the purified form. 
Actions: Astringent, antiseptic, antispasmodic. 
Dosage: 650mg to 1.3mg 
General properties: 
It cures gingivitis, eye diseases, ophthalmic, elephantiasis, vayu, tumour, sene of 
heat, gastric ulcer, hypertension, haemorrhage, dysentery, diarrhoea, children’s vomiting, 
whooping cough, spittle cough with expectorant, pharyngitis, menorrhagia and 
gonorrhoea. 
Uses: 
1. Alum(130 mg) is dissolved in 1 ounce of water and on washing it controls eye 
diseases. 
2. Alum (35mg) dissolved in 10.4 litres of water is used as a mouth wash and for 
washing the ulcers. 
22 
 
3. When a cloth is soaked in alum dissolved water is applied over the cut injuries, it 
may arrests bleeding. 
4. Alum, acacia catechu and bark of cinnamomum zeylanica (equal quantities) are 
powdered and mixed with 975mg of honey and given to control diarrhoea due to 
tuberculosis. 
5. 5.it also controls vomiting when given at a dose of 65mg. 
6. When the alum(195mg) is dissolved in rose water (14ml) and administered twice 
daily, the cough associated with asthma is controlled. 
7. Alum (65 to 130mg) is dissolved in distillated of ( Trachyspermum ammi) 
bishop’s weed theeneer and administered in whooping cough to control 
effectively. 
8. For whooping cough and chronic hiccup that produce vomiting it is given with 
honey in the dose of 4gm. 
9. Alum (4.7gm) dissolved in buttermilk is given for snake bite. 
10. For severe head injury, alum (130 mg) is administered along with sugar. 
11. Alum (2.6 gm) is given with sugar syrup for guinea worm infestation. 
12. In leucorrhoea with bleeding, alum is given with the juice of Adathoda vasica 
thrice daily. 
13. Alum is boiled along with milk and filtered; the filtrate is effective in the 
management of excessive menstrual blood flow; it is also effective in the 
treatment of toxic fever and haemorrhoid. 
14. Alum is dissolved in water and applied topically to control the bleeding in nose, 
teeth and penis. 
15. Alum is used in hair dye preparations. 
16. Alum is powdered and sprinkled on the pulp of aloes to get its juice. 
 
Siddha medicinal preparations of Seenakaram and its uses: 
1. Padikara parpam 
It cures the absolute suppression of urine, dysuria, stricture of urethra. 
2. Padikaara chendooram 
It cures dysentery, blood stained dysentery and menorrhagia. 
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3. Padikara patru 
It is applied around the eye to control redness of the eye and lacrimation eye. 
4.10.2. Alum 
Alum or alumen refers to a specific chemical compound and a class of chemical 
compounds. The particular composite is the hydrated Aluminium potassium sulfate 
whose formula is K2SO4.Al2SO4(24H2O) .It colourless transparent crystal with acid 
sweetish astringent taste. 
Tamil name  :  Padikaram 
Sanskrit name  :  Sphatikar 
English name  :  alum, sulphate of alumina 
Molecular formula :  KAL(so4)2.12H2O. 
Occurrence   :  Nepal, Bihar, Punjab, Rajputana 
Appearance  : White Crystal , transparent  
Colour   :  Colourless 
Taste   :  Acid, sweetish, astringent taste 
 
Properties 
• Melting point-660.370c 
• Boiling point-24670c 
• Specific gravity-2.6989 200c 
It is silvery-white metal, it is soft, light relatively non-toxic with a light thermal 
conductivity and high corrosion resistance. 
Actions 
• Astringent 
• Anti-spasmodic 
• Anti-septic 
• Haemostatic 
• Caustic 
24 
 
• Irritant and purgative in large doses 
• Emetic in repeated doses. 
Medicinal uses 
1. It is useful in haematuria. 
2. For urethral stricture injection made of alum 1-thola, blue vitriol -70 grains 
(4.5gms) and water is used as on urethral injection. 
3. Alum is used in many submit vaccine as an adjuvant to enhance the body 
response to immunogens 
4. Powered alum is commonly used as remedy for ulcer 
5. Preparation of alum is used to bleeding disorders 
4.10.3.Vediuppu 
Potassium nitrate 
Other names: Pottiluppu,Inangan, Padairaasan, Boomikoormai, Navasaramithru 
Preparation: 
 The sand comprising the crude salt is placed in a mud pot. Water is supplemented 
into it and mixed well and a straw is positioned is placed inside the pot and 
filtered. The filtrated mixture is heated to get the salt. 
 The potassium nitrate salt is used for the preparation of explosives. It is also used 
for cooling alcohol and to polish the gold ornaments. 
 The purified salt will appear as white thin rods. When placed in the tongue, it 
gives a cooling effect. 
Properties and uses: 
 Potassium nitrate salt has got demulcent, diuretic and diaphoretic properties. 
 The salt is also useful in the treatment of eight types of gunmam, uterous fibroids, 
anorexia, anaemia, urinary tract infections, dysuria etc. 
 The salt is also effective in fever, swellings, rheumatic disorders, haemorrhage, 
gonorrhoea, eye diseases and sore throat. 
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Dosage: 650 mg – 1300 mg. 
 Equal ratio of salt and tamarind are dissolved in water and boiled and the mixture 
is taken in semi-solid consistency and applied over the swelling and sprain by 
which haematoma will subside. 
 The salt is also used as one of the ingredients in tooth powders. 
 Insects entered in the ear, generative organs, anus will come out on spraying the 
salt water. 
 Dissolved salt water is given through the rectum to remove the worms in the large 
intestine. 
 The salt is also used as a preservative for fish, mutton and vegetables. 
 The salt is dissolved in water and given for the silver nitrated poisoning. 
Synonyms   :  Niter, potassium salt and salt peter. 
Chemical formula  :  KNO3 
Molecular weight   :  101.1 
Appearance   :  white crystals 
Odor    :  sour or salty 
Solubility   :  36 gm/100 ml water 
Specific gravity  :  2.1 
pH    :  7 
Boiling point   :  400oC (752oF) 
Melting point    :  333oC (631oF) 
Vapour density (Air=1)  : 3.00 
Vapour pressure (mm Hg)  : Negligible at 20oC 
Stability    :    Stable under ordinary conditions of use and 
storage 
Decomposition products :  Oxides of nitrogen and toxic metal fumes 
may form   
                                                      when heated to decomposition 
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Medicinal uses 
 Potassium nitrate in solution is a refrigerant, diuretic and diaphoretic 
 It acts on vascular system and thus reduces the pulse 
 In weak solutions, 1 to 2 drachms in a quart of thin warm rice conjee. 
 It is an excellent refrigerant drink in fevers, with hot and dry skin, parched 
tongue, with great thrist and scanty and high coloured urine. 
 It is useful in early stages of dropsy, measles, influenza, catarrh, gonorrhoea, 
acute rheumatism, bleeding from the lungs, stomach, uterus or other internal 
organs attended by fever. 
 In gonorrhoea a micture of nitre 10 grains in a wine glass full of decoction of 
abelomoschus esculentes twice or thrice a day. A powder of equal parts of salt 
petre, cardamom, cubeba, soap stone, olibanum and curcuma longa. The dose is 
35 grains 3 times a day. 
 A mixture of nitre 2 parts and leaf juice of radish 1 part given in dose of 80 grains 
to relieve scalding and retention of urine also suppression or scantiness of urine. 
Potassium nitrate is a chemical compound with the formula KNO3. It occurs as a 
mineral niter and is anatural solid source of nitrogen. Its common names include saltpetre 
(Salt peter in American English), from medieval latin sal petre ‘stone salt” or possibly 
“salt of petra” and nitrate of potash. The name peru saltpetre or chile saltpetre (American 
peru saltpetre or chile saltpetre) refers not to potassium nitrate but to a similar chemical 
sodium nitrate.  
Production 
 Potassium nitrate can be made by combining ammonium nitrate, and potassium 
hydroxide. 
 An alternative way of producing potassium nitrate without a by-product of 
ammonia is to combine ammonium nitrate and potassium chloride, easily 
obtained as a sodium free salt substitute. 
 Potassium nitrate can also be produced by neutralizing nitric acid with potassium 
hydroxide. This reaction is highly exothermic. 
 Properties: 
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 Potassium nitrate is a crystal in structure at room temperature, which transforms 
to another system at 1290C. Upon heating to temperature above 5600C., it 
decomposes into potassium nitrite, generating oxygen. 
 Potassium nitrate is moderately soluble in water, but its solubility increases with 
temperature. The aqueous solution is almost neutral, exhibiting pH6.2 at 14 0C for 
a 10% solution of commercial powder. It is not very hygroscopic, absorbing about 
0.03% water in 80% relative humidity over 50 days.  
4.10.4.Karsunna neer (Lime water)  
Slaked lime (70 gm) is placed in a flask with a stone cork. Water (4.2 litre) is then 
added and shake for two to three minutes. The flask is kept in a place and the 
clear liquid obtained is filtered and collected in a green coloured bottle which is 
closed air-tight. 
Uses: 
1. When given in cow’s milk at the dose of 21ml to 84 ml it moves the acidity in 
stomach, when given in cow’s milk for children, at the dose of 4ml., it controls 
vomiting. 
2. When the lime water and coconut oil are mixed in equal quantities and applied 
over the burns, the wounds heal. 
3. The limewater is given with milk as an antidote for the victims of poisonous 
acids. 
4. When the lime water is given in cow’s milk, it controls burning micturition. 
5. The lime water (28ml) is ground with 26ml of juice of Bombax malabaricum and 
taken internally for controlling white discharge and excessive menstruation. 
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5. MATERIALS AND METHODS 
5.1.Procurement of raw materials 
The raw material alum, potassium nitrate and slaked lime were procured from 
market sample at Govindhasamy chetty store, Chennai.  
5.2.Authentication of raw materials 
The minerals alum, potassium nitrate were authenticated by Dept of Geology, 
University of Madras, Guindy campus, Chennai.  
5.3.Purification of raw materials  
5.3.1.Seenakaram (Alum) 
Seenakaram otherwise known as Padikaaram, Cheenam and Padigi. This is 
available in nature and found in combination with certain special form of clay in places 
such as Nepal, kathiyawar, Punjab and bihar. The alum is separated from the clay. This 
appears like crystals and is white in colour. It has sweet, sour and also astringent taste. 
5.3.2.Purification and detoxification: 
The alum was dissolved in water; filtered, boiled when it attains consistency of jelly. 
It was cooled to get the purified form. 
5.3.3.Vediuppu: Potassium nitrate 
Other names: Pottiluppu ,Inangan, Padairaasan, Boomikoormai, Navasaramithru 
5.3.4.Preparation: 
The sand containing the crude salt was placed in a mud pot. Water is added into it and 
mixed well and a straw was placed inside the pot and filtered. The filtrated mixture was 
heated to get the salt. The purified salt was appeared as white thin rods. When placed in 
the tongue, it gives a cooling effect. As shown in figure 2 A and 2B. 
5.3.5.Karsunna neer : Lime water 
Slaked lime (70 gm) was placed in a flask with a stone cork. Water (4.2 litre) was 
then added and aggitated for two to three minutes. The flask was kept in a place and the 
clear liquid obtained was filtered and collected in a green colored bottle which was closed 
air-tight. 
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5.3.6.Preparation of the drug  
5.3.6.1.Raw materials: Seenakaaram, Vediuppu, Karchunnam. 
The above materials are identified and collected from different sources probably. 
These are authenticated by Geologist by analysing the following parameters: 
Macroscopic features, Optical properties, qualitative and quantitative analyses. 
5.3.7.Purification of Raw materials 51,52 :  
5.3.7.1.Purification of seenakaaram: 
  Required amount of seenakaaram is dissolved in water and filtered. Then it is 
boiled until it attains semisolid form(kuzhambu).it is then cooled to get the purified form. 
5.3.7.2.Purification of vediyuppu: 
  Potassium nitrate (1 part) , water (2 parts) are taken. Potassium nitrate is finely 
powdered and dissolved in water. The clear fluid is poured in white colored iron pot and 
heated till a semisolid consistency is obtained .This is then poured in a copper pot and 
placed in a cool place, now the salt will form, The process is repeated for five times. As 
shown in figure 2C and 2D.   
5.4.Preparation of Seenakara parpam 
1) Purified Seenakaaram (Alum / Alumen) 
              Equal quantity 
2) Purified Vediuppu (Potassium nitrate / salt petre)   
   
3) Karchunna Neer (Quick Lime solution)                 -    required quantity 
5.4.1.Method of preparation: 
All the materials used in preparation of parpam are subjected to the process of 
purification as mentioned in Siddha literature. The purified ingredients will be ground 
with Karchunna Neer (Quick Lime solution) and made into tablets and subjected to 
calcination with 10 cow dung cakes. The calcined tablets will be ground to fine powder 
and stored in an air tight glass container. As shown in figure 3 A to 3C.  
Human intended dosage as per text:  500 mg  
Adjuvant:  Palm Jaggery. 
Route of administration  : Oral 
Dosage of medicine   : 1 -1 ½ panavedai (500 mg) 
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Duration of treatment   : 45 days. 
Adjuvant   : Palm Jaggery 
Indications    : Kalladaippu, Neeradaippu. 
5.5.Analytical specifications of parpam as per PLIM guidelines 53 
This was done as per the protocol for testing of Ayurveda, Siddha and Unani 
medicines by Pharmacopoeia laboratory of Indian medicine, Ghaziabad (PLIM), New 
Delhi. 
5.6.Physiochemical Evaluation 
5.6.1.Percentage Loss on Drying 54  
Accurately weighed quantity of the drug Seenakara parpam of about 10gm was 
placed in evaporating dish and was allowed to dry at 105oC for nearly about five hours 
and then the final residue was weighed to calculate percentage loss on drying. 
 
5.6.2.Determination of Total Ash 55  
Accurately weighed quantity of the drug Seenakara parpam of about 3gm was 
placed in silica petri dish and was then incinerated using metal furnace at the temperature 
400 ºC until it turns white. Percentage of total ash will be calculated with reference to the 
weight of air-dried drug. 
5.6.3.Determination of Acid Insoluble Ash 
Accurately weighed quantity of the drug Seenakara parpam of about 0.5 gm was 
boiled with nearly 25 ml of dil HCl for about six minutes. The collected insoluble matters 
was washed and ignited to constant weight to get the percentage of acid insoluble ash. 
5.6.4.Determination of Water Soluble Ash 
Accurately weighed quantity of the drug Seenakara parpam of about 0.5 gm was 
boiled with nearly 25 ml of purified water for about five mins. The collected insoluble 
matters was washed and ignited for 20 mins to constant weight at the temperature of 
450oC to get the percentage of water-soluble ash. 
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5.6.5.Determination of pH 
About 5 g of Seenakara parpam was dissolved in 25ml of distilled water and the 
filtered solution was allowed to stand for 30 mins and the subjected to pH evaluation 
using pH meter. 
5.7. Characterization of Seenakara parpam by modern Analytical Techniques 
5.7.1.Atomic absorption spectroscopy Analysis 56 
Elemental analysis of sample SKP1, 2 and 3 were carried out with atomic 
absorption spectroscopy technique. Model of instrument used for analysis was thermo 
fisher M series, 650902 V1.27. Basic heavy metal profiling such as lead, cadmium, 
mercury and arsenic was analyzed using AAS technique. Wave length ranges from 180 to 
260 nm. Slit width of 0.5 mm with carrier gas used was argon and acetylene of flow rate 
of 1.1 L/min. Flame vapor technique was adopted for the study. 
5.7.2.Microbial load Analysis 
Test drug SKP1, 2 and 3 was prepared at the concentration of 10 – 100 µg/ml. 
Using the standard loop which carried 0.01ml of the test solution was inoculated in 
nutrient agar, blood agar and McConkey agar plates 57. The plates were then incubated at 
37°C overnight and the colonies were counted. The organisms were identified using 
biochemical tests such as Indole test, Triple sugar iron (TSI), Urease, Citrate, Mannitol 
Motility, and Phenyl pyruvic acid. 
5.7.3.Fourier Transform – Infra Red Spectroscopy Study 58 
The Perkine Elmer Spectrum - Fourier Transform Infrared (FTIR) Spectrometer 
was used to derive the spectrum of Seenakara parpam in Potassium Bromide (KBr) 
matrix with scan rate of 5 scan per minute at the resolution 4cm-1 in the wave number 
region 450-4000cm-1. The samples were chastised to fine powder using agate motor and 
pestle and the mixed with potassium bromide. They were then made in to pellet by 
applying pressure to prepare the specimen to record the FT- IR Spectra under Standard 
conditions. FT- IR Spectra were utilized for the purpose of identifying the presence of the 
functional groups and bands in the seenakara parpam.  
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5.7.4.Scanning Electron Microscopy with Energy Dispersive X-ray Spectroscopy 
(SEM/EDX) 59 
SEM with X-ray spectroscopy (EDX) was used to access the surface morphology of 
the particles present with in the sample SKP and further EDX data will be utilized to 
study the percentage proportion of potassium, carbon, alum and sulphur present in the 
varying batch samples of SKP1,2 and 3. Energy of electrons used of bombardment is 0.5 
– 30 kV. Surface topographic features on the outermost surface (< 5 nm) is achieved by 
using a primary electron beam with an energy of < 1 kV.  
5.7.5.XRD spectral Study 
The XRD analysis of SKP was carried out using Bruker discover D8 X ray 
diffractometer. Cu K Alpha radiation was used for recording the spectra 60. The range of 
diffraction angle 10-70o operating at 30kV and 20 mA.  
5.8.In-vitro Evaluation Techniques 
5.8.1.DPPH (2, 2-Diphenyl 1-2 picrylhydrazyl) radical scavenging Assay  
The antioxidant activity of SKP was determined using the 2,2-diphenyl 1-2 
picrylhydrazyl (DPPH) free radical scavenging assay 61. Stock solution of test drug SKP 
in required concentration (50, 100 and 200 mg/ml) was prepared in methanol. From the 
stock solution by serial dilution with same solvent were made the final volume of each 
test tube up to 10 ml whose concentration was then50 μg/ml, 100 μg/ml and 200μg/ml 
respectively. Ascorbic acid and BHA were used as standard was prepared in same 
concentration. Final reaction mixture containing 1 ml of 0.3 mM DPPH methanol 
solution was supplemented with 2.5 ml of sample of varying concentrations are allowed 
to react at room temperature. Absorbance and BHA in the presence of test drug at 
different concentration of (50 µg, 100 µg, and 200µg/ml) was noted after 15 min 
incubation period at 370C. Absorbance was read out at 517 nm using double-beam U.V 
Spectrophotometer by using methanol as blank.  
Percentage Scavenging Activity = [Absorbance maximum of control - Absorbance 
maximum of test sample/Absorbance maximum of control] X 100 
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5.8.2.Hydrogen peroxide radical scavenging (H2O2) assay  
 The tendency of SKP to effectively scavenge hydrogen ions can be estimated by 
hydrogen peroxide radical scavenging assay 62. A solution of hydrogen peroxide in 
phosphate buffer (50 mM pH 7.4) was prepared. The test drug SKP was prepared in 
varying strength (50,100 and 200 µg/ml) was admixed to hydrogen peroxide and 
absorbance was recorded at 230 nm. Blank solution containing phosphate buffer without 
H2O2. The percentage of hydrogen peroxide scavenging activity was calculated as 
follows: 
Percentage Scavenging Activity = [Absorbance maximum of control - Absorbance 
maximum of test sample/Absorbance maximum of control] X 100 
5.8.3.Nitric oxide radical scavenging assay 63 
The test sample SKP was prepared in the concentration of 50,100 and 200 µg/ml. Griess 
reagent was prepared as per the standard protocol by admixing equal amount of 1% 
sulphanilamide in 2.5% phosphoric acid and 0.1% 
naphthylethylenediaminedihydrochloride in 2.5% phosphoric acid. 1 ml of 10 mM 
sodium nitroprusside in buffered phosphate saline was added to it. Final reaction mixture 
consists of different concentration of SKP along with fresh Griess reagent followed by 
the brief incubation. The absorbance was measured at 546 nm. The percentage inhibition 
of the SKP extract and standard was calculated and recorded. The percentage nitrite 
radical scavenging activity of the SKP and standard ascorbic acid and BHA were 
calculated using the following formula: 
Percentage Scavenging Activity = [Absorbance maximum of control - Absorbance 
maximum of test sample/Absorbance maximum of control] X 100 
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5.8.4.In vitro struvite crystal growth evaluation by single diffusion gel growth 
technique 
Experimental simulation of crystal inhibition was performed by using single 
diffusion gel growth technique 64. In this method 0.5m of Ammonium Dihydrogen 
Phosphate was mixed with Sodium Metasilicate of sp gravity around 1.05. Reactant 
mixture was transferred in to the glass cylinder contains silica gel. Sufficient time period 
was allowed for the medium to set and mainly the gel seems to be non-reactive with any 
of the reactant added to it. Followed by this about 20 mL of 1.0 M magnesium acetate 
along with 1.0 M magnesium acetate containing 5 % W/V concentration of the test drug 
SKP were gently poured on the set gels in test tubes to study the growth inhibition of 
Struvite crystals. At the end of the experimental period fully grown crystals were gently 
removed from the medium of each test tube. Length of growth, mass and volume of each 
test tube will be calculated. The experiment was carried out in triplicate to get the average 
mean of individual values. Followed by this the isolated crystals was subjected to various 
analytical parameters such as XRD, FTIR, UV–vis, Powder XRD techniques. 
5.9.Toxicity Studies 
 Short term (Acute) and Sub-acute toxicity studies were carried out as per OECD- 
423 and OECD-407 guidelines respectively. Long term 90-days repeated oral toxicity in 
rodents was carried out as per OECD-408 guideline 
5.9.1.Acute Toxicity study  
Acute toxicity of the test drug Seenakara parpam was carried out in female rats as per the 
OECD Guideline – 423. Animals were divided in five groups 6 animals each. 
5.9.1.1.Animals 
Healthy adult albino wistar rats weighing between 150-180 g were used for the 
study. The animals were accommodated in poly propylene cages and were kept in well 
ventilated with 100 % fresh air by air conditioning. A 12 hr dark / light visual cycle was 
maintained .Room temperature was maintained between 22+2º C and humidity level of 
about 40–65%. Animals were provided with standard laboratory rodent food and water ad 
libitum. All the animals were acclimatized to the laboratory about 7 days prior to that of 
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the experimentation. The study protocol was reviewed and approved by Institutional 
Animal Ethical Committee (IAEC), NIS, Chennai, India, with the experimental protocol 
number 1248/ac/09/CPCSEA/4-41-2011. 
5.9.1.2.Experimental Methodology 
The animals were randomly grouped into five groups (n=6; female rats). Group I 
served as control group treated with palm jaggery in purified water and group II, III, IV 
and V served as drug treated groups administered with Seenakara parpam was admixed 
with palm jaggery juice at the dose of 5mg, 50mg, 300mg, 2000mg/kg.b.w by oral 
gavage.  
After drug administration the animals were observed continuously at 15, 30, 60, 
120 and 240 min up to 72 hours and then 14 days for any sign of behavioral changes, 
body weight changes and for mortality 65. 
The wellness parameters of animals were observed continuously for the first 
2h,4h,6h,8h,10h,12h,16h and 24 h further animals were observed periodically for the next 
14 days. C.N.S and A.N.S related toxicity were monitored continuously. Observations 
were made and recorded systematically and continuously after study drug administration 
66. 
At the end of the experiment all animals were subjected for gross necropsy and 
observed for pathological changes. 
5.9.2.Sub-Acute Toxicity study  
Repeated oral administration of Seenakara parpam were carried out for a period of 
28 days at three dose level ie low, mid and high dose in accordance with OECD guide 
line 407. Further, animals were observed for the entire study period of 28 days with 7 
days interval. Hematological and bio-chemical changes including histopathological 
analysis were carried out at the end of 28th day of drug administration 67. 
5.9.2.1.Animals 
Healthy adult albino wistar rats weighing between 150-180 g were used for the 
study. The animals were accommodated in poly propylene cages and were kept in well 
ventilated with 100 % fresh air by air conditioning. A 12 hr dark / light visual cycle was 
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maintained.Room temperature was maintained between 22+2º C and humidity level of 
about 40–65%. Animals were provided with standard laboratory rodent food and water 
ad libitum. All the animals were acclimatized to the laboratory about 7 days prior to that 
of the experimentation. The study protocol was reviewed and approved by Institutional 
Animal Ethical Committee (IAEC), NIS, Chennai, India, with the experimental protocol 
number 1248/ac/09/CPCSEA/4-41-2011 
5.9.2.2.Experimental Methodology 
The animals were randomly grouped into four groups (n=10; 5/sex). Group I 
served as control group palm jaggery in purified water and group II,III and IV served as 
drug treated groups of three different doses like low dose, mid dose and high dose.The 
animals were administrated with the study drug once daily for 28 days. The animals in 
control group received jaggery in purified water 5 ml/kg b.w. Seenakara parpam was 
admixed with palm jaggery juice. The animals belong to group II,III,IV received the 
study drug Seenakara parpam in three doses levels viz 100,200 and 400 mg/kg,p.o  
The rats were weighed weekly and observed for behavioral changes, food - water 
intake and morphological changes. At the end of the 28th day, before sacrifice, the 
animals were fasted for overnight with free access to water. On 29th day the animals were 
sacrificed with excess anesthesia. Blood samples were collected from aorta and stored in 
EDTA (ethylenediamine –tetra acetate) tubes for Hematological analysis and in test tubes 
for serum generation for biochemical analysis. The vivacious organs including lung, 
brain, heart, liver, spleen, kidneys and stomach were harvested and carefully investigated 
for gross lesions. The organs were preserved in 10% formalin for histopathological 
assessment. 
5.9.3.Sub-Chronic Repeated Dose 90-days Oral Toxicity study  
Sub-chronic toxicity study of Seenakara parpam were carried out for a period of 
90 days in accordance with OECD guideline 408. 90 days repeated oral administration of 
Seenakara parpam were proceed at three dose level ie low, mid and high dose. Further, 
animals were observed for the entire study period of 90 days with 7 days interval. 
Toxicological parameters such as body weight, food intake, water intake and change in 
behavior, urine analysis, hematological and bio-chemical changes including 
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histopathological analysis were carried out at the end of 90th day of drug administration 
68. 
5.9.3.1.Animals 
Healthy adult albino wistar rats weighing between 150-180 g were used for the 
study. The animals were accommodated in poly propylene cages and were kept in well 
ventilated with 100 % fresh air by air conditioning. A 12 hr dark / light visual cycle was 
maintained.Room temperature was maintained between 22+2º C and humidity level of 
about 40–65%. Animals were provided with standard laboratory rodent food and water ad 
libitum. All the animals were acclimatized to the laboratory about 7 days prior to that of 
the experimentation. The study protocol was reviewed and approved by Institutional 
Animal Ethical Committee (IAEC), NIS, Chennai, India, with the experimental protocol 
number 1248/ac/09/CPCSEA/4-41-2011 
5.9.3.2.Experimental Methodology 
The animals were grouped into four groups (n=20; 10/sex). Group I served as 
control group treated with palm jaggery in purified water and group II,III and IV served 
as drug treated groups of three different doses like low dose, mid dose and high dose. 
Seenaakara parpam was admixed with palm jaggery juice. The animals were 
administrated with the study drug once daily for 90 days. The animals in control group 
received jaggery in purified water 5 ml/kg b.w. The animals belong to group II,III,IV 
received the study drug Seenakara parpam in three doses of 100,200 and 400 mg/kg,p.o 
The rats were weighed weekly and observed for behavioral changes, food - water 
intake and morphological changes. At the end of 90th day, before sacrifice, the animals 
were fasted for overnight with free access to water. On 91st day the animals were 
sacrificed with excess anesthesia. Blood samples were collected from aorta and stored in 
EDTA (ethylenediamine –tetra actate) test tubes for Hematological analysis and in test 
tubes for serum generation for biochemical analysis. The vivacious organs including 
lung, brain, heart, liver, spleen, kidneys and stomach were harvested and carefully 
investigated for gross lesions. The organs were preserved in 10% formalin for 
histopathological assessment. 
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5.10.Hematological analysis 
Blood samples were analyzed using established procedures and automated Bayer 
Hematology analyzer. Parameters evaluated including Red Blood Cells (RBC) count, 
Hemoglobin (Hb), Platelet Count, Total and Differential White Blood Cell (WBC) count, 
Mean corpuscular volume (MCV) and Mean corpuscular hemoglobin concentration 
(MCHC). 
5.11.Biochemical analysis 
Serum samples were analyzed for Creatinine, Urea, Total Protein, Total 
Cholesterol,  Triglycerides (TGL), Glucose, Urea, Alkaline  Phosphatase (ALP), Alanine 
aminotransferase (ALT or SGPT) , Aspartate aminotransferase (AST or SGOT) and Total 
Bilirubin.  
5.12.Histopathological analysis  
Immediately after collecting the blood samples, vascular perfusion will be 
performed for tissue fixation using isotonic saline (250ml) followed by 10% buffered 
formalin solution (250ml). Organs such as Kidney, Heart, Liver, Brain, Lung, Spleen, 
Stomach, Testes, Uterus and Ovary will be removed and weighed immediately on an 
electronic balance for subsequent analysis. Tissues from all the groups will be embedded 
in paraffin and subjected to hematoxillin-eosin staining 69,70. The pathological 
observations of all tissues will be performed on gross and microscopic bases. Histological 
plates of the preserved tissues will be encrypted for analysis by a veterinary pathologist.   
5.13.Statistical analysis 
The statistical analysis was carried by one way analysis of variance ANOVA 
(GRAPH PAD PRISM 5 computer program). Results are expressed as ±SEM. The data 
are analysed statistically by One way analysis of variance followed by Dunnett’s multiple 
comparison test. The minimum probability values P < 0.05 were considered to be 
significant. 
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5.14. Pharmacological Screening in Animal Models 
5.14.1.Evaluation of Anti-Urolithiatic activity by Ethylene glycol induced 
urolithiasis in rats 
5.14.1.1.Animals 
Healthy adult male albino wistar rats weighing between 200-220 g were used for 
the study. Health status of the animals was ascertained by basic behaviors parameters 
before subjecting the animals for the study. The animals were accommodated in poly 
propylene cages and were kept in well ventilated with 100 % fresh air by air 
conditioning. A 12 hr dark / light visual cycle was maintained .Room temperature was 
maintained between 22+2º C and humidity level of about 40–65%. Animals were 
provided with standard laboratory rodent food and water ad libitum. All the animals were 
acclimatized to the laboratory about 7 days prior to that of the experimentation. The study 
protocol was reviewed and approved by Institutional Animal Ethical Committee (IAEC), 
with the experimental protocol number Dr.A.Mariappan/ 00070/ MD(s) PH.D 
/TNMGRMU/KMCP/IAEC/206/2015-16. 
5.14.1.2.Experimental Protocol  
Anti-urolithiatic potential of study drug SKP was evaluated using ethylene glycol 
induced hyperoxaluria animal model. Experimental animals were divided into 6 groups of 
6 animals each. All the experimental animals except normal control received ethylene 
glycol (0.75%) in drinking water for a period of 28 days and a single dose of sodium 
oxalate injection (35 mg/kg ,i.p) on 14th day for induction of urolithiasis 71. Seenaakara 
parpam was admixed with palm jaggery juice before administration. Treatment group rats 
was administered with SKP at the dose of 100,200 and 300 mg/kg b.wt, p.o from 1st to 
28st day, Animals belongs to standard group received cystone 500 mg/kg, p.o. 
5.14.1.3.Grouping 
Group I: Control group rats received palm jaggery in purified water  
Group II: Administered with ethylene glycol (0.75%) + Sodium oxalate injection 
(35mg/kg ,i.p) 
Group III: Administered with ethylene glycol and treated with SKP at 100 mg/kg, p.o 
Group IV: Administered with ethylene glycol and treated with SKP at 200 mg/kg, p.o 
Group V: Administered with ethylene glycol and treated with SKP at 300 mg/kg, p.o 
Group VI: Administered with ethylene glycol and treated with cystone 500 mg/kg, p.o 
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24 hours urine samples was collected on 14th and 24thday by housing rats at 
individual metabolic cages using sodium azide as preservative .In which urine volume 
was noted immediately after urine sample collection and stored at -80o C, for further 
electrolyte estimation. Blood will be collected from retro-orbital plexus of each rat, on 
day 28 and subjected to electrolytes estimation. 
5.14.1.4.Collection and analysis of urine 
All animals were kept in individual metabolic cages and urine samples were 
collected selectively on 14th, and 28th day of calculi induction treatment. Level of 
calcium in urine estimated using kit by “COBAS MIRA PLUS” auto analyzer. Urine 
were analyzed for oxalate 72, magnesium 73, phosphate 74, uric acid 75 , citrate and total 
protein 76. 
5.14.1.5.Serum analysis 
The blood was collected from the retro-orbital sinus under anesthetic condition 
and serum was separated by centrifugation at 10,000g for 10 min and analyzed for 
quantification of uric acid and creatinine level . The creatinine kit belongs to Reckon 
Diagnostics Pvt. Ltd, and uric acid diagnostic kit belongs to Span Diagnostics Ltd, were 
used to estimate serum creatinine and uric acid levels respectively. Estimation of calcium, 
oxalate, inorganic phosphorus and magnesium carried out using standard methods. 
5.14.2.Evaluation of Anti-Urolithiatic potential of SKP by zinc disc implantation 
induced urolithiasis model in rats 
5.14.2.1.Animals 
Healthy adult male albino wistar rats weighing between 200 - 220 g were used for 
the study. Health status of the animals was ascertained by basic behaviors parameters 
before subjecting the animals for the study. The animals were accommodated in poly 
propylene cages and were kept in well ventilated with 100 % fresh air by air 
conditioning. A 12 hr dark / light visual cycle was maintained. Room temperature was 
maintained between 22+2º C and humidity level of about 40–65%. Animals were 
provided with standard laboratory rodent food and water ad libitum. All the animals were 
acclimatized to the laboratory about 7 days prior to that of the experimentation. The study 
protocol was reviewed and approved by Institutional Animal Ethical Committee (IAEC), 
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with the experimental protocol number Dr.A.Mariappan /00070/ 
MD(s)PH.D/TNMGRMU/KMCP/IAEC/234/2015-16. 
5.14.2.2.Experimental Protocol  
Before the day of implantation Zinc disc were primed having weight 20 ± 4 mg. 
Prior to surgery, rats were fasted for 8–10 hours. Just before anesthesia, they were orally 
fed with 4mL of purified water to dilate the urinary bladders. Zinc disc implantations in 
urinary bladders were carried out by the standard method by Vermeulen et al 77. The 
animals were anesthetized with combination of ketamine and diazepam anesthesia. The 
urinary bladders were exposed through a small incision at suprapubic region. In which 
the zinc disc weighing 20 ± 4 mg were inserted and the incision were closed by sterile 
surgical sutures. Similar surgical procedure were carried out in in sham operated groups 
but without implantation of zinc disc in the bladder 78. Recovery period of about three 
days was allowed and further treatment was started 79.  Rats were divided into 6 groups of 
6 animals each and segregated as normal control group, sham operated group (Surgical 
procedure alone without imbedding of zinc disc), zinc disc imbedded group, zinc disc 
fixed group after recovery treated with Cystone 500mg/kg/day for the period of 7 days, 
Similarly zinc disc rooted rats treated with SKP admixed with palm jaggery juice at the 
dose of 200 and 400 mg/kg, p.o for seven days. 
5.14.2.3.Grouping 
Group I: Control group rats received palm jaggery in purified water 
Group II: Sham operated group without imbedding  
Group III: Disease control group surgically implanted with zinc disc. 
Group IV: Imbedded with zinc disc and treated with cystone 500 mg/kg, p.o 
Group V: Imbedded with zinc disc and treated with SKP at 200 mg/kg, p.o 
Group VI: Imbedded with zinc disc and treated with SKP at 400 mg/kg, p.o 
5.14.2.4.Urine Collection 
At the end of the treatment period, individual animal was placed in the metabolic 
cage for collection of 24-hours urine samples. Initially a drop of chlorhexidine gluconate 
was added to the test tubes as a preservative. 
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5.14.2.5.Radio Graphic Examination 
Radio graphic examination was done to ascertain the development of stones. The 
animals were maintained under anesthesia in anteroposterior position on the X-ray 
cassette to expose the pelvic region, with the use of X-ray instrument model (GE-525DX, 
USA) manufactured by Fuji system Japan. Machine was operated at 43 kV peak, 2mA 80. 
5.14.2.6.Calculi Weight 
At the end of the experimental period all animals was euthanized and by surgical 
incision the bladder were then exposed for enumeration of calculi weight. 
5.14.3.Evaluation of Diuretic activity of SKP by Lipschitz method. 
5.14.3.1.Animals 
Healthy adult male albino wistar rats weighing between 200-220 g were used for 
the study. Health status of the animals was ascertained by basic behaviors parameters 
before subjecting the animals for the study. The animals were accommodated in poly 
propylene cages and were kept in well ventilated with 100 % fresh air by air 
conditioning. A 12 hr dark / light visual cycle was maintained. Room temperature was 
maintained between 22+2º C and humidity level of about 40–65%. Animals were 
provided with standard laboratory rodent food and water ad libitum. All the animals were 
acclimatized to the laboratory about 7 days prior to that of the experimentation. The study 
protocol was reviewed and approved by Institutional Animal Ethical Committee (IAEC), 
with the experimental protocol number Dr.A.Mariappan/ 00070/ MD(s) 
PH.D/TNMGRMU/KMCP/IAEC/244/2015-16 
5.14.3.2.Experimental Protocol  
The method of  Lipschitz 81 were employed for the assessment of diuretic activity 
of the drug SKP. The animals were divided into 5 groups of 6 rats each as follows; Group 
I: received palm jaggery in purified water, Group II: received Furosemide 20 mg/kg, 
Group III: received Seenakara Parpam admixed with palm jaggery juice at 100 mg/kg 
body weight p.o., Group IV: received Seenakara Parpam admixed with palm jaggery 
juice at 200 mg/kg body weight p.o and Group V: received Seenakara Parpam admixed 
with palm jaggery juice at 300 mg/kg body weight p.o.  
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5.14.3.3.Diuretic activity  
Rats were fasted overnight and treated with vehicle, Furosemide and Seenakara 
Parpam as stated above along with palm jaggery in purified water. The routine urine 
samples were collected for 24h using metabolic cage and measured. The amount of urine 
(in ml) collected for 24 h was compared and tabulated 82.  
5.14.3.4.Natriuretic activity  
Flame photometric method was followed for the estimation of sodium and 
potassium concentration in the urine of the experimental animals was. The ratio of 
Na+/K+ is calculated for Natriuretic activity83. 
5.15. Statistical analysis 
The results were uttered as mean ± standard error mean (SEM). The statistical 
significance was assessed using one-way analysis of variance (ANOVA) followed by 
Newmannkeul’s multiple range tests and the minimum p value of p < 0.05 was 
considered as significant. 
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6. RESULTS 
6.1. Purification of padigaram and vediuppu 
 
The raw materials such as padigaram and vediuppu used in the formulation SKP was 
purified as per the standard procedure prescribed in the literature. Purified padigaram was 
ascertained by its color, texture and consistency As sown in figure 2A to 2D. 
 
Figure 2 : Raw and Purified Raw Materials used for Seenakara parpam 
   
A. Padigaram (Raw)   B.Padigaram (Purified) 
 
   
C.  Vediuppu (Raw)           D. Vediuppu (Purified) 
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6.2. Evaluation of Seenakara parpam final formulation 
The evaluation of final formulation seenakara parpam was evaluated by its unique 
character of its white amorphous powder by appearance. Further the characteristic feature 
of final formulation SKP was evaluated by its tendency to float on water.  Quality of size 
reduced particles in the finished product is further justified by the retention of the 
formulation in the papillary ridges of the thumb finger. As sown in figure 3A to 3C. 
 
Figure 3 : Characterisation of Seenakara parpam 
A.Seenakara Parpam Final Formulation      B.SKP floats on Water  
 
 
 
 
 
 
 
C.The SKP shows papillary ridges of thumb finger 
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6.3.Result of Raw drug Analysis of Seenakara parpam 
Analysis of raw material shows that all the materials of genuine and was retains 
its quality with the prescribed standard. The analytical results were tabulated in Table 1. 
Table 1: Nature of Raw material used 
Parameters Raw Materials 
Alum Potassium Nitrate Lime stone 
Habit Water soluble Moderate soluble in water Water soluble 
Physical State White crystal powder White crystalline solid White crystal 
powder 
Colour White/ Colorless White/ Colorless  
Cleavage Good Very good Perfect of three 
dimension 
Fracture Conchoidal Brittle Conchoidal 
Luster Vitreous Vitreous Vitreous 
Streak White White White 
Specific gravity 1.76 2.1 2.71 
Density 1.76 g/cm³ 2.11g/cm3 2560 kg/m3 
  
6.4.Result of Physicochemical Evaluation of Seenakara parpam 
      The results obtained from the physicochemical evaluation of the sample SKP 1, 2 and 
3 revels that the total ash value of SKP was found to 87.23 to 94.12%. Correspondingly 
the acid insoluble ash value was found to be 9.42 to 11.27 % and water soluble ash value 
of SKP was fond to be 68.38 to 78.16% w/w respectively. The loss on drying value of 
SKP at 105°C was found to be 4.16 % to 4.85% w/w. pH of the SKP was found to be 
4.40 to 4.81. The results of physicochemical analysis were tabulated in Table 2. 
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Table 2: Physico chemical Analysis of SKP 1, SKP 2 and SKP 3 
Physico chemical Parameter SKP 1 SKP 2 SKP 3 
pH 4.70 4.81 4.40 
Total Ash 90.31 % 87.23 % 94.15 % 
Water Soluble Ash 76.89 % 68.38 % 78.16 % 
Acid insoluble Ash 10.20 % 9.42 % 11.27 % 
Loss on Drying at 105o C 4.43 % 4.16 % 4.85 % 
6.5.Result of Atomic absorption spectroscopy Analysis of Seenakara parpam 
The results of heavy metal analysis by AAS technique reveals that the heavy 
metals such as lead and mercury present in the formulations are within the WHO 
prescribed limit. The results of heavy metal analysis were tabulated in Table 3. 
Table 3: Elemental Analysis of SKP 1, SKP 2 and SKP 3 by AAS Technique 
Elements SKP 1 SKP 2 SKP 3 Permissible limit 
Lead 0.935 ppm 0.553 ppm 0.612 ppm 10 ppm 
Cadmium BDL BDL BDL 0.3 ppm 
Mercury 0.024 ppm 0.010 ppm 0.031 ppm 1 ppm 
Arsenic BDL BDL BDL 3 ppm 
BDL- Below detective level 
6.6.Result of Microbial load Analysis of Seenakara parpam 
The results of microbial analysis of all three samples of SKP shows that the 
product is of high sterile and no evidence for the presence of the following pathogens 
such as enterobacter, E-coli, salmonella and staphylococcus species. Further the total 
bacterial and fungal count of SKP are within the prescribed limit. The results of microbial 
analysis were tabulated in Table 4. 
 
 
 
 
 
48 
 
 
Table 4: Microbial load analysis of sample SKP 1, SKP 2 and SKP 3 
 
Parameters SKP 1 SKP 2 SKP 3 Permissibl
e limit 
Total Bacterial Count 
(TBC) 
Less than 10 CFU/g Less than 10 CFU/g Less than 10 
CFU/g 
105 CFU/g 
Total Fungal Count 
(TFC) 
Less than 10 CFU/g Less than 10 CFU/g Less than 10 
CFU/g 
103 CFU/g 
Enterobacter Absent - NDG Absent - NDG Absent - NDG 103 CFU/g 
E-Coli Absent - NDG Absent - NDG Absent - NDG 10 CFU/g 
Salmonella Species Absent - NDG Absent - NDG Absent - NDG Absent 
Staphylococcus aureus Absent - NDG Absent - NDG Absent - NDG Absent 
CFU- Colony forming units 
NDG- No detected growth 
6.7.Result of Fourier Transform – Infra Red Spectroscopy analysis of Seenakara 
parpam 
IR spectrum of all the three samples of SKP belongs to various batches showing 
sharp intense peak at 1116 cm-1 corresponds to C-N stretching. Similarly another sharp 
peak was observed in the region of 3480 – 3451 cm-1 shows the presence of usual O-H 
bending. 
Peak emerging in the region of 618 cm-1 corresponds to C- H deformation and 
presence of less intense peak in the range of 679 - 662 cm-1 corresponds to N-H wagging 
Peaks emerging in the range of 1635- 1641 cm-1 shows the C=C variations. FT-IR 
spectral data’s of sample SKP1, SKP2 and SKP 3were represented in Figure 4 to 6. FT-
IR results of all three samples of SKP having more or less closely similar results. 
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Figure  4 : FT-IR Spectrum of Sample SKP 1 
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Figure 5 : FT-IR Spectrum of Sample SKP 2 
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Figure 6 : FT-IR Spectrum of Sample SKP 3 
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6.8.Result of SEM/EDX analysis of Seenakara parpam 
The results of SEM analysis of samples SKP1,2 and 3 illustrates that the sample 
SKP1 reveals the presence of nanoparticle in the size range of 42.1 to 92.4 nm, similarly 
the sample SKP2 with particle size distribution ranges from 82.3nm to 128.9 nm. Sample 
SKP3 has nano particle in the size range of 93.4nm to 184.7 nm. Overall observation 
clarifies that the lowest size of nano particle found in analysis is 42.1 and the highest will 
be 184.7 nm. The SEM analysis of all three samples SKP1, SKP2 and SKP 3were 
represented in Figure 7 to 9. 
Figure 7 : SEM images of Sample SKP1 
         
Figure 8 : SEM images of Sample SKP2 
        
 
 
 
 
A B 
A B 
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Figure 9 : SEM images of Sample SKP3 
 
             
  
Weight percentage of carbon present in the range of 26.65 to 36.08 % with respect 
to the outermost cell K shell excitation. Oxygen with percentage range of 27.03 to 50.03 
and aluminium with 5.40 to 8.18%. Similarly sulphur with 10.44 to 13.33 % and 
potassium with 18.28 to 26.91 %. The EDX analysis of all three samples SKP1, SKP2 
and SKP 3were represented in Table 5 and Figure 10 to 12. 
Table 5 : Atomic Weight Percentage of sample SKP in EDX analysis 
Elements SKP 1 units in Wt % SKP 2 units in Wt % SKP 3 units in Wt % 
CK 36.08 26.65 26.70 
OK 27.03 30.03 27.67 
AlK 8.17 6.31 5.40 
SK 10.44 12.93 13.33 
KK 18.28 24.08 26.91 
 
 
 
 
 
A 
B 
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Figure 10: EDX images of Sample SKP1 
 
 
 
 
 
 
 
 
Figure 11: EDX images of Sample SKP2 
 
 
Figure 12: EDX images of Sample SKP3 
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6.9. Result of XRD spectral Study of Seenakara parpam 
X-ray diffraction (XRD) patterns are obtaining for Nanoparticles with different 
precursor of aluminum, potassium nitrite and lime stone. All the diffraction peaks were 
found to be polycrystalline in nature of nano particle with planes (222), (101), (511), 
(440), (103), (200), (114), (211) and (116) respectively. The XDR peaks are indexed into 
diffraction pattern of one cubic and tetragonal structure, observed with JCPDS cord no. 
01-1156 and 65-267. The XRD spectrum illustrated that the diffraction peaks are slight 
shift to the higher direction was detected at different concentrations of precursor. Hence it 
indicates that the as-deposited thin films are well crystalline nature at different value of 
composite. From the favorite (103) reflection peaks are estimated full width at half 
maximum (FWHM) values of the nanoparticle. The XRD analysis report of all three 
samples SKP1, SKP2 and SKP 3were represented in Figure 12. 
Figure 13 : XRD Spectrum of Sample SKP 1, SKP2 and SKP 3 
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6.10. Effect of SKP on DPPH (2, 2-Diphenyl 1-2 picrylhydrazyl) radical scavenging 
Assay  
Results of DPPH radical scavenging activity shows that SKP has significant percentage 
inhibition ranges from 17.88 to 50.99 % when compare to that of the standard ascorbic 
acid (55.34 – 68.26 %) and BHA (57.57 – 71.24 %). As tabulated in table 6 and 
represented in figure 14. 
Table 6: Percentage inhibition of SKP on DPPH (2, 2-Diphenyl 1-2 picrylhydrazyl) 
radical scavenging Assay  
Concentration(mg.ml-1) % inhibition on DPPH radical generation 
ASCORBIC 
ACID 
BHA SKP 
              50 55.34±0.40 57.57±0.35 17.88±3.50 
             100 59.90±1.76 66.25±1.76 34.43±0.76 
             200 68.26±1.26 71.24±1.28 50.99±1.01 
The values are expressed as mean of three replicates ± S.E.M. The statistical analysis was 
carried out by using one way ANOVA. 
 
Figure 14: Percentage inhibition of SKP on DPPH radical scavenging Assay  
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6.11. Effect of SKP on Hydrogen peroxide radical scavenging (H2O2) assay  
Results of Hydrogen peroxide radical scavenging (H2O2) assay shows that SKP has 
significant percentage inhibition ranges from 15.59 to 57.15 % when compare to that of 
the standard ascorbic acid (24.42 – 58.84 %) and BHA (18.28 – 2.64 %). As tabulated in 
table 7 and represented in figure 15. 
Table 7: Percentage inhibition of SKP on Hydrogen peroxide radical scavenging 
(H2O2) assay  
Concentration(mg.ml-1) % inhibition on Hydrogen peroxide radical generation 
ASCORBIC 
ACID 
BHA SKP 
              50 24.42.69 18.28±0.48 15.59±3.78 
             100 49.16±0.18 48.64±0.26 38.07±0.80 
             200 58.84±0.37 62.64±0.27 57.15±1.54 
The values are expressed as mean of three replicates ± S.E.M. The statistical analysis was 
carried out by using one way ANOVA. 
 
Figure 15: Percentage inhibition of SKP on Hydrogen peroxide radical scavenging 
Assay  
6.12. Effect of SKP on Nitric Oxide radical scavenging assay 
Results ofnitric oxide radical scavenging assay shows that SKP has significant percentage 
inhibition ranges from 2.55 to 45.43 % when compare to that of the standard ascorbic 
56 
 
acid (15.82  – 78.82 %) and BHA (19.84 – 88.68 %). As tabulated in table 8 and 
represented in figure 16. 
  
Table 8: Percentage inhibition of SKP on Nitric Oxide radical scavenging assay 
Concentration(mg.ml-1) % inhibition on Nitric Oxide radical generation 
ASCORBIC ACID BHA SKP 
              50 15.82±0.68 19.84±0.86 2.55±0.64 
             100 28.48±0.25 52.58±1.89 16.28±1.60 
             200 78.82±0.29 88.68±1.42 45.43±4.85 
The values are expressed as mean of three replicates ± S.E.M. The statistical analysis was 
carried out by using one way ANOVA. 
 
 
Figure 16: Percentage inhibition of SKP Nitric Oxide radical scavenging Assay  
6.13. Effect of SKP on In vitro struvite crystal growth inhibition assay 
The result obtained from In vitro struvite crystal growth inhibition assay clearly reflects 
that SKP added medium shows significantly less number of crystal (11 ± 2.3) when 
compare to that of the control system (28 ± 3.9). The average weight of crystals belongs 
to SKP added medium seems to be 1.4 ± 0.2g when compare to that of the control 
medium with average weight of 1.6 ± 0.3g. As tabulated in Table 9 and Figure 17 
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Table 9: Effect of SKP on In vitro struvite crystal growth inhibition by single 
diffusion gel growth technique 
Group Average number of crystals Average Weight of crystals in gms 
Control System 28 ± 3.9 1.6 ± 0.3 
Medium + SKP 11 ± 2.3 1.4 ± 0.2 
The values are expressed as mean of three replicates ± S.E.M. The statistical analysis was 
carried out by using one way ANOVA. 
Figure 17: Effect of SKP number and weight of struvite crystal in single diffusion 
gel growth technique 
 
6.14. Effects of SKP on Nature and characterization of struvite crystals  
FT-IR spectrum of fully grown crystal typically resembles to that of the genuine 
struvite crystals and hence forth the grown crystal was identified as struvite nature as 
shown in figure 18. It is further justified with the UV spectral values observed between 
200 to 800 nm.The band gap for the struvite crystals grown in the control system was 
found to be 5.07 eV and in SKP treated medium the band gap energy of grown crystal 
observed to be decreased as shown in figure 19. Results of XRD analysis shows that there 
is no major shift in the peak values from those of the SKP added group this implies that 
there is no significant lattice distortion due to the addition of seenikaraiparpam (SKP). 
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The well definedpeaks at specific 2θ shows good crystallinity of the grown sample. As 
shown in figure 20. 
 
Figure 18:  FTIR spectrum of struvite crystal 
 
Figure 19:  UV–visible spectrum of struvite crystal 
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Figure 20:  Powder XRD pattern of struvite crystal 
 
 
6.15.Result Investigation of Acute Toxicity Profile of Seenakara parpam  
           As per the standard regulatory guideline the acute toxicity study of SKP was 
carried out at varying dose level starting from low dose of 
5mg,50mg,300mg,2000mg/kg.b.w.  The test drug Seenakara parpam administered at the 
maximum of 2000 mg / kg b.w did not revealed any abnormal clinical signs in any of the 
animals. All the rats were survived and no treatment related mortality occurred during the 
period of 14 days. Gross necropsy did not reveal any abnormal pathology in any of the 
animal. No significant difference in body weight gain was observed between control and 
test group. Weight loss was not observed in any of the groups treated with Seenakara 
parpam. Similarly there is no significant change in C.N.S, A.N.S and C.V.S related 
behavioral activity in drug treated group. The results were tabulated in table 10. Further, 
there is no significant change in sensory response of the drug treated group. No 
significant change was found in gross pathological observation of any of the vital of 
treatment group when compare to that of the control group animals. The results were 
tabulated in table 12 in which up to 2000mg/kg there was no toxicity were observed, so 
the LD50 cut off is unclassified. 
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6.16.Effect of SKP on Body weight of female rats in acute toxicity study 
No significant change was observed in body weight of female rats treated with 
SKP at the dose of 5mg,50mg,300mg,2000mg/kg.b.w. The results were tabulated in 
Table 11. 
6.17.Effect of SKP on clinical signs of female and male rats in Sub-acute oral 
toxicity study. 
Clinical sings with respect to lacrimation, salivation, appearance ,convulsion, skin 
Color, diarrhea, touch response, mortality and general Behavior were observed for the 
period of 28days in both male and female rats treated with SKP at the dose of 100,200 
and 400 mg/kg in which there is no significant measurable toxicity were encountered at 
C.N.S,A.N.S and C.V.S level. The results were tabulated in Table 13. 
6.18.Effect of SKP on Body weight of female and male rats in Sub-acute oral toxicity 
study.  
Body weight measurement is considerably important parameters in enumerating 
the toxic effect of drug at long term exposure. The body weight of male and female rats 
were monitored on weekly basis in both control and drug SKP treated group at the dose 
of 100,200 and 400 mg/kg in which there is no significant change and variation was 
observed with respect to the body weight of both male and female rats when compare to 
that of the control group. The results were tabulated in Table 14 and 15. 
 
6.19.Effect of SKP on hematological profile of female and male rats in Sub-acute 
oral toxicity study.  
At the end of the study blood samples were collected from all the animals before 
sacrifice and was subjected to completed blood cell count analysis. The results of the 
study reveals that there is no statistically significant differences with respect to 
WBC,RBC, Platelet, Hemoglobin, Mean corpuscular volume and Mean corpuscular 
hemoglobin concentration in both male and female rats treated with SKP at the dose of 
100,200 and 400 mg/kg. The results were tabulated in Table 16 and 17. 
6.20.Effect of SKP on serum biochemistry profile of female and male rats in Sub-
acute oral toxicity study.  
The results of the study reveals that there is no statistically significant differences 
with respect to blood glucose concentration, lipid profile, blood urea concentration, total 
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protein, liver and kidney function biomarkers of male and female rats treated with SKP at 
the dose of 100,200 and 400 mg/kg. The results were tabulated in Table 18 and 19. 
 
6.21.Effect of SKP on Histopathological changes of male and female rat in Sub-acute 
oral toxicity study 
A the end of the sub-acute toxicity study all the rats were sacrificed and 
the vital organs were observed for gross pathological changes. The results were 
tabulated in Table 20. Further samples such as Kidney, Heart, Liver, Brain, Lung, 
Spleen, Stomach, Testes, Uterus and Ovary was preserved in 10% formalin saline 
and was subjected to histological findings. 
Brain 
Light microscopic observation of brain samples belongs to rats treated 
with low, mid and high dose of test drug SKP signifies that projection of neurons 
on cerebrum and cerebellum appears normal. DG, CA1 and CA2 regions appears 
normal in both male and female e rats treated with SKP. No signs of inflammation 
and hemorrhage was observed in any of the control and drug treated animals. 
Histopathology findings were represented in Figure 21- 24. 
Heart 
Heart sample belongs to control and drug treated group reveals the 
arrangement of cardiac muscle fiber was normal and regular with well projected 
nucleus in between prominence further no signs of infarction, inflammation, 
thrombus and extra cellular depositions was observed in both male and female 
rats belongs to control and drug treated groups. Histopathology findings were 
represented in Figure 25- 28. 
Lung 
Histopathological section of lung samples reveals that appearance of 
smooth muscle and connective tissues normal. Circulated alveoli with epithelial 
lining was observed with normal projection of tertiary bronchus lumen , cartilage 
and mucosa. No signs of inflammation or migration of immune cells in both male 
and female rats belongs to control and drug treated groups. Histopathology 
findings were represented in Figure 29 - 32. 
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Stomach 
Stained section of stomach reveals that the Lumen shows evidence of 
crypts and lymph nodes. Presence of gastric gland, serosa, muscularis externa , 
outer longitudinal muscle ,inner circular muscle , gastric pit and muscularis 
mucosae appears normal in both male and female rats belongs to control and drug 
treated groups. Histopathology findings were represented in Figure 33- 36. 
Spleen  
LF – lymphoid follicle; PALS – periarterial lymphoid sheath was normal 
with no significant signs of inflammation and abnormalities in both male and 
female rats treated with low, mid and high dose of SKP. No signs of nodular 
enlargement and immune cell differentiation were observed in control and drug 
treated groups. Histopathology findings were represented in Figure 37- 40. 
Liver 
Histology of Liver samples shows well projected hepatocytes with dark 
prominent nucleus with no signs of inflammation and cirrhosis. Presence of well 
differentiated sinusoids were observed with regular intervals of uniform 
morphology and architecture. Histopathology findings were represented in Figure 
41- 44. 
 
Kidney 
Microscopic observation of kidney section reveals that proximal 
convoluted tubules appears normal with simple cuboidal microvilli. Podocytes 
appears prominent with parietal layer of squamous cells and regularly arranged 
bowmans capsule. No signs of tubular degeneration, glomerular degeneration and 
calcification / calculus were observed in both male and female rats belongs to 
control and drug treated groups. Histopathology findings were represented in 
Figure 45- 48. 
Uterus 
Appearance of myometrium, endometrium and perimetrium was normal 
with widen lumen was observed in female rats treated with low, mid and high 
dose of SKP. Presence of uterine gland appears normal with no signs of cellular 
degeneration. Histopathology findings were represented in Figure 49- 52. 
63 
 
Ovary 
Primordial follicular appears normal with emerging oocytes was observed 
in control and drug treated female rats. Well prominent primary follicles with 
layered oocytes and primary follicules were observed in female rats treated with 
low, mid and high dose of SKP. Histopathology findings were represented in 
Figure 51- 52. 
Testes 
Arrangement of seminiferous tubules was normal with no signs of 
testicular degeneration. Various phases of sperm maturation includes primary and 
secondary spermatocytes with early and late spermatids was clearly observed in 
male rats belongs to control and drug treated groups. Histopathology findings 
were represented in Figure 53- 54. 
6.22.Effect of SKP on clinical signs of female and male rats in Sub-chronic 
oral toxicity study. 
Clinical signs with respect to lacrimation, salivation, appearance 
,convulsion, skin Color, diarrhea, touch response, mortality and general Behavior 
were observed for the period of 90 days in both male and female rats treated with 
SKP at the dose of 100,200 and 400 mg/kg in which there is no significant 
measurable toxicity were encountered at C.N.S,A.N.S and C.V.S level. The 
results were tabulated in Table 21.  
6.23.Effect of SKP on Body weight of female and male rats in Sub-Chronic 
oral toxicity study.  
The body weight of male and female rats were monitored on weekly basis 
in both control and drug SKP treated group at the dose of 100,200 and 400 mg/kg 
on weekly basis for the period of 90 days in which there is no significant change 
and variation was observed with respect to the body weight of both male and 
female rats when compare to that of the control group. The results were tabulated 
in Table 22 and 23. 
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6.24.Effect of SKP on hematological profile of female and male rats in Sub-
Chronic oral toxicity study.  
The results of the study reveals that there is no statistically significant 
differences with respect to WBC,RBC, Platelet, Hemoglobin, Mean corpuscular 
volume and Mean corpuscular hemoglobin concentration in both male and female 
rats treated with SKP at the dose of 100,200 and 400 mg/kg. The results were 
tabulated in Table 24 and 25. 
 
6.25.Effect of SKP on serum biochemistry profile of female and male rats in 
Sub-Chronic oral toxicity study.  
The results of the study reveals that there is no statistically significant 
differences with respect to blood glucose concentration, lipid profile, blood urea 
concentration, total protein, liver and kidney function biomarkers of male and 
female rats treated with SKP at the dose of 100,200 and 400 mg/kg. The results 
were tabulated in Table 26 and 27. 
6.26.Effect of SKP on Histopathological changes of male and female rat in 
Sub-Chronic oral toxicity study 
At the end of the sub-acute toxicity study all the rats were sacrificed and 
the vital organs were observed for gross pathological changes. The results were 
tabulated in Table 28. Further samples such as Kidney, Heart, Liver, Brain, Lung, 
Spleen, Stomach, Testes, Uterus and Ovary was preserved in 10% formalin saline 
and was subjected to histological findings.  
Brain 
Microscopic observation of brain samples belongs to rats treated with low, 
mid and high dose of test drug SKP shows normal axonal density with no signs of 
apoptosis and neuronal degeneration in both control and drug treated group. 
Morphological arrangement of neurons and their inter neuronal space appears 
regular in neocortex and cerebellar regions of rat. Histopathology findings were 
represented in Figure 55- 58. 
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Heart 
Histological observation of heart shows that the appearance of cardio 
myocytes and Left ventricular cavity was normal in heart sample of both male and 
female rats. 
Bundle of purkinje fibers appears normal with no signs of infarction, 
inflammation, thrombus and extra cellular depositions was observed in in both 
male and female rats belongs to control and drug treated groups. Histopathology 
findings were represented in Figure 59- 62. 
Lung 
Pathological observation lung sample shows well project bronchioles with 
no signs of accumulation and constriction. Regular histology of alveolar duct was 
observed 
Pulmonary artery and lymphoid tissues appears normal with no signs of 
inflammation or migration of immune cells in both male and female rats belongs 
to control and drug treated groups. Bundle of smooth muscles are located in 
between the mucosa and cartilage plates. Histopathology findings were 
represented in Figure 63- 66. 
Stomach 
Microscopic observation rat stomach reveals that the lumen of stomach 
appears normal and arranged with regular interval. Gastric glans, mucosa and sub 
mucosal layers of stomach appears normal and regular with no signs of ulceration 
and infiltrations in both male and female rats belongs to control and drug treated 
groups. Histopathology findings were represented in Figure 67- 70. 
Spleen 
Histopathology of spleen reveals that appearance of normal architecture of 
red and white pulp. Observation of germinal centre, trabecular vein and central 
artery was normal. LF – lymphoid follicle; PALS – periarterial lymphoid sheath 
was normal with no significant signs of inflammation and abnormalities in both 
male and female rats treated with low, mid and high dose of SKP. No signs of 
nodular enlargement and immune cell differentiation were observed in control and 
drug treated groups. Histopathology findings were represented in Figure 71- 74. 
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Liver 
Stained section of liver samples reveals that the portal canal and hepatic 
portal venues appears normal in both male and female rats belong to control and 
drug treated groups. Liver parenchyma appears normal with well-defined lobular 
boundary. Presence of portal vein and hepatic artery was normal and well defined. 
There is no evidence of inflammation ,cirrhosis and lobular degeneration  in both 
male and female rats belongs to control and drug treated groups. Histopathology 
findings were represented in Figure 75- 78. 
Kidney 
Histopathological observation of kidney reveals that regular arrangement 
of medullary ray with prominent glomeruli was observed. Appearance of distal 
tubules, collecting tubules was normal with mono layer of epithelial cells. No 
sings of tubular degeneration, glomerular degeneration and calcification / calculus 
was observed in both male and female rats belongs to control and drug treated 
groups. Renal tubular ,lumen appears normal with no signs of cellular necrosis. 
Histopathology findings were represented in Figure 79- 82. 
Uterus 
Appearance of myometrium, endometrium and perimetrium was normal 
with widen lumen was observed in female rats treated with low, mid and high 
dose of SKP. 
Presence of uterine gland appears normal with no signs of cellular 
degeneration. Histopathology findings were represented in Figure 83- 84. 
Ovary 
Microscopic observation of ovary samples reveals that the primordial 
follicular appears normal with emerging oocytes was observed in control and drug 
treated rats. Well prominent primary follicles with layered oocytes and primary 
follicules were observed in female rats treated with low, mid and high dose of 
SKP. Histopathology findings were represented in Figure 85- 86. 
Testes 
Histological section of testes shows that the appearance of spermatogonia, 
spermatids and primary spermatocytes was normal with surrounded smooth 
muscles. Mature interstitial leydig and sustenticular sertoli cells was observed in 
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male rats treated with low, mid and high dose of SKP. Histopathology findings 
were represented in Figure 87- 88 
 
Table 10 :Effect of SKP on Clinical signs in Acute Toxicity Study 
Clinical Signs  Group I 
(Control) 
Group II 
  (SKP 5 mg/kg) 
Group III 
  (SKP 50 mg/kg) 
Group IV 
(SKP 300 mg/kg) 
Group V 
(SKP 2000 mg/kg) 
Lacrimation 
Absent Absent Absent Absent Absent 
Salivation 
Absent Absent Absent Absent Absent 
Animal appearance Normal Normal Normal Normal Normal 
Convulsion 
Absent Absent Absent Absent Absent 
Skin Color Normal Normal Normal Normal Normal 
Diarrhea 
Absent Absent Absent Absent Absent 
Touch Response Normal Normal Normal Normal Normal 
Mortality Nil Nil Nil Nil Nil 
Behavior Normal Normal Normal Normal Normal 
 
Table  11: Effect of SKP on Body weight of Female rats in Acute Toxicity Study 
Group  Treatment 
Body Weight in gm 
0th Day 7th Day 14th Day 
Group I Normal Control 174.2 ± 4.60 183.4 ± 4.67 194.6 ± 4.29 
Group II 
Treatment with SKP 
5mg/kg 176.5 ± 6.08 183.3 ± 5.53 193.5 ± 6.73 
Group III 
Treatment with SKP 
50mg/kg 172 ± 4.46 179.3 ± 3.87 188 ± 4.12 
Group IV 
Treatment with SKP 300 
mg/kg 178 ± 4.52 186.2 ± 4.48 197.3 ± 4.68 
Group V 
Treatment with SKP 2000 
mg/kg 175.2 ± 1.47 186.7 ± 2.14 198.7 ± 1.49 
• Values are mean ± SEM (n = 6 ) 
•  One way ANOVA followed by Dunnett’s test 
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Table 12: Effect of SKP on gross observation of vital organs of Female rats in Acute 
Toxicity Study 
 
Organ  Group I 
(Control) 
Group II 
  (SKP 5 mg/kg) 
Group III 
  (SKP 50 mg/kg) 
Group IV 
(SKP 300 
mg/kg) 
Group V 
(SKP 2000 
mg/kg) 
Brain 
Normal Normal Normal Normal Normal 
Lung Normal Normal Normal Normal Normal 
Heart Normal Normal Normal Normal Normal 
Liver Normal Normal Normal Normal Normal 
Stomach Normal Normal Normal Normal Normal 
Spleen Normal Normal Normal Normal Normal 
Kidney Normal Normal Normal Normal Normal 
Uterus Normal Normal Normal Normal Normal 
Ovary Normal Normal Normal Normal Normal 
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Table 13: Effect of SKP on Clinical signs of male and female rats in Sub-acute 
Toxicity Study 
Clinical Signs  Group I 
(Control) 
Group II 
(SKP 100 mg/kg) 
Group III 
  (SKP 200 mg/kg) 
Group IV 
(SKP 400 mg/kg) 
Lacrimation 
Absent Absent Absent Absent 
Salivation 
Absent Absent Absent Absent 
Animal appearance Normal Normal Normal Normal 
Convulsion 
Absent Absent Absent Absent 
Skin Color Normal Normal Normal Normal 
Diarrhea 
Absent Absent Absent Very mild 
Touch Response Normal Normal Normal Normal 
Mortality Nil Nil Nil Nil 
Behavior Normal Normal Normal Normal 
 
Table 14: Effect of SKP on Body weight of female rats in Sub-acute Toxicity Study 
 
Group Treatment 
Body Weight in gm 
0th day 1st week 2nd week 3rd week 4th week 
Group I  Normal Control 173.6 ± 1.75 185.2 ± 2.20 196.8 ± 2.90 208.8 ± 3.59 220.7 ± 2.91 
Group II 
Treatment with 
SKP 100 mg/kg 168.6 ± 2.7 178.9 ± 3.72 188.3 ± 2.63 198.8 ± 3.48 214.6 ± 4.83 
Group III 
Treatment with 
SKP 200 mg/kg 173.5 ± 2.03 184.9 ± 2.36 197.3 ± 3.42 209.2 ± 4.44 222.3 ± 3.28 
Group IV 
Treatment with 
SKP 400 mg/kg 174.8 ± 1.77 186.6 ± 1.92 198.4 ± 2.68 210.6 ± 3.79 224.9 ± 2.36 
• Values are mean ± SEM (n = 5 ) 
•  One way ANOVA followed by Dunnett’s test 
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Table 15: Effect of SKP on Body weight of male rats in Sub-acute Toxicity Study 
 
Group Treatment 
Body Weight in gm 
0th day 1st week 2nd week 3rd week 4th week 
Group I 
Normal 
Control 171.6 ± 2.36 183.7 ± 2.99 192.1 ± 2.36 203.1 ± 3.11 220.8 ± 3.38 
Group II 
Treatment with 
SKP 100mg/kg 170.5 ± 2.58 181.2 ± 3.32 190.5 ± 2.5 201.1 ± 3.14 218.2 ± 4.36 
Group III 
Treatment with 
SKP 200mg/kg 172.1 ± 2.01 183.6 ± 2.34 194.9 ± 3.19 205.7 ± 4.16 220.5 ± 2.92 
Group IV 
Treatment with 
SKP 400mg/kg 176.7 ± 1.46 189.1 ± 1.95 199.2 ± 2.27 211.7 ± 3.00 225.7 ± 1.98 
• Values are mean ± SEM (n = 5 ) 
•  One way ANOVA followed by Dunnett’s test 
Table 16: Effect of SKP on Haematology profile of female rats in Sub-acute Toxicity Study 
 
Parameters Group I Group II Group III Group IV 
WBC 
TOTAL 
(109/L) 9.857 ± 0.17 10.97 ± 0.17 11.08 ± 0.25 11.53 ± 0.16 
N (%) 21.97 ± 0.12 26.14 ± 0.25 24.88 ± 0.82 23.39 ± 0.33 
L (%) 72.87 ± 0.29 76.16 ± 0.40 73.48 ± 1.13 73.09 ± 0.70 
E (%) 0.33 ± 0.05 0.36 ± 0.02 0.34 ± 0.01 0.31 ± 0.02 
M (%) 0.61 ± 0.02 0.63 ± 0.02 0.66 ± 0.02 0.65 ± 0.01 
B (%) 0.13 ± 0.01 0.22 ± 0.01 0.24 ± 0.01 0.2 ± 0.01 
RBC (1012/L) 7.06 ± 0.02 7.27 ± 0.17 7.83 ± 0.34 7.74 ± 0.10 
HGB (g/dL) 10.83 ± 0.37 13.22 ± 0.22 12.95 ± 0.19 12.26 ± 0.32 
MCV (fL) 55.74 ± 0.38 56.01 ± 0.71 54.37 ± 0.79 52.35 ± 0.40 
MCHC (g/dL) 
31.78 ± 0.24 34.9 ± 0.36 36.07 ± 0.58 33.37 ± 0.36 
PLT (109/L) 
371.8 ± 1.73 378.5 ± 1.39 372.7 ± 3.34 370.8 ± 4.67 
• Values are mean ± SEM (n = 5 ) 
•  One way ANOVA followed by Dunnett’s test 
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Table 17: Effect of SKP on Haematology profile of male rats in Sub-acute Toxicity Study 
 
Parameters 
Group I 
(Control) 
Group II 
(SKP 100 
mg/kg) 
Group III 
  (SKP 200 
mg/kg) 
Group IV 
(SKP 400 mg/kg) 
WBC 
TOTAL 
(109/L) 9.784 ± 0.08 10.8 ± 0.01 12.51 ± 0.19 10.41 ± 0.26 
N (%) 21.48 ± 0.26 25.78 ± 0.25 23.78 ± 0.65 25.18 ± 0.50 
L (%) 71.28 ± 0.57 76.92 ± 0.36 73.11 ± 0.54 73.12 ± 0.56 
E (%) 0.16 ± 0.01 0.3 ± 0.02 0.45 ± 0.04 0.27 ± 0.01 
M (%) 0.63 ± 0.02 0.61 ± 0.02 0.67 ± 0.02 0.6 ± 0.01 
B (%) 0.15 ± 0.01 0.17 ± 0.01 0.19 ± 0.02 0.2 ± 0.02 
RBC (1012/L) 
5.947 ± 0.04 7.043 ± 0.19 8.677 ± 0.15 7.827 ± 0.20 
HGB (g/dL) 
11.67 ± 0.23 13.85 ± 0.22 14.72 ± 0.09 14.25 ± 0.29 
MCV (fL) 51.33 ± 0.47 55.58 ± 0.36 55.28 ± 0.38 53.19 ± 0.73 
MCHC (g/dL) 
30.75 ± 0.40 35.69 ± 0.28 35.87 ± 0.30 32.78 ± 0.48 
PLT (109/L) 
379.4 ± 4.23 374.1 ± 3.06 370.5 ± 2.79 371.4 ± 3.86 
• Values are mean ± SEM (n = 5 ) 
•  One way ANOVA followed by Dunnett’s test 
 
 
 
 
 
 
 
 
72 
 
Table 18: Effect of SKP on Bio-chemistry profile of female rats in Sub-acute 
Toxicity Study 
 
Parameters 
Group I 
(Control) 
Group II 
(SKP 100 mg/kg) 
Group III 
  (SKP 200 mg/kg) 
Group IV 
(SKP 400 mg/kg) 
B.SUGAR mg/dl 
112.8 ± 0.82 117.2 ± 0.68 121 ± 3.31 121.1 ± 0.74 
B.UREA mg/dl 11.81 ± 0.21 14.69 ± 0.5 14.49 ± 0.44 14.78 ± 0.28 
Sr. CREAT mg/dl 
0.538 ± 0.02 0.688 ± 0.02 0.842 ± 0.02 0.705 ± 0.02 
Sr.CHOL mg/dl 
70.24 ± 0.32 83.18 ± 0.25 87.75 ± 0.58 90.32 ± 0.61 
Sr.TGL mg/dl 41.16 ± 0.33 44.23 ± 0.45 45.95 ± 0.62 43.98 ± 0.33 
SGOT U/L 
151.7 ± 1.23 163.5 ± 1.77 172.4 ± 2.69 166.7 ± 1.74 
SGPT U/L 50.88 ± 0.32 53.89 ± 0.32 58.16 ± 1.02 54.77 ± 0.30 
Sr.ALP U/L 361.5 ± 2.03 364.1 ± 6.31 368.7 ± 7.5 362.8 ± 2.25 
T.Biln mg/dl 0.561 ± 0.02 0.732 ± 0.03 0.784 ± 0.02 0.85 ± 0.02 
Sr.TP g/dl 9.238 ± 0.09 10.3 ± 0.15 7.674 ± 0.18 9.61 ± 0.15  
• Values are mean ± SEM (n = 5 ) 
•  One way ANOVA followed by Dunnett’s test 
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Table 19: Effect of SKP on Bio-chemistry profile of male rats in Sub-acute Toxicity 
Study 
 
Parameters 
Group I 
(Control) 
Group II 
(SKP 100 
mg/kg) 
Group III 
  (SKP 200 
mg/kg) 
Group IV 
(SKP 400 mg/kg) 
B.SUGAR mg/dl 
112.4 ± 0.45 117.3 ± 0.75 116 ± 3.43 122.3 ± 0.42 
B.UREA mg/dl 13.41 ± 0.28 15.14 ± 0.24 16.93 ± 0.37 15.13 ± 0.51 
Sr. CREAT mg/dl 
0.499 ± 0.02 0.653 ± 0.02 0.867± 0.03 0.66 ± 0.02 
Sr.CHOL mg/dl 
71.65 ± 0.89 83.28 ± 0.45 87.11 ± 1.04 90.69 ± 0.23 
Sr.TGL mg/dl 40.8 ± 0.34 44.35 ± 0.25 46.49 ± 0.77 44.53 ± 0.45 
SGOT U/L 150.5 ± 0.88 163.3 ± 0.59 170.1 ± 2.45 165.8 ± 3.58 
SGPT U/L 50.45 ± 0.22 55.66 ± 0.40 59.84 ± 1.21 55.42 ± 0.22 
Sr.ALP U/L 325.4 ± 0.71 406.6 ± 52.07 384.2 ± 2.35 370.6 ± 3.42 
T.Biln mg/dl 0.685 ± 0.01 0.859 ± 0.02 0.801 ± 0.02 0.833 ± 0.04 
Sr.TP g/dl 9.224 ± 0.07 10.27 ± 0.23 8.44 ± 0.10 9.443 ± 0.06 
• Values are mean ± SEM (n = 5 ) 
•  One way ANOVA followed by Dunnett’s test 
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Table 20: Effect of SKP on gross observation of vital organs of Female and male 
rats in Sub-acute Toxicity Study 
Organ  Group I 
(Control) 
Group II 
(SKP 100 
mg/kg) 
Group III 
  (SKP 200 
mg/kg) 
Group IV 
(SKP 400 
mg/kg) 
Brain 
(Male / Female) 
Normal Normal Normal Normal 
Lung 
(Male / Female) 
Normal Normal Normal Normal 
Heart 
(Male / Female) 
Normal Normal Normal Normal 
Liver 
(Male / Female) 
Normal Normal Normal Normal 
Stomach 
(Male / Female) 
Normal Normal Normal Normal 
Spleen 
(Male / Female) 
Normal Normal Normal Normal 
Kidney 
(Male / Female) 
Normal Normal Normal Normal 
Testes 
(Male) 
Normal Normal Normal Normal 
Uterus 
(Female) 
Normal Normal Normal Normal 
Ovary 
(Female) 
Normal Normal Normal Normal 
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Table 21: Effect of SKP on Clinical signs of male and female rats in Sub-Chronic 
Toxicity Study 
Clinical Signs  Group I 
(Control) 
Group II 
(SKP 100 
mg/kg) 
Group III 
  (SKP 200 
mg/kg) 
Group IV 
(SKP 400 
mg/kg) 
Lacrimation 
Absent Absent Absent Absent 
Salivation 
Absent Absent Absent Absent 
Animal appearance Normal Normal Normal Normal 
Convulsion 
Absent Absent Absent Absent 
Skin Color Normal Normal Normal Normal 
Diarrhea 
Absent Absent Absent Very mild 
Touch Response Normal Normal Normal Normal 
Mortality Nil Nil Nil Nil 
Behavior Normal Normal Normal Normal 
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Table  22 
 
Effect of SKP on Body weight of Male rats in Sub-Chronic Toxicity Study 
Group Treatment 
Time in weeks 
0 1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th 
Group I 
Normal 
Control 
162.1 
± 
2.881 
172.1 
± 
2.248 
183.2 
± 
2.525 
192.7 
± 
2.534 
202.2 
± 
2.356 
214.3 
± 
2.305 
225.5 
± 
2.083 
233.3 
± 
1.707 
241 
± 
2.055 
253.9 
± 
2.452 
262 
± 
1.909 
274.7 
± 
1.647 
285.2 
± 
1.737 
299 
± 
1.732 
Group II 
Treatment 
with SKP 
100 mg/kg 
168.4 
± 
4.042 
180.4 
± 
3.715 
189.4 
± 
4.272 
199.1 
± 
4.355 
210.5 
± 
4.498 
221.8 
± 
4.12 
232.8 
± 
3.958 
243.4 
± 
5.54 
254.6 
± 
5.04 
266.7 
± 6.5 
277.5 
± 
5.896 
285.1 
± 
6.594 
296.5 
± 
6.306 
310 
± 
4.752 
Group 
III 
Treatment 
with SKP 
200 mg/kg 
158 ± 
2.319 
169.2 
± 
1.104 
179.2 
± 
2.048 
188.4 
± 
1.875 
197.9 
± 
1.516 
210 
± 
1.422 
222.3 
± 
1.46 
231.3 
± 
1.399 
237.5 
± 
1.327 
250.2 
± 
2.065 
260.3 
± 
1.713 
273.1 
± 
1.251 
284.1 
± 
1.433 
297.9 
± 
1.748 
Group 
IV 
Treatment 
with SKP 
300 mg/kg 
168.3 
± 
3.004 
179.9 
± 
3.132 
188.5 
± 
3.622 
197.2 
± 
3.577 
208.6 
± 
4.151 
219.6 
± 
3.694 
230.4 
± 
3.361 
240.3 
± 
4.405 
249.7 
± 
4.107 
259.8 
± 
5.684 
270.3 
± 
5.315 
276.3 
± 
5.856 
289.4 
± 
5.624 
306.1 
± 
3.845 
 
• Values are mean ± SEM (n = 10 ) 
• One way ANOVA followed by Dunnett’s test 
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Table 23 
 
Effect of SKP on Body weight of Female rats in Sub-Chronic Toxicity Study 
Group Treatment 
Time in weeks 
0 1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th 12th 13th 
Group I 
Normal 
Control 
163.8 
± 
3.741 
177 
± 
3.293 
185.9 
± 
3.665 
195.1 
± 
3.764 
205.9 
± 
3.911 
217.8 
± 
3.639 
229.4 
± 
3.354 
238.3 
± 
4.49 
249.6 
± 
4.167 
260.9 
± 
5.137 
271.6 
± 
4.902 
279.6 
± 
5.156 
290 
± 
5.209 
303 
± 
4.364 
Group 
II 
Treatment 
with SKP 
100 mg/kg 
166.4 
± 
3.953 
178.2 
± 
3.428 
188 
± 
4.131 
196.7 
± 
4.224 
208.1 
± 
4.21 
219.6 
± 
3.888 
230.2 
± 
3.809 
240.4 
± 
5.256 
250.2 
± 
4.781 
261.7 
± 6.3 
271.5 
± 
5.952 
278.9 
± 
6.85 
290.9 
± 
6.276 
306.4 
± 
4.684 
Group 
III 
Treatment 
with SKP 
200 mg/kg 
156.5 
± 
2.072 
168.8 
± 
1.02 
178.1 
± 
1.804 
187.3 
± 
1.764 
196.6 
± 
1.284 
208.8 
± 
1.153 
221.2 
± 
1.306 
230.3 
± 
1.212 
236.6 
± 
1.368 
248.4 
± 
2.093 
259.1 
± 
1.433 
272.3 
± 
1.23 
283.7 
± 
1.521 
297.4 
± 
1.845 
Group 
IV 
Treatment 
with SKP 
300 mg/kg 
170.8 
± 
2.808 
183.1 
± 
2.983 
191.4 
± 
3.331 
200.5 
± 
3.397 
212.6 
± 
3.908 
223.2 
± 
3.499 
233.8 
± 
3.238 
244.7 
± 
4.336 
254.6 
± 
4.298 
266 ± 
5.686 
276.4 
± 
5.365 
282.5 
± 
5.868 
295.6 
± 
5.606 
310.1 
± 
3.822 
 
• Values are mean ± SEM (n = 10 ) 
• One way ANOVA followed by Dunnett’s test 
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Table 24:  Effect of SKP on Haematology profile of female rats in Sub-Chronic 
Toxicity Study 
Parameters 
Group I 
(Control) 
Group II 
(SKP 100 
mg/kg) 
Group III 
  (SKP 200 
mg/kg) 
Group IV 
(SKP 400 mg/kg) 
WBC 
TOTAL 
(109/L) 9.736 ± 0.11 11.21 ± 0.23 11.66 ± 0.11 10.4 ± 0.16 
N (%) 21.82 ± 0.22 26.57 ± 0.45 26.43 ± 0.60 25.51 ± 0.41 
L (%) 72.87 ± 0.29 77.24 ± 0.48 73.9 ± 1.95 77.04 ± 0.39 
E (%) 0.18 ± 0.01 0.4 ± 0.02 0.46 ± 0.04 0.3 ± 0.02 
M (%) 0.45 ± 0.02 0.77 ± 0.015 0.76 ± 0.69 ± 
B (%) 0.12 ± 0.01 0.15 ± 0.01 0.24 ± 0.01 0.2 ± 0.01 
RBC (1012/L) 6.061 ± 0.01 10.97 ± 0.01 9.352 ± 0.21 8.377 ± 0.30 
HGB (g/dL) 11.02 ± 0.3 13.41 ± 0.2 14.46 ± 0.25 15.02 ± 0.15 
MCV (fL) 45.11 ± 0.78 57.24 ± 0.78 57.06 ± 0.61 64.61 ± 0.79 
MCHC (g/dL) 
31.9 ± 0.30 36.68 ± 0.19 37.85 ± 1.35 36.23 ± 0.47 
PLT (109/L) 350.5 ± 4.61 404.7 ± 0.37 391.1 ± 1.94 385.6 ± 0.86 
 
• Values are mean ± SEM (n = 10 ) 
•  One way ANOVA followed by Dunnett’s test 
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Table 25: Effect of SKP on Haematology profile of male rats in Sub-Chronic 
Toxicity Study 
Parameters 
Group I 
(Control) 
Group II 
(SKP 100 
mg/kg) 
Group III 
  (SKP 200 
mg/kg) 
Group IV 
(SKP 400 
mg/kg) 
WBC 
TOTAL 
(109/L) 9.806 ± 0.10 11.25 ± 0.19 10.92 ± 0.19 11.27 ± 0.17 
N (%) 21.88 ± 0.22 25.4 ± 0.26 25.98 ± 0.54 23.78 ± 0.65 
L (%) 70.82 ± 0.37 76.17 ± 0.35 73.16 ± 0.93 76.16 ± 0.40 
E (%) 0.17 ± 0.01 0.28 ± 0.02 0.5 ± 0.03 0.27 ± 0.01 
M (%) 0.38 ± 0.03 0.71 ± 0.03 0.73 ± 0.02 0.76 ± 0.02 
B (%) 0.15 ± 0.01 0.15 ± 0.16 0.19 ± 0.02 0.2 ± 0.02 
RBC (1012/L) 5.932 ± 0.04 7.143 ± 0.15 8.281 ± 0.16 7.193 ± 0.18 
HGB (g/dL) 11.65 ± 0.21 13.61 ± 0.22 14.81 ± 0.25 14.47± 0.41 
MCV (fL) 51.04 ± 0.44 55.17 ± 0.38 55.06 ± 0.86 54.5 ± 1.31 
MCHC (g/dL) 
30.54 ± 0.35 34.81 ± 0.28 35.96 ± 0.7 33.74 ± 0.65 
PLT (109/L) 345.2 ± 7.2 387.2 ± 6.5 371.2 ± 1.8 363.8 ±2.80 
• Values are mean ± SEM (n = 10 ) 
•  One way ANOVA followed by Dunnett’s test 
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Table 26: Effect of SKP on Bio-chemistry profile of female rats in Sub-Chronic 
Toxicity Study 
Parameters 
Group I 
(Control) 
Group II 
(SKP 100 
mg/kg) 
Group III 
  (SKP 200 
mg/kg) 
Group IV 
(SKP 400 
mg/kg) 
B.SUGAR mg/dl 
113.7 ± 0.73 119.7 ± 1.45 115 ± 2.77 121.3 ± 0.60 
B.UREA mg/dl 12.09 ± 0.21 15.02 ± 0.18 17.3 ± 0.31 16.02 ± 0.46 
Sr. CREAT mg/dl 
0.528 ± 0.02 0.789 ± 0.04 0.909 ± 0.01 0.761 ± 0.04 
Sr.CHOL mg/dl 
71.34 ± 0.91 87.66 ± 0.33 91.72 ± 1.37 90.96 ± 0.26 
Sr.TGL mg/dl 40.93 ± 0.33 44.23 ± 0.45 46.65 ± 0.60 45.95 ± 0.62 
SGOT U/L 
150.3 ± 1.60 166.2 ± 0.54 180  ± 1.14 177.9 ± 0.77 
SGPT U/L 50.88 ± 0.32 57.18 ± 0.52 65.09 ± 0.67 56.25 ± 0.38 
Sr.ALP U/L 324.9 ± 1.17 352 ± 4.02 380.1 ± 4.60 380.3 ± 1.71 
T.Biln mg/dl 0.592 ± 0.02 0.914 ± 0.01 0.815 ±0.02 1.084 ± 0.06 
Sr.TP g/dl 9.272 ± 0.09 9.903 ± 0.19 8.084 ± 0.11 9.93  ± 0.21 
 
• Values are mean ± SEM (n = 10 ) 
•  One way ANOVA followed by Dunnett’s test 
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Table 27:  Effect of SKP on Bio-chemistry profile of male rats in Sub-Chronic 
Toxicity Study 
Parameters 
Group I 
(Control) 
Group II 
(SKP 100 
mg/kg) 
Group III 
  (SKP 200 
mg/kg) 
Group IV 
(SKP 400 
mg/kg) 
B.SUGAR mg/dl 
112.3± 0.68 120.9 ± 2.1 119.6 ± 2.63 123.5 ± 0.58 
B.UREA mg/dl 13.34 ± 0.21 14.48 ± 0.5 15.45 ± 0.64 14.45 ± 0.45 
Sr. CREAT mg/dl 
0.499 ± 0.01 0.681 ± 0.02 0.871 ± 0.01 0.616 ± 0.02 
Sr.CHOL mg/dl 
70.35 ± 0.28 85.09 ± 0.45 89.22 ± 1.3 92.58± 0.48 
Sr.TGL mg/dl 40.69 ± 0.31 44.76 ± 0.66 47.09 ± 0.83 46.49 ± 0.77 
SGOT U/L 
151.9 ± 0.62 164.4 ± 0.63 173.9 ± 1.9 168.2 ± 1.23 
SGPT U/L 51.5 ± 0.43 55.12 ± 0.61 60.21 ± 0.96 56.12 ± 0.51 
Sr.ALP U/L 333 ± 3.3 351.7 ± 10.2 382.4 ± 3.9 363.3 ± 2.05 
T.Biln mg/dl 0.659 ± 0.01 0.891 ± 0.01 0.866 ± 0.01 0.945 ± 0.02 
Sr.TP g/dl 
9.2 ± 0.07 
10.75  ± 
0.18 8.183 ± 0.11 9.36 ± 0.08 
• Values are mean ± SEM (n = 10 ) 
•  One way ANOVA followed by Dunnett’s test 
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Table 28: Effect of SKP on gross observation of vital organs of Female and male 
rats in Sub-Chronic Toxicity Study 
Organ  Group I 
(Control) 
Group II 
(SKP 100 
mg/kg) 
Group III 
  (SKP 200 
mg/kg) 
Group IV 
(SKP 400 
mg/kg) 
Brain 
(Male / Female) 
Normal Normal Normal Normal 
Lung 
(Male / Female) 
Normal Normal Normal Normal 
Heart 
(Male / Female) 
Normal Normal Normal Normal 
Liver 
(Male / Female) 
Normal Normal Normal Normal 
Stomach 
(Male / Female) 
Normal Normal Normal Normal 
Spleen 
(Male / Female) 
Normal Normal Normal Normal 
Kidney 
(Male / Female) 
Normal Normal Normal Normal 
Testes (Male) Normal Normal Normal Normal 
Uterus (Female) Normal Normal Normal Normal 
Ovary (Female) Normal Normal Normal Normal 
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Histopathology of Brain (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
            
                   GROUP I             GROUP II 
                            
GROUP III             GROUP IV 
Figure 21: Histopathology of Brain (Female Rat) Low Magnification in Sub- acute 
toxicity  Study  
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Histopathology of Brain (Female Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
 
           
GROUP I            GROUP II 
       
GROUP III             GROUP IV 
Figure 22: Histopathology of Brain (Female Rat) High Magnification in Sub- acute 
toxicity  Study  
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Histopathology of Brain (male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
             
GROUP I            GROUP II 
           
GROUP III            GROUP IV 
 
Figure 23: Histopathology of Brain (Male Rat) Low Magnification in Sub- acute 
toxicity Study  
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Histopathology of Brain (male Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
       
GROUP I            ROUP II 
          
GROUP III            GROUP IV 
 
Figure 24: Histopathology of Brain (Male Rat) High Magnification in Sub- acute 
toxicity Study  
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Histopathology of Heart (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
         
GROUP I                 GROUP II   
         
GROUP III         GROUP IV    
Figure 25: Histopathology of Heart (Female Rat) Low Magnification in Sub- acute 
toxicity Study 
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Histopathology of Heart (Female Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
 
          
GROUP I                 GROUP II   
        
GROUP III        GROUP IV    
Figure 26: Histopathology of Heart (Female Rat) High Magnification in Sub- acute 
toxicity Study 
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Histopathology of Heart (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
              
GROUP I                GROUP II   
               
GROUP III        GROUP IV    
Figure 27: Histopathology of Heart (Male Rat) Low Magnification in Sub- acute 
toxicity Study 
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Histopathology of Heart (Male Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
 
          
GROUP I                 GROUP II   
         
GROUP III         GROUP IV    
Figure 28: Histopathology of Heart (Male Rat) High Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Lung (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
         
GROUP I           GROUP II 
         
GROUP III            GROUP IV 
Figure 29 : Histopathology of Lung (Female Rat) Low Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Lung (Female Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
          
GROUP I            GROUP II 
          
GROUP III            GROUP IV 
Figure 30: Histopathology of Lung (Female Rat) High Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Lung (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
         
GROUP I            GROUP II 
         
GROUP III            GROUP IV 
Figure 31 : Histopathology of Lung (Male Rat) Low Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Lung (Male Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
 
         
GROUP I            GROUP II 
          
GROUP III            GROUP IV 
Figure 32 : Histopathology of Lung (Male Rat) High Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Stomach (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
         
GROUP I                 GROUP II             
         
                   GROUP III       GROUP IV    
Figure 33: Histopathology of Stomach (Female Rat) Low Magnification in Sub- 
acute toxicity  Study 
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Histopathology of Stomach (Female Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
         
GROUP I                 GROUP II             
         
GROUP III         GROUP IV    
Figure 34: Histopathology of Stomach (Female Rat) High Magnification in Sub- 
acute toxicity  Study 
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Histopathology of Stomach (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
         
GROUP I                 GROUP II             
          
GROUP III         GROUP IV    
Figure 35 : Histopathology of Stomach (Male Rat) Low Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Stomach (Male Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
 
          
GROUP I                GROUP II             
         
GROUP III         GROUP IV    
Figure 36: Histopathology of Stomach (Male Rat) High Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Spleen (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
             
GROUP I                 GROUP II             
         
GROUP III         GROUP IV    
Figure 37 : Histopathology of Spleen (Female Rat) Low Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Spleen (Female Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
          
GROUP I                 GROUP II             
          
GROUP III         GROUP IV    
Figure 38: Histopathology of Spleen (Female Rat) High Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Spleen (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
          
GROUP I                 GROUP II             
             
GROUP III         GROUP IV    
Figure 39: Histopathology of Spleen (Male Rat) Low Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Spleen (Male Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
           
GROUP I                 GROUP II             
            
GROUP III         GROUP IV    
Figure 40: Histopathology of Spleen (Male Rat) High Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Liver (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
                
GROUP I                 GROUP II             
              
GROUP III         GROUP IV    
Figure 41: Histopathology of Liver (Female Rat) Low Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Liver (Female Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
 
           
GROUP I                GROUP II             
           
GROUP III         GROUP IV    
Figure 42 : Histopathology of Liver (Female Rat) High Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Liver (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
                  
GROUP I                 GROUP II             
 
             
    GROUP III       GROUP IV    
Figure 43: Histopathology of Liver (Male Rat) Low  Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Liver (Male Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
 
          
 GROUP I                GROUP II             
          
GROUP III         GROUP IV    
Figure 44 : Histopathology of Liver (Male Rat) High Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Kidney (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
  
  
                   GROUP I               GROUP II   
 
   
   GROUP III       GROUP IV    
Figure 45: Histopathology of Kidney (Female Rat) Low Magnification in Sub- acute 
toxicity  Stud       
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Histopathology of Kidney (Female Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
 
 
 
 
 
 
                        
                   GROUP I                     GROUP II             
                       
 
GROUP III       GROUP IV    
    
Figure 46: Histopathology of Kidney (Female Rat) High Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Kidney (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
                
            GROUP I                                           GROUP II   
                 GROUP III       GROUP IV    
 
Figure 47 : Histopathology of Kidney (Male Rat) Low Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Kidney (Male Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
 
 
 
  
  
 
 
 
          GROUP I                              GROUP II             
             
 
GROUP III        GROUP IV 
 
Figure 48: Histopathology of Kidney (Male Rat) High Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Uterus (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
           
            GROUP I                                 GROUP II             
             
GROUP III         GROUP IV    
 
Figure  49: Histopathology of Uterus  (Female Rat) Low Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Uterus (Female Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
         
GROUP I                 GROUP II             
               
GROUP III         GROUP IV    
 
Figure 50: Histopathology of Uterus  (Female Rat) High Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Ovary (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
         
GROUP I                 GROUP II 
         
GROUP III          GROUP IV    
Figure 51 : Histopathology of Ovary (Female Rat) Low Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Ovary (Female Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
            
GROUP I                 GROUP II 
                  
GROUP III         GROUP IV    
Figure 52 : Histopathology of Ovary (Female Rat) High Magnification in Sub- acute 
toxicity  Study 
 
 
115 
 
Histopathology of Testes (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
          
GROUP I            GROUP II 
                
GROUP III            GROUP IV 
Figure 53 : Histopathology of Testes (Male Rat) Low Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Testes (Male Rat) in Sub-acute toxicity Study 
High Power Magnification 40X 
         
GROUP I             GROUP II 
          
GROUP III             GROUP IV 
Figure 54: Histopathology of Testes (Male Rat) High Magnification in Sub- acute 
toxicity  Study 
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Histopathology of Brain (Female Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
 
              
GROUP I                GROUP II             
              
GROUP III                GROUP IV 
Figure  55 : Histopathology of Brain (Female Rat) Low Magnification in Sub-
Chronic toxicity  Study  
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Histopathology of Brain (Female Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
                          
GROUP I               GROUP II             
                  
  
GROUP III        GROUP IV    
Figure 56: Histopathology of Brain (Female Rat) High Magnification in Sub-
Chronic toxicity  Study  
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Histopathology of Brain (Male Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
          
GROUP I                 GROUP II             
         
    
 GROUP III        GROUP IV    
Figure 57 : Histopathology of Brain (Male Rat) Low Magnification in Sub-Chronic 
toxicity  Study  
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Histopathology of Brain (Male Rat) in Sub-Chronic toxicity Study 
High  Power Magnification 40X 
            
           GROUP I                GROUP II             
            
 
 GROUP III         GROUP IV    
Figure 58 : Histopathology of Brain (Male Rat) High Magnification in Sub-Chronic 
toxicity  Study  
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Histopathology of Heart (Female Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
 
          
GROUP I                 GROUP II   
         
GROUP III        GROUP IV    
Figure 59 : Histopathology of Heart (Female Rat) Low Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Heart (Female Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
          
GROUP I                GROUP II   
          
GROUP III        GROUP IV    
Figure 60: Histopathology of Heart (Female Rat) High Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Heart (Male Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
 
            
GROUP I                GROUP II   
            
GROUP III        GROUP IV    
Figure 61: Histopathology of Heart (Male Rat) Low Magnification in Sub-Chronic 
toxicity  Study 
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Histopathology of Heart (Male Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
        
GROUP I                GROUP II   
     
GROUP III        GROUP IV    
Figure 62 : Histopathology of Heart (Male Rat) High Magnification in Sub-Chronic 
toxicity  Study 
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Histopathology of Lung (Female Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
 
         
GROUP I            GROUP II 
         
GROUP III            GROUP IV 
 
Figure 63 : Histopathology of Lung (Female Rat) Low Magnification in Sub-
Chronic toxicity  Study 
126 
 
Histopathology of Lung (Female Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
 
         
GROUP I            GROUP II 
         
GROUP III            GROUP IV 
 
Figure 64 : Histopathology of Lung (Female Rat) High Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Lung (Male Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
 
          
GROUP I            GROUP II 
          
GROUP III            GROUP IV 
Figure 65: Histopathology of Lung (Male Rat) Low Magnification in Sub-Chronic 
toxicity  Study 
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Histopathology of Lung (Male Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
 
         
GROUP I            GROUP II 
         
GROUP III            GROUP IV 
Figure 66 : Histopathology of Lung (Male Rat) High Magnification in Sub-Chronic 
toxicity  Study 
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Histopathology of Stomach (Female Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
        
GROUP I                GROUP II             
 
         
GROUP III         GROUP IV    
Figure 67: Histopathology of Stomach (Female Rat) Low Magnification in Sub-
Chronic toxicity  Study 
 
130 
 
Histopathology of Stomach (Female Rat) in Sub-Chronic toxicity Study  
High Power Magnification 10X 
          
GROUP I                 GROUP II             
 
  
        
GROUP III         GROUP IV    
 
Figure 68: Histopathology of Stomach (Female Rat) High Magnification in Sub-
Chronic toxicity  Study 
 
131 
 
Histopathology of Stomach (Male Rat) in Sub-Chronic toxicity Study  
Low Power Magnification 10X 
 
         
GROUP I                 GROUP II             
          
GROUP III         GROUP IV    
Figure 69: Histopathology of Stomach (Male Rat) Low Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Stomach (Male Rat) in Sub-Chronic toxicity Study 
High Power Magnification 10X 
         
GROUP I                GROUP II             
         
GROUP III        GROUP IV    
Figure 70: Histopathology of Stomach (Male Rat) High Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Spleen (Female Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
          
GROUP I                 GROUP II             
         
GROUP III         GROUP IV    
 
Figure 71 : Histopathology of Spleen (Female Rat) Low Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Spleen (Female Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
          
GROUP I                 GROUP II             
           
GROUP III         GROUP IV    
 
Figure 72 : Histopathology of Spleen (Female Rat) High Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Spleen (Male Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
           
GROUP I                 GROUP II             
           
GROUP III         GROUP IV    
 
Figure 73: Histopathology of Spleen (Male Rat) Low Magnification in Sub-Chronic 
toxicity  Study 
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Histopathology of Spleen (Male Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
           
GROUP I                 GROUP II             
       
GROUP III         GROUP IV    
 
Figure 74 : Histopathology of Spleen (Male Rat) High Magnification in Sub-Chronic 
toxicity  Study 
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Histopathology of Liver (Female Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
 
                   
GROUP I                GROUP II             
          
GROUP III         GROUP IV    
Figure 75: Histopathology of Liver (Female Rat) Low Magnification in Sub-Chronic 
toxicity  Study 
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Histopathology of Liver (Female Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
           
            GROUP I                     GROUP II             
           
            GROUP III              GROUP IV    
Figure 76 : Histopathology of Liver (Female Rat) High Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Liver (Male Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
 
          
 GROUP I                GROUP II             
            
GROUP III         GROUP IV    
 
Figure 77 : Histopathology of Liver (Male Rat) Low  Magnification in Sub-Chronic 
toxicity  Study 
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Histopathology of Liver (Male Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
 
            
GROUP I                GROUP II   
               
GROUP III        GROUP IV    
 
Figure  78: Histopathology of Liver (Male Rat) High Magnification in Sub-Chronic 
toxicity  Study 
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Histopathology of Kidney (Female Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
 
         
GROUP I                 GROUP II               
         
GROUP III         GROUP IV    
 
Figure 79 : Histopathology of Kidney (Female Rat) Low Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Kidney (Female Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
 
         
GROUP I                 GROUP II               
          
GROUP III         GROUP IV    
Figure 80 : Histopathology of Kidney (Female Rat) High Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Kidney (Male Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
         
GROUP I                 GROUP II               
        
GROUP III       GROUP IV    
 
Figure 81: Histopathology of Kidney (Male Rat) Low Magnification in Sub-Chronic 
toxicity  Study 
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Histopathology of Kidney (Male Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
         
GROUP I                 GROUP II               
         
GROUP III         GROUP IV    
 
Figure 82: Histopathology of Kidney (Male Rat) High Magnification in Sub-Chronic 
toxicity  Study 
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Histopathology of Uterus (Female Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
  
GROUP I                 GROUP II             
             
GROUP III         GROUP IV    
 
Figure 83: Histopathology of Uterus  (Female Rat) Low Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Uterus (Female Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
              
GROUP I               GROUP II 
                 
     GROUP III         GROUP IV    
 
Figure 84: Histopathology of Uterus  (Female Rat) High Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Ovary (Female Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
         
GROUP I                 GROUP II 
        
           GROUP III             GROUP IV    
 
Figure 85: Histopathology of Ovary (Female Rat) Low Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Ovary (Female Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
 
          
        GROUP I                      GROUP II 
         
           GROUP III          GROUP IV    
Figure 86 : Histopathology of Ovary (Female Rat) High Magnification in Sub-
Chronic toxicity  Study 
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Histopathology of Testes (Male Rat) in Sub-Chronic toxicity Study 
Low Power Magnification 10X 
              
GROUP I            GROUP II 
            
GROUP III             GROUP IV 
Figure 87 : Histopathology of Testes (Male Rat) Low Magnification in Sub-Chronic 
toxicity  Study 
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Histopathology of Testes (Male Rat) in Sub-Chronic toxicity Study 
High Power Magnification 40X 
                
GROUP I             GROUP II 
               
GROUP III             GROUP IV 
Figure 88 : Histopathology of Testes (Male Rat) High Magnification in Sub-Chronic 
toxicity  Study 
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6.27.Effect of Seenakara Parpam on Urine volume output on Day 0, 14th and 28th 
Day in Ethylene glycol induced urolithiasis in rats 
Data’s obtained from the 24 hrs urine samples collected on 0th, 14th and 28th day 
shown that there is a significant decrease in the urine volume excretion in disease control 
(lithiatic) control group treated with (0.75%) ethylene glycol for 28 consecutive days. 
Whereas treatment with SKP at the dose of 100mg/kg, 200mg/kg, 300mg/kg to group 3 
to 5 and cystone 500mg/kg to group 6 shown significant (P<0.01) increase in urine 
volume rate on 14th and 28th day of the study period. The results are shown in the table no 
29. 
6.28.Effect of Seenakara Parpam on Urinary Parameters on Day 14th and 28th Day in 
Ethylene glycol induced urolithiasis in rats 
The result of 24hrs urine collection on 14th and 28th day shows that there is a marginal 
(P < 0.001) increase in the level of oxalate in the animals belongs to group II treated with 
(0.75%) ethylene glycol alone. Treatment with SKP at the dose of 100mg/kg, 200mg/kg, 
300mg/kg to group 3 to 5 and cystone 500mg/kg to group 6 shown significant (P<0.01) 
reduction in the level of oxalate excretion in animals belongs to treatment group. The results 
are shown in the table no 30 and 31. 
The urinary calcium excretion was 5.70±0.52mg/dl/24hr and 7.10±0.72mg/dl/24hr on day 
14th& 28th respectively of control group rats .It increased significantly to 25.15± 
1.94mg/dl/24hr and 21.55± 1.50mg/dl/24hr (P < 0.01) on day 14th and 28th day in animals 
belongs to group II. 
The level of calcium excretion was significantly reduced in animals treated treatment 
with SKP at a dose of 100, 200 and 300mg/kg and cystone herbal tablet at a dose of 
500mg/kg (Group III to VI). The results are shown in the table no: 30 and 31. 
Urinary phosphate, protein, uric acid and creatinine excretion rate were gradually 
increased in group II animals on the 14th& 28th day. However treatment with SKP and 
standard drug cystone to group III to VI shown considerable decrease in the level of 
phosphate, protein, uric acid and creatinine in the urine sample collected for analysis. 
Magnesium excretion rate of control group animals was estimated as 4.25±0.50 mg/dl/24hr, 
4.22±0.48 mg/dl/24hr on 14th& 28th day. Treatment with ethylene glycol to group II animals 
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shows gradual decrease in magnesium level to 1.05±0.12 mg/dl/24hr on 14th day and 1.85± 
0.51 mg/dl/24hr on 28th day. Treatment with SKP and cystone shows significant increase in 
magnesium level of 2.55±0.25 mg/dl/24hr, 2.05±0.37mg/dl/24hr in group III , 
2.80±0.35mg/dl/24hr,3.96± 0.55 mg/dl/24hr in group IV, 2.60± 0.40 mg/dl/24hr, 3.65± 0.50 
mg/dl/24hr in group V, 3.30±0.60 mg/dl/24hr, 3.52±0.50 mg/dl/24hr on group VI (P< 0.01) 
respectively on 14th day & 28th day. The results are shown in the table no: 30 and 31. 
 6.29.Effect of SeenakaraParpam on Serum Parameters on 28 days treatment of 
Ethylene glycol induced urolithiasis in rats 
The result obtained from the study shows that the calcium, uric acid, creatinine, 
oxalate, phosphate levels were increased significantly in lithiatic control groups. Treatment 
with SKP at the dose of 100,200 and 300mg/kg to group III to V and cystone 500mg/kg to 
group VI shown significant decrease in the level of calcium, uric acid, creatinine, oxalate and 
phosphate. On contrary the magnesium levels were decreased significantly in lithiatic control 
animals. After treatment with SKP at a dose of 100mg/kg, 200mg/kg and 300mg/kg to group 
III to V and cystone at the dose of 500mg/kg to group VI restored the magnesium level near 
to normal level. The results were tabulated in table no 32. 
6.30.Effect of Seenakara Parpam on Urine volume, Calcium and Calculi weight in 
zinc disc implantation induced urolithiasis model 
It was observed that there was a significant decrease in urine volume of rats belongs 
to zinc disc im ‬planted group (1.5±0.1ml) when compared with that of the normal control 
(2.6±0.2ml). Treatment with SKP at both the dose shown significant increase in urine 
volume of about 2.3ml in 200mg/kg treated group and 2.4ml in 400mg/kg treated group. It 
was also observed that group administered with standard drug cystone 500mg/kg shows 
urine volume of (2.5±0.2ml). Group administered with SKP showed dose reliant increase in 
urine output. The results were tabulated in table no 33. 
Urolithiatic animal group showed increase urinary calcium excretion of about 
(23.8±4.6mg/dL). Treatment with SKP at both the dose level had shown significant decrease 
in calcium excretion of about 11.6±3.1mg/dl in 200mg/kg treated group and 10.2±2.5mg/dl 
in 400mg/kg treated rats. Similar type of results was observed in standard drug cystone 
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500mg/kg treated group (12.3±3.9mg/dl). Rats treated with SKP showed dose dependent 
increase in urine output. The results were tabulated in table no 33. 
 At the end of the study all the experimental animals were sacrificed with excess 
dose of pentobarbitone and the zinc discs was removed for calculating the average weight 
of each disc. The average weight of zinc discs along with the deposited crystals in disc 
embedded group was found to be 113.55±7.90mg. Group that received Cystone 500 
mg/kg, showed significant reduction in the depositions hence there was significant 
difference in the bladder weight content as compared to zinc disc embedded group (𝑃𝑃< 
0.001). Similarly, the rats treated with 200 and 400mg/kg of test drug SKP has showed 
reduced formation of depositions around the zinc disc (𝑃𝑃< 0.001) and the corresponding 
results were tabulated in Table 34. 
The X-ray radiographic images of rats revealed presence of aggregates around the 
embedded zinc disc. Treatment with SKP at both the dose level and Cystone at dose of 
500mg/kg reveals significantly decrease in the formation of such deposits. These 
observations were confirmed in actual weights of the bladder contents. As shown in 
Figure 95 (A-E). 
Results tabulated in table 35 clearly reflects that the total urine volume collected 
over 24 hrs period of all the experimental animals in which the volume of urine excreted 
by SKP treated animals is significantly higher than the control rats.  Results obtained 
from the natriuretic evaluation study of SKP depicts that the rate of sodium ion excretion 
in SKP treated animals is much significant when compare to that of the control rats. 
Furosemide treated group shown significant increase in both sodium and potassium 
excretion. The results were tabulated in table no 36. 
The results clearly shows that the Seenakara Parpam at doses of 100, 200 and 300 
mg/kg produced significant dose dependent increase in urinary excretion and urinary 
sodium when compare to that of the control and standard drug administered rats.  
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Table 29: Effect of SKP on 0th, 14th and 28th day of urinary output in Ethylene glycol 
induced urolithiasis in rats 
Days Urinary output ( in units/ml) by various group 
GP1 GP2 GP3 GP4 GP5 GP6 
0 7.60± 
0.40 
7.45± 
0.42 a 
7.80± 
0.70b 
7.55± 
0.75 b 
8.50± 
0.95 
8.25± 
0.90 
14 7.80± 
0.60 
6.90± 
0.35 a** 
8.35± 
0.90 b** 
9.05± 
1.30 b** 
10.30± 
1.50 b ** 
11.25± 
1.60 b ** 
28 8.30± 
0.70 
6.30± 
0.25 a** 
8.60± 
1.20 b** 
10.20± 
1.35 b** 
11.50± 
1.65 b ** 
11.90± 
1.75 b ** 
• Values are expressed as mean ± S.E.M. (n=6), comparisons were made between: a- 
Group I vs. Group II, b- Group II vs Group III, IV, V and VI. 
• Symbols represent statistical significance: **p<0.01. ONE WAY ANOVA Followed 
by Newman keul’s multiple test. 
 
 
 
Figure 89: Effect of SKP on 0th, 14th and 28th day of urinary output in Ethylene 
glycol induced urolithiasis in rats 
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Table 30: Effect of SKP on Urinary Biochemical Parameters on 14th Day of 
Induction in Ethylene glycol induced urolithiasis in rats 
• Values are expressed as mean ± S.E.M. (n=6), comparisons were made between: a- 
Group I vs. Group II, b- Group II vs Group III, IV, V and VI. 
• Symbols represent statistical significance: **p<0.01. ONE WAY ANOVA Followed 
by Newman keul’s multiple test. 
 
 
 
 
 
 
 
 
 
Figure 90: Effect of SKP on Urinary Biochemical Parameters on 14th Day of 
Induction in Ethylene glycol induced urolithiasis in rats 
Group 
Protein 
(mg/dl) 
Magnesium 
(mg/dl) 
Calcium 
(mg/dl) 
Uric acid 
(mg/dl) 
Creatinine 
(mg/dl) 
Oxalate 
(mg/dl) 
Phosphate 
(mg/dl) 
GP1 
70.90± 
2.90 
4.25± 
0.50 
5.70± 
0.52 
8.22± 
0.65 
0.84± 
0.10 
17.80± 
1.43 
35.90± 
2.80 
GP2 
155.20 ± 
5.25 a ** 
1.05 ± 
0.12 a ** 
25.15± 
1.94 a ** 
16.56 ± 
1.62 a ** 
1.59 ± 
0.12 a ** 
30.65 ± 
3.12 a ** 
76.60 ± 
4.26 a ** 
GP3 
88.30 ± 
3.90  b ** 
2.55 ± 
0.25 b ** 
19.45 ± 
2.10 b ** 
10.56 ± 
0.94 b ** 
0.98 ± 
0.09 b ** 
24.22 ± 
2.46 b ** 
45.55 ± 
3.73 b ** 
GP4 
83.70 ± 
3.60 b ** 
2.80 ± 
0.35 b ** 
13.90 ± 
0.82 b ** 
12.20 ± 
0.85 b ** 
0.89 ± 
0.11 b ** 
22.30 ± 
2.29 b ** 
40.80 ± 
3.15 b ** 
GP5 
85.50± 
3.65 b ** 
2.60 ± 
0.40 b ** 
15.75 ± 
0.63 b ** 
9.90 ± 
0.80 b ** 
0.87 ± 
0.09 b ** 
23.10 ± 
1.89 b ** 
36.30 ± 
2.28 b ** 
GP6 
80.25± 
2.95 b ** 
3.30 ± 
0.60 b ** 
17.75 ± 
0.45 b ** 
8.90 ± 
0.80 b ** 
0.81 ± 
0.10 b ** 
20.20 ± 
1.90 b ** 
35.30 ± 
2.28 b ** 
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Table 31: Effect of SKP on Urinary Biochemical Parameters on 28th Day of 
Induction in Ethylene glycol induced urolithiasis in rats 
Group 
Protein 
(mg/dl) 
Magnesium 
(mg/dl) 
Calcium 
(mg/dl) 
Uric acid 
(mg/dl) 
Creatinine 
(mg/dl) 
Oxalate 
(mg/dl) 
Phosphate 
(mg/dl) 
GP1 
74.90 
±3.86 
4.22 
±0.48 
7.10 
±0.72 
3.40 
±0.52 
0.90 
±0.28 
18.40 
±1.40 
31.50 
±2.44 
GP2 
163.40 
±8.30 a ** 
1.85 
±0.51 a ** 
21.55 
±1.50 a ** 
13.520 
±1.42 a ** 
1.56 
±0.54 a ** 
50.30 
±4.55 a ** 
80.56 
±4.76 a ** 
GP3 
90.15 
±5.58 b ** 
2.05 
±0.37 b ** 
14.55 
±0.55 b ** 
8.50 
±0.56 b ** 
1.12 
±0.15 b ** 
26.58 
±2.60 b ** 
47.72 
±3.34 b * 
GP4 
87.46 
±5.36 b ** 
3.96 
±0.55 b ** 
12.46 
±0.70 b ** 
8.25 
±0.16 b ** 
1.24 
±0.50 b ** 
23.50 
±2.50 b ** 
44.45 
±3.16 b ** 
GP5 
83.22 
±4.55 b ** 
3.65 
±0.5 b ** 
11.75 
±0.45 b ** 
7.95± 
0.50 b ** 
1.55 
±0.00 b ** 
21.22 
±2.09 b ** 
41.10 
±2.70 b ** 
GP6 
84.55 
±4.87 b ** 
3.52 
±0.50 b * 
11.15 
±0.05 b ** 
7.12± 
0.30 b ** 
1.24 
±0.50 b ** 
20.72 
±2.10 b ** 
40.70 
±2.20 b ** 
•   Values are expressed as mean ± S.E.M. (n=6), comparisons were made between: a- 
Group I vs. Group II, b- Group II vs Group III, IV,V and VI. 
• Symbols represent statistical significance: **p<0.01. ONE WAY ANOVA Followed 
by Newman keul’s multiple test. 
 
Figure 91: Effect of SKP on Urinary Biochemical Parameters on 28th Day of 
Induction in Ethylene glycol induced urolithiasis in rats 
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Table 32 :Effect of SKP on Serum Parameters on 28th Day in Ethylene glycol 
induced urolithiasis in rats 
Group 
Magnesium 
(mg/dl) 
Calcium 
(mg/dl) 
Uric acid 
(mg/dl) 
Creatinine 
(mg/dl) 
Oxalate 
(mg/dl) 
Phosphate 
(mg/dl) 
GP1 
4.90 
±0.56 
10.50 
±1.52 
3.25 
±0.20 
0.46 
±0.23 
6.5 
±0.67 
12.86 
±1.53 
GP2 
1.98 
±0.45 a ** 
17.40 
±2.44 a ** 
9.72 
±1.20 a ** 
1.21 
±0.53 a ** 
13.50 
±1.65 a ** 
29.21 
±3.45 a ** 
GP3 
3.78 
±0.56b** 
12.75 
±1.78 b ** 
4.25 
±0.52 b ** 
0.68 
±0.99 b ** 
9.48 
±0.88 b ** 
24.10 
±2.85 b ** 
GP4 
3.97 
±0.22 b ** 
12.82 
±1.50 b * 
4.10 
±0.40 b ** 
0.73 
±0.01 b ** 
8.82 
±1.78 b ** 
22.85 
±2.75 b ** 
GP5 
3.86 
±0.55 b ** 
11.08 
±1.42 b ** 
3.76 
±0.42 b ** 
0.59 
±0.05 b ** 
8.85 
±0.75 b ** 
18.23 
±1.55 b ** 
GP6 
4.10 
±0.55 b ** 
10.01 
±1.42 b ** 
3.01 
±0.42 b ** 
0.52 
±0.05 b ** 
7.04 
±0.15 b ** 
17.23 
±1.75 b ** 
• Values are expressed as mean ± S.E.M. (n=6), comparisons were made between: a- 
Group I vs. Group II, b- Group II vs Group III, IV,V and VI. 
Symbols represent statistical significance: **p<0.01. ONE WAY ANOVA Followed by 
Newman keul’s multiple test. 
• Newman keul’s multiple test. 
 
 
 
 
 
Figure 92: Effect of SKP on Serum Parameters on 28th Day in Ethylene glycol 
induced urolithiasis in rats 
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Table 33: Effect of Seenakara Parpam on Urine volume and Calcium level in zinc 
disc implantation induced urolithiasis model 
Group Urine output (mL) Urinary calcium output 
(mg/dL) 
GP1 2.6 ± 0.2 - 
GP2 2.2 ± 0.1 10.4 ± 2.5 
GP3 1.5 ± 0.1a* 23.8 ± 4.6 a 
GP4 2.5 ± 0.2 b* 12.3 ± 3.9 b ** 
GP5 2.3 ± 0.2 b* 11.6 ± 3.1 b ** 
GP6 2.4 ± 0.2 b* 10.2 ± 2.5 b ** 
 
• Values are expressed as mean ± S.E.M. (n=6), comparisons were made between: a- 
Group II vs. Group III, b- Group III vs Group IV,V and VI. 
• Symbols represent statistical significance: *p<0.05, ONE WAY ANOVA Followed 
by Newman keul’s multiple test. 
 
Figure 93: Effect of Seenakara Parpam on Urine volume and Calcium level in zinc 
disc implantation induced urolithiasis model 
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Table 34:  Effect of Seenakara Parpam on Calculi weight in zinc disc implantation 
induced urolithiasis model 
Group Weight of calculi (mg) 
GP1 - 
GP2 - 
GP3 113.55 ± 7.90a*** 
GP4 6.90 ± 1.95 b*** 
GP5 11.6 ± 2.35 b *** 
GP6 10.5± 1.93 b *** 
 
• Values are expressed as mean ± S.E.M. (n=6), comparisons were made between: a- 
Group II vs. Group III, b- Group III vs Group IV,V and VI. 
• Symbols represent statistical significance: ***p<0.001. ONE WAY ANOVA 
Followed by Newman keul’s multiple test. 
 
 
 
Figure 94: Effect of Seenakara Parpam on Calculi weight in zinc disc implantation 
induced urolithiasis model 
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Figure 95 Shows the results of effects of Seenakara Parpam on zinc disc 
implantation model of urolithiasis. 
       
A. Sham operated group      B. Disease control group  
 
      
          C. Zinc disc + Cystone 500 mg/kg                         D. Zinc disc + SKP 200 mg/kg 
 
 
E. Zinc disc + SKP 400 mg/kg 
Figure 95: X-ray of image of rats in zinc disc implantation model of urolithiasis. (a) 
Sham operated (b) Zinc disc implanted, (c) Cystone treated, (d) SKP 200mg/kg, (e) 
SKP 400mg/kg. 
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Table no 35:  Diuretic activity of Seenakara Parpam in 24 hr urine volume 
collection study 
Group Treatment Urine Volume 
In (ml) 
I Palm jaggery in purified water 
10ml/kg 
7.90±0.60a 
II Furosemide 20mg/kg 13.60±0.90b** 
III Seenakara Parpam 100mg/kg 11.05±0.72 b ** 
IV Seenakara Parpam 200mg/kg 12.20±0.80 b ** 
V Seenakara Parpam 300mg/kg 13.10±0.82 b ** 
 
• Values are expressed as mean ± S.E.M. (n=6), comparisons were made between: a- 
Group I vs. Group II, b- Group II vs Group III, IV and V. 
• Symbols represent statistical significance: *p<0.05, **p<0.01, ***p<0.001. ONE 
WAY ANOVA Followed by Newman keul’s multiple test. 
 
Figure 96: Diuretic activity of Seenakara Parpam in 24 hr urine volume collection 
study 
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Table 36: Natriuretic activity of Seenakara Parpam on Rats 
Group Treatment Na+ (mM) K+ (mM) Na+/K+ 
I Palm jaggery in purified 
water 10ml/kg 
1.70±0.08a 0.68±0.02a 2.50 
II Frusemide 20mg/kg 3.20±0.22 b ** 0.85±0.04 b ** 3.76 
III Seenakara Parpam 100mg/kg 1.95±0.10 b * 0.70±0.01ns 2.79 
IV Seenakara Parpam 200mg/kg 2.20±0.20 b ** 0.68±0.02ns 3.24 
V Seenakara Parpam 300mg/kg 2.05±0.15 b ** 0.69±0.02ns 2.97 
 
• Values are expressed as mean ± S.E.M. (n=6), comparisons were made between: a- 
Group I vs. Group II, b- Group II vs Group III, IV and V. 
• Symbols represent statistical significance: *p<0.05, **p<0.01, NS - not significant. 
ONE WAY ANOVA Followed by Newman keul’s multiple test. 
 
 
 
 
Figure 97: Natriuretic activity of Seenakara Parpam on Rats 
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7. DISCUSSION 
7.1. Standardization and Characterization  
Physiochemical Evaluation of Seenakara parpam 
Efficacy of the formulation always depends on the genuinity of the raw drug used 
in formulating the drug. Suprious drug or adultrated raw materials not only decreases the 
potency bu also causes some undesirable toxic effect in humans as well as in anaimls. 
AYUSH made a standard potocol on specification of most of the raw materialsused in 
siddha system of medicine. As per this code of ethics drug prepared as per the prescribed 
standard methods render its fulle efficay against particular disease 84. In the present 
investigation analysis of raw material shows that all the raw materials used in preparation 
are geninune and was retains its quality with the prescribed standard.  
Ash values are generally a good indicator for establishing the nature of minerals 
present in a particular formulation. Total ash value, water soluble and acid insoluble ash 
values. Loss on drying value denotes the moisture content of the formulation. pH of the 
formulation has a very critical role in absorption and bioavailability of the particular 
formulation. The results obtained from the physicochemical evaluation of the sample 
SKP 1, 2 and 3 revels that the total ash value of SKP was found to 87.23 to 94.12%. 
Correspondingly the acid insoluble ash value was found to be 9.42 to 11.27 % and water 
soluble ash value of SKP was fond to be 68.38 to 78.16% w/w respectively. The loss on 
drying value of SKP at 105°C was found to be 4.16 % to 4.85% w/w. pH of the SKP was 
found to be 4.40 to 4.81. 
Prevalence of heavy metals in siddha preparations has been documented by 
several researchers. Heavy metal accumulation in biological system impairs the function 
of vital metabolic organs mainly kidney and liver 85. 
Atomic absorption spectroscopy Analysis of Seenakara parpam 
Other than these heavy metals are known for causing inflammatory disorders in 
brain, heart, liver and kidney. Recent evidence also suggests that heavy metal renders 
allergic and immunogenic response to the animals and humans. Polluted soil becomes the 
ultimate source of leaching heavy metals in to the raw materials and also to the finished 
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product. Thus it becomes a part of the quality regulatory process that formulation should 
pass the limit test for heavy metals and proves the content of elements should be within 
the permissible limit 86. The results of heavy metal analysis by AAS technique reveals 
that the heavy metals such as lead and mercury present in the formulations are within the 
WHO prescribed limit. 
Microbial load Analysis of Seenakara parpam 
Apart from food and water now a days drugs also become a potential source of 
infection to the humans. The frequent contaminants reported are E-Coli and streptococcus 
as these organisms are responsible for causing wide range of infections starting from 
urinary tract infection, pulmonary edema, gastro enteritis, meningitis and other life 
threatening infection in consumers 87. The results of microbial analysis of all three 
samples of SKP shows that the product is of high sterile and no evidence for the presence 
of the following pathogens such as enterobacter, E-coli, salmonella and staphylococcus 
species. Further the total bacterial and fungal count of SKP is within the prescribed limit. 
 
Fourier Transform – Infra Red Spectroscopy analysis of Seenakara parpam 
FT-IR holds greater importance as it accounts for elaborating the detail on 
significance of functional group to the researchers. The presence of organic compound, 
inorganic and their core structural activity with respect to the functional group shall be 
identified with FT-IR spectral analysis. In the presence of electromagnetic radiation each 
electron undergo spin-spin coupling and it emerges in the form of stretching and bending 
vibrations 88. IR spectrum of all the three samples of SKP belongs to various batches 
showing sharp intense peak at 1116 cm-1 corresponds to C-N stretching. Similarly 
another sharp peak was observed in the region of 3480 – 3451 cm-1 shows the presence of 
usual O-H bending. 
Peak emerging in the region of 618 cm-1 corresponds to C- H deformation and 
presence of less intense peak in the range of 679 - 662 cm-1 corresponds to N-H wagging 
Peaks emerging in the range of 1635- 1641 cm-1 shows the C=C variations. FT-IR results 
of all three samples of SKP having more or less closely similar results. From the data of 
165 
 
the FT-IR analysis it was confirmed that all the three samples of SKP did not varying 
much with respect to its functional group. 
SEM/EDX analysis of Seenakara parpam 
SEM analysis provided evidence based data on the structural morphology of the 
nano particle with in the formulation. Further the average particle size distribution of the 
drug renders information on the biological significance of the nano particles present with 
in the drug 89. The results of SEM analysis of samples SKP1,2 and 3 illustrates that the 
sample SKP1 reveals the presence of nanoparticle in the size range of 42.1 to 92.4 nm, 
similarly the sample SKP2 with particle size distribution ranges from 82.3nm to 128.9 
nm. Sample SKP3 has nano particle in the size range of 93.4nm to 184.7 nm. Overall 
observation clarifies that the lowest size of nano particle found in analysis is 42.1 and the 
highest will be 184.7 nm. Recent days nano particles have rich biological application in 
the treatment of cancer, neuronal inflammation and metabolic disorder like diabetes 90. 
Results of SEM analysis clearly reflects all three samples of SKP has uniform 
distribution of nano particles with average nano size range .The presence of smallest nano 
particle with in the formulation could definitely attributes to the wider biological action 
against stipulated disease target. 
EDX works behind the principle of electron collision. Each ion has a unique 
tendency of reflecting the high energy electrons. The characteristic spectrum obtained by 
the migration of electrons from the outer most shell and its valence score depicts the 
individuality of the EDX analysis 91. Weight percentage of carbon present in the range of 
26.65 to 36.08 % with respect to the outermost cell K shell excitation. Oxygen with 
percentage range of 27.03 to 50.03 and aluminium with 5.40 to 8.18%. Similarly sulphur 
with 10.44 to 13.33 % and potassium with 18.28 to 26.91 % .From the result of EDX 
analysis it was observed that SKP 1,2 and 3 has no much variations with respect to the 
atomic and weight percentage . 
XRD spectral Analysis of Seenakara parpam 
X-ray diffraction analysis provides greater information on mineral content of the 
formulation, system generated signals on diffraction peak fraction corresponds to the 
concentration of the minerals correlated good justification for quantification of mineral 
content 92. X-ray diffraction (XRD) patterns are obtaining for Nanoparticles with 
different precursor of aluminum, potassium nitrite and lime stone. All the diffraction 
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peaks were found to be polycrystalline in nature of nanoparicle with planes (222), (101), 
(511), (440), (103), (200), (114), (211) and (116) respectively. The XDR peaks are 
indexed into diffraction pattern of one cubic and tetragonal structure, observed with 
JCPDS cord no. 01-1156 and 65-267. The XRD spectrum illustrated that the diffraction 
peaks are slight shift to the higher direction was detected at different concentrations of 
precursor. Hence it indicates that the as-deposited thin films are well crystalline nature at 
different value of composite. From the favorite (103) reflection peaks are estimated full 
width at half maximum (FWHM) values of the nanoparticle. The XRD spectrum 
illustrated that the diffraction peaks are slight shift to the higher direction was detected at 
different concentrations of precursor. Hence it indicates that the as-deposited thin films 
are well crystalline nature at different value of composite. 
7.2. In-vitro Evaluation of Seenakara parpam 
In-vitro Antioxidant Evaluation of Seenakara parpam 
Various techniques are available for screening the antioxidant potential of a drug 
candidate these includes, nitric oxide, DPPH ,hydrogen peroxide radical scavenging 
assay etc. These assay methods simulate the condition of oxidative stress by generation of 
active radical species. Being an unstable molecule radical tries to quench the nearby 
molecule and get one electron to become stabilize. Drug act as an antioxidant by effective 
scavenging of those generated radicals 93. 
Results of in-vitro anti-oxidant assay study clearly shows that the test drug SKP 
shown potential anti-oxidant property in all the tested in-vitro assay such as DPPH,NO 
and H2O2 radical scavenging assay this shows the oxidative stress blocking tendency of 
the study drug SKP. 
 
In vitro struvite crystal growth inhibition of Seenakara parpam  
It is a well-known fact that most of the cases kidney stone are identified as 
Struvitestaghorn calculi, this account for 10-20% of all renal stone 94. Ability of a drug to 
act as anti-urolithiatic agents is now better identified by the results of the in-vitro struvite 
crystal growth assay. Crystals are allowed to grow in controlled medium and the ability 
of the drug that inhibit the growth and progression of crystal was identified. 
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The result obtained from In vitro struvite crystal growth inhibition assay clearly 
reflects that SKP added medium shows significantly less number of crystal when 
compare to that of the control system. The average weight of crystals belongs to SKP 
added medium seems to be less when compare to that of the control medium. 
7.3. Toxicity profiling of Seenakara parpam  
Toxicity studies provides an evidence based data’s on the kinetic and dynamic 
aspect of the test drug. In the present investigation test drug Seenakara parpam was 
subjected to short term, mid and long term toxicity studies in rodents as per the OECD 
guideline. The individual components of the drug SKP such as alum, potassium nitrate 
and quick lime is not reported with known toxicity as per the literature evidence but the 
combined synergistic activity has to be investigated as per the AYUSH guidelines. 
Most of the drug which acts as an allergen will bring immune modulatory 
response in living biological system this could emerge as toxicity in the form of allergic 
syndrome mediated by histamine and pro-inflammatory cytokines release. Further release 
of histamine could aggravate the bronchoconstriction leads to inflammatory responses. 
Finding of such toxic response in rodents was characterized by increased mucous 
secretion, respiratory distress and change in hematological values. Treatment with SKP 
even at the highest dose of 2000mg/kg has no such evidence in treated animals. Results 
of sub-acute and sub-chronic toxicity studies reveals that there is no statistically 
significant differences with respect to WBC,RBC, Platelet, Hemoglobin, Mean 
corpuscular volume and Mean corpuscular hemoglobin concentration in both male and 
female rats treated with SKP at the dose of 100,200 and 400 mg/kg. 
Neurotoxic potential of the drug was calibrated by the invivo psycho motor 
behavioral changes on the treated animals. C.N.S toxicity manifested as convulsion, 
depression, anxiety, sedation, body posture, muscle integrity etc. A.N.S toxicity 
manifested in the form of increased purgation, dizziness, lacrimation, salivation etc. 
Cardio vascular toxicity primarily manifested by irregular rhythm, cardiac dysfunction, 
circulatory collapse etc. The results obtained from the acute, sub-acute and sub-chronic 
toxicity studies reveals that there is no significant measurable toxicity were encountered 
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at C.N.S,A.N.S and C.V.S activity of the treated rats when compare to that of the control 
group animals. 
Body weight of the animal is an important indicator in the toxicity studies on 
rodents which reflects the internal health of the drug exposed animals. Health animals 
will gain weight on weekly basis as it could have normal habit of food and water intake. 
Drug induced factors such as depression, stress, ulceration, pain, inflammation, psycho 
behavioral abnormalities will all tend to affect the normal food intake and in turn 
fluctuates the average body weight of the group 95.  
The results of acute, sub-acute and sub-chronic toxicity studies reveals that  there 
is no significant change was observed in body weight of both male and female rats 
treated with SKP at the dose of 5 to 2000mg/kg.b.w in acute and 100,200 and 400 mg/kg 
in long term toxicity studies. This denotes that the drug SKP is safe for long term 
administration in rodents. 
The core hematological data on toxicity studies provides valuable information 
such as hemolytic property, inflammation, immune response, infection, bone marrow 
function etc. As per the recommendation it is mandatory to screen WBC,RBC, Platelet, 
Hemoglobin, MCV and MCHC values of the rodents exposed to long term repeated dose 
studies 96. 
Inflammation and infection is manifested by increased population of neutrophils. 
High eosinophil’s count reflects allergic condition such as eosinophilia, Further 
hemolysis of drug attributes low RBC. Impaired bone marrow function leads to low level 
of hemoglobin. Platelet count indicates the signs of tissue repair and healing. Result of 
hematological profiling of male and female rats subjected to sub-acute and sub-chronic 
toxicity study reveals that there is no statistically significant differences with respect to 
WBC,RBC, Platelet, Hemoglobin, Mean corpuscular volume and Mean corpuscular 
hemoglobin concentration. This evident showcase the hemo compatibility property and 
safety profile of the test drug SKP 
Biomarkers  plays a prominent role in the toxicological and pharmacological 
research of new drug entity. The efficiency of each organ was calculated by the 
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metabolite clearance rate ie. Function of kidney was estimated by creatinine clearance 
rats. Physiology of  liver by SGOT and SGPT level. Urea is major nitrogenous end 
product of protein and amino acid catabolism, produced by liver and distributed 
throughout intracellular and extracellular fluid. The index of kidney function also 
determined by the level of blood urea. Inflammatory liver disease tend to rise the serum 
markers SGOT,SGPT levels. Toxic effect of the drug on liver will be monitored by these 
former enzymes. Injury to liver hepatocytes also disturbs the lipid metabolism 97,98. 
Clinical histopathology findings are sometimes useful in elucidating the 
mechanism of toxic responses observed in animals and their extrapolation to humans 99. 
Clinical biochemical investigation of sub-acute and sub-chronic toxicity studies reveals 
that there are no statistically significant differences with respect to blood glucose 
concentration, lipid profile, blood urea concentration, total protein, liver and kidney 
function biomarkers of male and female rats treated with SKP at the dose of 100,200 and 
400 mg/kg. 
Histopathological analysis of vital organs becomes mandatory in evaluation of 
organo toxic potential of the study drug. The evaluation of histopathological changes in 
organs remains a cornerstone in safety assessment of medicines 100,101.  
Gross necropsy observation of vital organs such as Kidney, Heart, Liver, Brain, 
Lung, Spleen, Stomach, Testes, Uterus and Ovary reveals that treatment with SKP has no 
significant organ toxicity in both male and female rats subjected for the toxicity study. 
Light microscopic observation brain shows regular arrangement of neurons and heart 
shows the presence of normal myocardium, further histology of liver projects prominent 
hepatocytes and spleen with normal lymphoid follicles. Pathological observation lung 
sample shows well project bronchioles with no signs of accumulation and constriction. 
Stained section of kidney shows well differentiated tubules with distinct glomeruli and 
stomach reveals the layered arrangement of mucosa and sub-mucosal layers. Histology of 
uterus reveals arrangement of peri, endo and myometrium. Pathological observation of 
ovary projects well prominent primary follicles with layered oocytes. Testicular histology 
shows the presence of various phases of sperm maturation includes primary  
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7.4. Pharmacological Screening of Seenakara Parpam  
Effect of Seenakara Parpam on Ethylene glycol induced urolithiasis in rats 
It was estimated that 1 in 1000 was affected with urinary stone, the most 
important consequences in this clinical condition is reoccurrence. Demography reflects 
that rate of reoccurrence will be 14% at 1 year, 35% at 5 years, and 52% at 10 years. 
Some factors that contributes to urolithiasis includes acidic urines, increased excretion of 
calcium oxalate, recurrent infection, increased intake of dietary proteins 102. 
Research suggested that high level of urinary calcium forms bonding with 
available oxalate and phosphorus and this step favors the formation and aggregation of 
calcium oxalate crystals103. Stone formation in ethylene glycol-fed animals is caused by 
hyperoxaluria, which causes increased renal retention and excretion of oxalate 104. 
Data’s obtained from the 24 hrs urine samples collection on the selective on 0th, 
14th and 28th day shown that treatment with SKP at the dose of 100mg/kg, 200mg/kg, 
300mg/kg to group 3 to 5 and cystone 500mg/kg to group 6 shown significant (P<0.01) 
increase in urine volume. Data’s of urine biochemistry profile on 28th day of SKP treated 
rats shown that there was a significant decrease in urine calcium, oxalate, uric acid, 
creatinine and phosphate level when compare to that of lithiatic control rats. Similarly 
there was significant decrease in urine magnesium level was observed in treated rats. 
Urolithiasis is now becomes the third most predominant disorder of the excretory 
system that is approximately 2–3% of general population. Urinary stone, if not properly 
treated, may cause serious medical concerns such as extreme obstruction, inflammation 
and swollen kidney, infection, and hemorrhage in the urinary tract 105.  Present medical 
treatment available for clinical management of calculi includes surgery, ultrasound 
assisted lithotripsy and laser mediated calculus disruption to remove the calculi. 
However, these procedures are associated with the risk of acute renal injury leading to 
decrease in renal function 106.  
Effect of Seenakara Parpam on zinc disc implantation induced urolithiasis model 
The results of zinc implantation study shown that urolithiatic animals showed 
increase urinary calcium excretion of about (23.8 ± 4.6 mg/dL). Treatment with SKP at 
both 200 and 400 mg/kg dose had shown significant decrease in calcium excretion of 
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about 11.6 ± 3.1 mg/dl in 200mg/kg treated group and 10.2 ± 2.5 mg/dl in 400mg/kg 
treated rats. Similar type of results were observed in standard drug cystone 500 mg/kg 
treated group (12.3 ± 3.9 mg/dl). Rats treated with SKP showed dose dependent increase 
in urine output. The average weight of zinc discs along with the deposited crystals in the 
only disc implanted group without any treatment was found to be 113.55 ± 7.90 mg. 
Group that received Cystone 500 mg/kg, showed significant reduction in the depositions 
hence there was significant difference in the weight of bladder content as compared to 
zinc disc implanted group (𝑃𝑃< 0.001). Similarly, the rats treated with SKP 200 and 
400mg/kg showed reduced formation of depositions around the zinc disc (𝑃𝑃< 0.001) 
Diuretic activity of Seenakara Parpam 
Diuretic agents play a remarkable role in the management of urolithiasis. These 
agents’ acts by increasing the urine excretion along with biologically important sodium 
and potassium ions and aids in maintains these ions concentration. Clinical use of diuretic 
are recommended for management of various life threatening conditions 107.  
Currently available diuretic has several adverse effects such as increase tissue 
oxidative stress, electrolyte imbalance and metabolic disorders etc. The use of alternate 
therapy for the clinical management of urolithiasis found useful in treating patients with 
less or no side effects. One such noble formulation is Seenakara Parpam with potential 
diuretic property 108. 
Urinary retention was found to be most common problem for the patients with 
urolithiasis like metabolic disorders further the retention volume presumes increased 
sodium level in blood may lead to profuse hypertension and other cardiovascular 
disorders. Hence the formulation used for therapeutic treatment of urolithiasis found 
grateful if it also serves as diuretic agent. The results of the present investigation clearly 
emphasizes that SKP was a potent diuretics and render significant natriuretic effect in the 
treated rats. SKP at the dose of 100, 200 and 300 mg/kg exhibited dose dependent 
increase in urine excretion when compare with that of the standard drug Fursemide 
20mg/kg. Hence results of the study clearly reflects that formulation SKP has extended 
versatile pharmacological action as it acts on multiple mechanism of reducing crystal 
growth ,increasing the urine volume , promotes sodium excretion, reduce calculi weight, 
maintains calcium homeostasis. 
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7.5.Siddha basis of trial drug therapy 
 Kalladaippu or urolithiathis is a result of increased vatham and pitham humours 
leading to dehydration and in turn crystallization of mineral stones along the urinary tract. 
 The siddha line of treatment for urolithiasis aims at mitigating the increased 
vatham and pitham. This is achieved by means of vediuppu as an ingredient (salt petre) in 
the formulation which is having salty taste, diuretic and cooling properties 109. Padigaram 
(alum) another ingredient has astringent taste. By virtue of their above properties, root 
causes of kalladaippu disease are removed and therefore the disease itself. 
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8. SUMMARY AND CONCLUSION 
The present investigation was carried out to evaluate the safety and efficacy of the 
siddha formulation Seenakara parpam in the management of Kalladaippu noi 
(Urolithiasis) by suitable in-vitro and in-vivo experimental models. 
• Physiochemical evaluation of SKP proves the standard and genuinity of the 
prepared formulations.  
• Presence of biologically active functional groups like C-N, N-H and O-H renders 
promising efficacy to the drugs against urolithiasis. Further AAS analysis of 
sample shown that the presences of heavy metals are very low and below the 
prescribed limit. 
• Uniform distribution of nano particles may enhance the bio-availability and 
therapeutic property of the formulation. 
• Characteristic pattern of diffraction peaks observed at XRD analysis reveals the 
presence of polycrystalline nano particle with unique planes. 
• Standardization and analytical evaluation studies shows that the formulation SKP 
is of high standard and has good stable nano particles with active functional 
groups and devoid of toxic trace metals. Hence forth the biological activity of the 
drug may also be due to the presence of bio-active nano particle and other 
significant functional group present with in the formulation. 
• In-vitro DPPH, NO and H2O2 analysis exhibits that SKP has potential anti-
oxidant property against the free radicals. 
• In vitro struvite crystal growth inhibition assay clearly reflects that SKP added 
medium shows significantly less number of crystal when compare to that of the 
control system. The average weight of crystals belongs to SKP added medium 
seems to be less when compare to that of the control medium. SKP has tendency 
to halt the growth and progression of crystal growth and hence it may serves as a 
better therapeutic drug for the clinical management of metabolic disorder like 
urolithiasis. 
174 
 
• The acute toxicity study results have revealed that the drug SKP was safe at the 
maximum dose level of 2000mg/kg which was higher than the normal therapeutic 
dose of the drug. 
• The results of sub-acute and sub- chronic toxicity studies shows that long term 
administration of SKP at the dose level of 200 and 400 mg/kg was absolutely safe 
and has no evidence of adverse or toxic effect in any of the animals subjected to 
the study. Results of clinical biochemistry, Hematology and histopathological 
findings support the evidence of safety of the drug SKP in rodents upon long term 
administration. 
• The results of anti-urolithiatic activity by Ethylene glycol method revealed that 
the drug SKP at the dose of 100, 200 and 300 mg/kg has significantly increased 
the urine volume and also lowers the level of calcium, excretion in treated 
animals. Further there was a considerable decrease in the level of phosphate, 
protein, uric acid and creatinine in the urine sample.  
• The anti-urolithiatic evaluation by zinc implantation method revealed that the 
drug SKP at the dose level of 200 and 400 mg/kg was effective both in preventive 
and curative aspects. The drug significantly reduced the stone size and X-ray 
findings too revealed the same. 
• The anti-urolithiatic activity SKP are more convincing and promising when 
compare to that of the standard cystone in both ethylene glycol and Zinc 
implantation models.  
• The drug SKP at the dose of 100,200 and 300 mg/kg has significantly increased 
the urine output and excretion of urinary sodium and had no effect on the urinary 
potassium excretion. This proves the diuretic potential of the formulation. 
 
Conclusion 
 
In conclusion the siddha formulation Seenakara Parpam belongs to indian system       
of traditional medicines showed potential anti-oxidant, anti-urolithiatic and 
diuretic activity in the experimental animals. Hence this study provides evidence 
based results on the use of Seenakara Parpam for clinical management of kidney 
stone related metabolic disorders in humans.  
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9. RECOMMENDATIONS 
 
• The drug Seenakara parpam (SKP) should be subjected to clinical trial to validate 
the efficacy of the drug for the clinical management of urolithiasis in human. 
• The drug is also recommended to be validated for its preventive effects and also 
as a supportive therapy to other conventional medical expulsive therapies. 
• The pharmacological activity by which the drug is helpful in the management of 
urolithiasis was successfully validated in the present investigation. Hence in 
further the pharmacokinetic and pharmacodynamics studies has to be carried out 
to detail the mechanism of action of the drug. 
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Urinary calculi are the third prevalent disorder of the urinary system. Approximately 
80% of these calculi are composed of calcium oxalate and calcium phosphate. In 
India, urolithiasis constitutes one of the commonest afflictions requiring surgical 
intervention and by conservative estimates there are about 5–7 million patients 
suffering from urinary calculus disease in India. It is not only the higher prevalent 
disease condition which requires early attention, but rather the more problematic 
disorder with, higher rate of recurrence after surgical removal. The main aim of the 
present study is to investigate the anti-urolithiatic activity of Seenakaraparpam (SKP) 
on ethylene glycol-induced urolithiasis in wistar albino rats. All the experimental 
animals except normal control received ethylene glycol (0.75%) in drinking water for 
a period of 28 days for induction of urolithiasis. Rat belongs to treatment group co-
administered with SKP at the dose of 100,200 and 300 mg/kg b.wt, p.o from 1st to 28st 
day, Animals belongs to standard group received cystone 500 mg/kg, p.o. Parameters 
such as volume and urinary biochemical parameters were measured after 14 & 28 
days, Blood was collected on the 28st day for biochemical estimation. Treatment with 
SKP significantly reduced the excretion of oxalate and Ca and phosphate, protein, 
uric acid and creatinine in compared to lithiatic control group.The results of the study 
also shows that serum parameters such as calcium, uric acid, creatinine, oxalate, 
phosphate levels were increased significantly in animals belongs to lithiatic control. 
Treatment with SKP at the dose of 100, 200 and 300mg/kg and standard drug cystone 
at the dose of 500 mg/kg shown significant decrease in serum calcium, uric acid, 
creatinine, oxalate, phosphate levels. The level of magnesium was restored near to 
normal in treatment group animals. In conclusion formulations like SKP may be 
considered as a potential lead for the clinical management of urolithiasis 
 
 
Introduction  
Urinary stone disease has afflicted humankind since antiquity and can persist, with serious medical consequences, 
throughout a patient’s lifetime. In addition, the incidence of kidney stones has been increased in western societies in 
the last five decades, in association with economic development. Most calculi in the urinary system arise from a 
common component of urine, e.g. calcium oxalate (CaOx), representing up to 80% of analyzed stones [1].Currently, 
open renal surgery for nephrolithiasis is unusual and used only rarely since the introduction of extracorporeal 
shockwave lithotripsy (ESWL), which has revolutionized urological practice and almost become the standard 
procedure for eliminating kidney stones. However, in addition to the traumatic effects of shock waves, persistent 
residual stone fragments and the possibility of infection, suggest that ESWL may cause acute renal injury, a decrease 
in renal function and an increase in stone recurrence [2,3].  
 
Kidney stone formation is a complex process and it results as a cascade of events, including crystal nucleation, 
growth and aggregation, crystal retention within the renal tubules [4]. Usually kidney stones are yellow or brown 
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color with a smooth or gagged structure. Some common type of kidney stones are calcium oxalate, calcium 
phosphate, struvite, uric acid and cysteine, among of which calcium stones are the most common form of kidney 
stones in both humans and rats [5]. Urolithiasis, also called calculi or uroliths, is a condition which involves the 
process of stone formation in the kidney. Renal stones are a universal cause of blood in the urine and pain in the 
abdomen, with a reported incidence about 12% in the general population [6] 
 
A number of vegetable drugs have been used in India and elsewhere which claim efficient cure of urinary stones [7]. 
In the indigenous system of medicine, the SeenakaraParpam (SKP) is reported to be useful in the treatment of 
urinary stones. However, so far no systematic study has been reported with respect to the anti-urolithiatic property of 
SKP. Hence the main aim of the present study is to evaluate the anti-urolithiatic property of SKP using ethylene 
glycol induced hyperoxaluria model in rats 
 
Materials and methods 
Evaluation of Anti-urolithiatic activity by Ethylene glycol induced urolithiasis in rats 
 
Animals 
Healthy adult albino wistar rats weighing between 200-220 g were used for the study. The animals were housed in 
poly propylene cages and were kept in well ventilated with 100 % fresh air by air conditioning. A 12h light/dark 
cycle was maintained. Room temperature was maintained between 22+2º C and relative humidity 40–65%. They 
were provided with food and water ad libitum. All the animals were acclimatized to the laboratory about 7 days 
prior to experimentation 
 
Experimental Protocol  
Ethylene glycol induced hyperoxaluria method was used to assess the anti-urolithiatic activity in albino wistar rats. 
Animals were divided into 6 groups of 6 animals each. All the experimental animals except normal control received 
ethylene glycol (0.75%) in drinking water for a period of 28 days and a single dose of sodium oxalate injection (35 
mg/kg ,i.p) on 14th day for induction of urolithiasis. Rat belongs to treatment group co-administered with SP at the 
dose of 100,200 and 300 mg/kg b.wt, p.o from 1st to 28st day, Animals belongs to standard group received cystone 
500 mg/kg, p.o. 
 
Grouping 
Group I: Control group rats received normal saline  
Group II: Administered with ethylene glycol (0.75%) + Sodium oxalate injection (35mg/kg ,i.p) 
Group III: Administered with ethylene glycol and treated with SKP at 100 mg/kg, p.o 
Group IV: Administered with ethylene glycol and treated with SKP at 200 mg/kg, p.o 
Group V: Administered with ethylene glycol and treated with SKP at 300 mg/kg, p.o 
Group VI: Administered with ethylene glycol and treated with cystone 500 mg/kg, p.o 
24 hour urine samples will be collected on 14th and 24thday by housing rats at individual metabolic cages using 
sodium azide as preservative .Parameters such as volume, specific gravity and pH of the urine will be noted 
immediately after urine sample collection and stored at -80o C, for further electrolyte estimation. Blood will be 
collected from retro-orbital plexus of each rat, on day 28 and subjected to electrolytes estimation. 
 
Collection and analysis of urine 
All animals were kept in individual metabolic cages and 24 h urine samples were collected on 14th, and 28th day of 
calculi induction treatment. The volume and calcium content of urine were measured. Calcium in urine was 
estimated using kit by “COBAS MIRA PLUS” auto analyzer. Urine was analyzed for oxalate [8], magnesium [9], 
phosphate [10], uric acid [11], citrate [12] and total protein [13]. 
 
Serum analysis 
The blood was collected from the retro-orbital sinus under anesthetic condition and serum was separated by 
centrifugation at 10,000g for 10 min and analyzed for creatinine and uric acid. The creatinine kit (Reckon 
Diagnostics Pvt. Ltd., India) and uric acid diagnostic kit (Span Diagnostics Ltd., India) were used to estimate serum 
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creatinine and uric acid levels respectively. Estimation of calcium, oxalate, inorganic phosphorus and magnesium 
carried out using standard methods. 
 
Statistical analysis 
The results were expressed as mean ± standard error mean (SEM). The statistical significance was assessed using 
one-way analysis of variance (ANOVA) followed by Newmannkeul’s multiple range tests and p < 0.05 was 
considered significant. 
 
Results  
Effect of SeenakaraParpam on Urine volume output on Day 0, 14 and 28th Day 
The result of 24hrs urine collection on 0th, 14th and 28th day shows that there is a significant decrease in the urine 
volume excretion in lithiatic control group treated with ethylene glycol. Treatment with SKP at the dose of 
100mg/kg, 200mg/kg, 300mg/kg to group 3 to 5 and cystone 500mg/kg to group 6 shown significant (P<0.01) 
increase in urine volume rate on 14th and 28th day of the study period.  
 
Table 1: Effect of SKP on urinary output in urolithiasis induced rats. 
Days GP1 GP2 GP3 GP4 GP5 GP6 
0 7.60± 
0.40 
7.45± 
0.42 
7.80± 
0.70 
7.55± 
0.75 
8.50± 
0.95 
8.25± 
0.90 
14 7.80± 
0.60 
6.90± 
0.35** 
8.35± 
0.90** 
9.05± 
1.30** 
10.30± 
1.50** 
11.25± 
1.60** 
28 8.30± 
0.70 
6.30± 
0.25** 
8.60± 
1.20** 
10.20± 
1.35** 
11.50± 
1.65** 
11.90± 
1.75** 
 
 Values are expressed as mean ± SEM 
 Values were found out by using ONE WAY ANOVA Followed by Newman keul’s multiple 
range tests. 
 
Effect of SeenakaraParpam on Urinary Parameters on Day 14th and 28th Day  
The result of 24hrs urine collection on 14th& 28th day shows that there is a significant (P < 0.001) increase in the level of 
oxalate in the animals belongs to group II treated with ethylene glycol alone. Treatment with SKP at the dose of 
100mg/kg, 200mg/kg, 300mg/kg to group 3 to 5 and cystone 500mg/kg to group 6 shown significant (P<0.01) reduction 
in the level of oxalate excretion in animals belongs to treatment group. The results are shown in the table no 2 and 3. 
 
Table 2 :Effect of SKP on Urinary Biochemical Parameters on 14th Day of Induction 
GP 
Protein 
(mg/dl) 
Magnesium 
(mg/dl) 
Calcium 
(mg/dl) 
Uric acid 
(mg/dl) 
Creatinine 
(mg/dl) 
Oxalate 
(mg/dl) 
Phosphate 
(mg/dl) 
GP1 
70.90± 
2.90 
4.25± 
0.50 
5.70± 
0.52 
8.22± 
0.65 
0.84± 
0.10 
17.80± 
1.43 
35.90± 
2.80 
GP2 
155.20 ± 
5.25** 
1.05 ± 
0.12** 
25.15± 
1.94** 
16.56 ± 
1.62** 
1.59 ± 
0.12** 
30.65 ± 
3.12** 
76.60 ± 
4.26** 
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 Values are expressed as mean ± SEM 
 Values were found out by using ONE WAY ANOVA Followed by Newman keul’s multiple range tests. 
 
Table 3 : Effect of SKP on Urinary Biochemical Parameters on 28th Day of Induction 
GP 
Protein 
(mg/dl) 
Magnesium 
(mg/dl) 
Calcium 
(mg/dl) 
Uric acid 
(mg/dl) 
Creatinine 
(mg/dl) 
Oxalate 
(mg/dl) 
Phosphate 
(mg/dl) 
GP1 
74.90 
±3.86 
4.22 
±0.48 
7.10 
±0.72 
3.40 
±0.52 
0.90 
±0.28 
18.40 
±1.40 
31.50 
±2.44 
GP2 
163.40 
±8.30**(a) 
1.85 
±0.51**(a) 
21.55 
±1.50**(a) 
13.50 
±1.42**(a) 
1.56 
±0.54**(a) 
50.30 
±4.55**(a) 
80.56 
±4.76**(a) 
GP3 
90.15 
±5.58**(b) 
2.05 
±0.37**(b) 
14.55 
±0.55**(b) 
8.50 
±0.56**(b) 
1.12 
±0.15**(b) 
26.58 
±2.60**(b) 
47.72 
±3.34**(b) 
GP4 
87.46 
±5.36**(b) 
3.96 
±0.55**(b) 
12.46 
±0.70**(b) 
8.25 
±0.16**(b) 
1.24 
±0.50**(b) 
23.50 
±2.50**(b) 
44.45 
±3.16**(b) 
GP5 
83.22 
±4.55**(b) 
3.65 
±0.5**(b) 
11.75 
±0.45**(b) 
7.95± 
0.50**(b) 
1.55 
±0.00**(b) 
21.22 
±2.09**(b) 
41.10 
±2.70**(b) 
GP6 
84.55 
±4.87**(b) 
3.52 
±0.50*(b) 
11.15 
±0.05**(b) 
7.12± 
0.30**(b) 
1.24 
±0.50**(b) 
20.72 
±2.10**(b) 
40.70 
±2.20**(b) 
 
 Values are expressed as mean ± SEM 
 Values were found out by using ONE WAY ANOVA Followed by Newman keul’s multiple range tests. 
The urinary calcium excretion was 5.70±0.52mg/dl/24hr and 7.10±0.72mg/dl/24hr on day 14 th& 28th respectively of 
control group rats .It increased significantly to 25.15± 1.94mg/dl/24hr and 21.55± 1.50mg/dl/24hr (P < 0.01) on day 14 th 
and 28th day in animals belongs to group II. 
 
The level of calcium excretion was significantly reduced in animals treated treatment with SKP at a dose of 100 200 and 
300mg/kg and cystone herbal tablet at a dose of 500mg/kg (Group III to VI). The results are shown in the table no: 2 and 
3. 
 
Urinary phosphate, protein, uric acid and creatinine excretion rate were gradually increased in group II animals on the 
14th& 28th day. However treatment with SKP and standard drug cystone to group III to VI shown considerable decrease 
in the level of phosphate, protein, uric acid and creatinine in the urine sample collected for analysis. 
 
Magnesium excretion rate of control group animals was estimated as 4.25±0.50 mg/dl/24hr, 4.22±0.48 mg/dl/24hr on 
14th& 28th day. Treatment with ethylene glycol to group II animals shows gradual decrease in magnesium level to 
1.05±0.12 mg/dl/24hr on 14th day and 1.85± 0.51 mg/dl/24hr on 28th day. Treatment with SKP and cystone shows 
GP3 
88.30 ± 
3.90 ** 
2.55 ± 
0.25** 
19.45 ± 
2.10** 
10.56 ± 
0.94** 
0.98 ± 
0.09** 
24.22 ± 
2.46** 
45.55 ± 
3.73** 
GP4 
83.70 ± 
3.60** 
2.80 ± 
0.35** 
13.90 ± 
0.82** 
12.20 ± 
0.85** 
0.89 ± 
0.11** 
22.30 ± 
2.29** 
40.80 ± 
3.15** 
GP5 
85.50± 
3.65** 
2.60 ± 
0.40** 
15.75 ± 
0.63** 
9.90 ± 
0.80** 
0.87 ± 
0.09** 
23.10 ± 
1.89** 
36.30 ± 
2.28** 
GP6 
80.25± 
2.95** 
3.30 ± 
0.60** 
17.75 ± 
0.45** 
8.90 ± 
0.80** 
0.81 ± 
0.10** 
20.20 ± 
1.90** 
35.30 ± 
2.28** 
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significant increase in magnesium level of 2.55±0.25 mg/dl/24hr, 2.05±0.37mg/dl/24hr in group III , 
2.80±0.35mg/dl/24hr,3.96± 0.55 mg/dl/24hr in group IV, 2.60± 0.40 mg/dl/24hr, 3.65± 0.50 mg/dl/24hr in group V, 
3.30±0.60 mg/dl/24hr, 3.52±0.50 mg/dl/24hr on group VI (P< 0.01) respectively on 14 th day & 28th day. 
 
Effect of SeenakaraParpam on Serum Parameters on 28 days treatment. 
The result obtained from the study shows that the calcium, uric acid, creatinine, oxalate, phosphate levels were increased 
significantly in lithiatic control groups. Treatment with SKP at the dose of 100,200 and 300mg/kg to group III to V and 
cystone 500mg/kg to group VI shown significant decrease in the level of calcium, uric acid, creatinine, oxalate and 
phosphate. On contrary the magnesium levels were decreased significantly in lithiatic control animals . After treatment 
with SKP at a dose of 100mg/kg, 200mg/kg and 300mg/kg to group III to V and cystone at the dose of 500mg/kg to 
group VI restored the magnesium level near to normal level. The results were tabulated in table no 4. 
 
Table 4 :Effect of SKP on Serum Parameters on 28th Day 
GP 
Magnesium 
(mg/dl) 
Calcium 
(mg/dl) 
Uric acid 
(mg/dl) 
Creatinine 
(mg/dl) 
Oxalate 
(mg/dl) 
Phosphate 
(mg/dl) 
GP1 
4.90 
±0.56 
10.50 
±1.52 
3.25 
±0.20 
0.46 
±0.23 
6.5 
±0.67 
12.86 
±1.53 
GP2 
1.98 
±0.45**(a) 
17.40 
±2.44**(a) 
9.72 
±1.20**(a) 
1.21 
±0.53**(a) 
13.50 
±1.65**(a) 
29.21 
±3.45**(a) 
GP3 
3.78 
±0.56**(b) 
12.75 
±1.78**(b) 
4.25 
±0.52**(b) 
0.68 
±0.99**(b) 
9.48 
±0.88**(b) 
24.10 
±2.85**(b) 
GP4 
3.97 
±0.22**(b) 
12.82 
±1.50*(b) 
4.10 
±0.40**(b) 
0.73 
±0.01**(b) 
8.82 
±1.78**(b) 
22.85 
±2.75**(b) 
GP5 
3.86 
±0.55**(b) 
11.08 
±1.42**(b) 
3.76 
±0.42**(b) 
0.59 
±0.05**(b) 
8.85 
±0.75**(b) 
18.23 
±1.55**(b) 
GP6 
4.10 
±0.55**(b) 
10.01 
±1.42**(b) 
3.01 
±0.42**(b) 
0.52 
±0.05**(b) 
7.04 
±0.15**(b) 
17.23 
±1.75**(b) 
 
 Values are expressed as mean ± SEM 
 
Values were found out by using ONE WAY ANOVA Followed by Newman keul’s multiple range tests. 
 
Discussion 
Once kidney stone develops, the recurrence rate is estimated to be 14% at 1 year, 35% at 5 years, and 52% at 10 years. 
The incident in general population is about 1 in 1000 adults per year. The cause of urolithiasis is still unknown but 
probably positive family history, overweight, obesity, or increased BMI. Some other causes include low urine volume 
<1500 mL/day, high dietary animal protein intake, increased urine excretion of calcium oxalate, uric acid and cystine. 
Urinary tract structural abnormalities leading to stasis of urine flow [14]. 
 
Increased urinary calcium is a factor favoring the nucleation and precipitation of calcium, oxalate or phosphate from 
urine and consequent crystal growth. It has been reported that hyperabsorption of calcium is due to defective renal 
tubular reabsorption [15]. Stone formation in ethylene glycol-fed animals is caused by hyperoxaluria, which causes 
increased renal retention and excretion of oxalate [16]. 
 
Siddha preparations are ‘parpam’, ‘chenduram’, ‘chunnam’, ‘mezhugu’. These are metallic and mineral preparations by 
transmutation processes of converting the metal to ashes and waxy constituency which exerts only therapeutic properties 
and devoid of any metallic traces. These are also the byproducts noticed during Siddhars Alchemical practices. 
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Siddha systems of medicine have several medicines/formulations towards the clinical management of urolithiasis which 
ensures the safety and efficacious treatment,that are time tested and used so far. Hence, the present study aimed at 
evaluating the safety and efficacy of Seenakaraparpam, a Siddha formulation indicated for the management of 
urolithiasis in order to validate its traditional claim.In the present study, male rats were selected to induce urolithiasis 
because the urinary system of male rats resembles that of humans[17] and also earlier studies have shown that the 
amount of stone deposition in female rats was significantly less [18]. 
 
Urinary supersaturation with respect to stone-forming constituents is generally considered to be one of the causative 
factors in calculogenesis. Evidence in previous studies indicated that in response to 28 day period of ethylene glycol (1% 
v/v) administration, young male albino rats form renal calculi composed mainly of calcium oxalate [19].The 
biochemical mechanisms for this process are related to an increase in the urinary concentration of oxalate. Stone 
formation in ethylene glycol fed animals is caused by hyperoxaluria, which causes increased renal retention and 
excretion of oxalate. Similar results have been obtained when rats were treated with ethylene glycol and ammonium 
oxalate. Therefore, this model was used to evaluate the antilithiatic effect of SKP at a dose of 100,200 and 300mg/kg 
and cystone herbal tablet at a dose of 500mg/kg against urolithiasis [20,21]. 
 
Nearly 8% of kidney stones are composed of calcium salts, and the most common metabolic abnormality associated with 
kidney stones in humans is excessive urinary calcium excretion (idiopathic hypercalciuria [IH]). About 40–45% of 
patients with IH have a family history of nephrolithiasis [22]. The worldwide incidence of urolithiasis is quite high, and 
in spite of tremendous advances in the field of medicine, there is no truly satisfactory drug for the treatment of renal 
calculi. However, surgery is the last resort; persistent endeavors have been made to overcome this painful disease [23]. 
 
In the present study oxalate and calcium excretion progressively increased in calculi- induced animals belongs to group 
II, since it is accepted that hyperoxaluria, is a far more risk factor in the pathogenesis of renal stones than hypercalciuria 
[24], and the changes in urinary oxalate levels are relatively much more important than those of calcium [25]. Increased 
urinary calcium is a factor favouring the nucleation and precipitation of calcium oxalate (or) apatite (calcium phosphate) 
from urine and subsequent crystal growth [26]. However treatment with SKP at a dose of 100, 200 and 300mg/kg and 
cystone tablet at the dose of 500mg/kg significantly lowered the levels of oxalate as well as calcium excretion. An 
increase in urinary phosphate is observed in calculi induced rats belongs to disease control group. Increased urinary 
phosphate excretion along with oxalate stress seems to provide an environment appropriate for stone formation by 
forming calcium phosphate crystals, which is epitaxially induces calcium oxalate deposition [27]. Treatment with SKP 
at the dose of 100, 200 and 300mg/kg and cystone herbal tablet at a dose of 500mg/kg  restored phosphate level, thus 
reducing the risk of stone formation. 
 
Medicinal ingredients in Siddha Vaidya are classified into three main groups: Thavaram (medicines derived from 
plants), Jangamam (those derived from animals), and Thatu (those derived from earth and organic toxins). Thavaram 
includes the thousands of whole plants and plant products [28].The National Siddha Formulary of India lists more than 
10000 well practiced Siddha formulations described in Gunavagadam (Siddha pharmacology) [29].For a medicine to be 
effective, the inorganic substances have to be brought to their atomic form. Siddhars developed the knowledge of 
bringing inorganic substances into atomic and ionic form which is easily absorbed by the system, when ground with 
herbal juices and put on the fire. The specialized  
 
The increases in urinary uric acid excretion were observed in urolithiatic rats. Increased excretion of uric acid has been 
reported in stone formers and hyperoxaluric rats. Uric acid interferes with calcium oxalate solubility and it binds and 
reduces the inhibitory activity of glycosaminoglycans. The predominance of uric acid crystals in calcium oxalate stones 
and the observation that uric acid binding proteins are capable of binding to calcium oxalate and modulate its 
crystallization also suggests its primary role in stone formation. Treatment with SKP at the dose of 100,200 and 
300mg/kg and cystone herbal tablet at a dose of 500mg/kg lowered the excretion of uric acid and reduces the risk of 
stone formation. 
 
Supersaturation, a step in the pathogenesis of nephrolithiasis, occurs when substances that make up the stone are found 
in the high concentration in urine, when urine volume decreases, and when urinary concentration of chemicals that 
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inhibit stone formation decreases. Inhibitors of crystallization include citrate, magnesium, phosphate; nephrocalcinetc 
[30,31].Low urinary magnesium content is a common feature in stone formers [32]. A similar condition was observed in 
group II rats. Treatment with SKP at a dose of 100,200 and 300mg/kg and cystone herbal tablet at a dose of 500mg/kg 
elevated the urinary magnesium level, and thus, reduced the propensity to crystallize, thereby creating an ambience 
unfavourable for precipitation. 
 
Increased excretion of proteins has been noted in hyperoxaluric rats and stone formers [33].A high urinary colloidal 
concentration favors crystal growth [34]. Such a condition was observed with ethylene glycol treated rats, in this study. 
Administration of SKP at the dose of 100,200 and 300mg/kg and cystone herbal tablet at a dose of 500mg/kg reduced 
the urinary protein excretion in the treated group rats, and hence minimizes the conditions favourable for crystal growth. 
In urolithiasis, the Glomeruli Filtration Rate (GFR) decreases due to the obstruction to the outflow of urine by stones in 
the urinary system. Due to this, the waste products, particularly nitrogenous substances such as creatinine and uric acid 
get accumulated [35].Also increased lipid peroxidation and decreased levels of antioxidant potential have been reported 
in the kidneys of rats supplemented with a calculi- producing diet (CPD) [36]. Elevated oxalate has been reported to 
induce lipid peroxidation and to cause renal tissue damage by reacting with poly unsaturated fatty acids in the cell 
membrane [37]. In urolithiatic rats there is a marked renal degeneration was observed as indicated by the elevated serum 
levels of creatinine and uric acid. However, the prophylactic treatment SKP at a dose of 100, 200 and 300mg/kg and 
cystone herbal tablet at a dose of 500mg/kg causes diuresis and hastens the process of dissolving the preformed stones 
and prevention of new stone formation in the urinary system. Increase in calcium and oxalate levels in the renal tissue of 
EG-treated rats were observed. Prophylactic treatment with SKP at the dose of 100,200 and 300mg/kg and cystone 
500mg/kg suppresses this increase in intracellular calcium. It was concluded from the result of the present investigation 
that the siddha formulations like Seenakaraparpam may be considered as a potential lead for the clinical management of 
urolithiasis. 
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Abstract
Urolithiasis is one such disease that after extensive research in the field of urology has remained incurable in allopathy. It is a
process of stone formation which occurs either in the kidney (commonly known as nephrolithiasis) and or in any part of the
urinary tract, including the ureters (known as ureteral stone) and bladder (bladder stone). Urolithiasis has an important effect on
the health care system with a prevalence of >10% and an expected recurrence rate of ∼50%.Siddha system of medicine is a
source of treatment for many ailments. Some medicinal plants and proprietary composite herbal preparations are reported to be
effective in the treatment as well as prevention of recurrence of renal calculi with minimal side effects. In Indian indigenous
system of medicine, several formulations including Seenakara parpam are (SKP) claimed to be useful for the renal calculi but
needs scientific documentation. The present investigation was aimed at evaluating the anti-urolithiatic activity of Seenakara
parpam (SKP) on zinc disc implantation induced experimental urolithiasis on wistar albino rats. Implantation was carried out by a
surgical procedure followed by the recovery period of three days. Soon after recovery animals were treated with SKP at the dose
of 200 and 400 mg/kg b.wt, p.o. Animals belonging to standard group received cystone 500 mg/kg, p.o. for a period of 7 days.
Parameters such as urine volume, urinary calcium output and calculi weight were measured at the end of the study. Treatment
with SKP and cystone significantly reduced the excretion of calcium further the volume of urine output increased  in treatment
group when compared to that of the disc implanted group rats. Weight of the calculi is considered to be one of the important
parameter in evaluating the efficacy of the drug. The results of the study clearly reflects that  treatment with SKP at the dose of
200 and 400 mg/kg and standard drug cystone 500 mg/kg shown significant decrease in the weight of calculi from 113.5 mg to
10.5 mg. In conclusion formulations like SKP may be considered as a potential lead for the clinical management of urolithiasis.
Keywords: Seenakara parpam, zinc disc, urolithiasis, cystone, urine volume, calcium output, calculi weight.
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Introduction
Urolithiasis is the third prevalent disorder of the
urinary system that is approximately 2–3% in the
general population. Urinary calculi, if untreated, may
cause serious medical consequences such as extreme
obstruction, hydronephrosis, infection, and
hemorrhage in the urinary tract system [1]. Surgical
operation, lithotripsy, and local calculus disruption
using high-power laser are commonly used techniques
to remove the calculi. However, these procedures are
associated with the risk of acute renal injury leading to
decrease in renal function. Moreover, an increase in
stone recurrence is also observed [2].The recurrence
rate without preventive treatment is approximately
10% at 1st year, 33% at 5th year, and 50% at 10th year
indicating the need to develop suitable alternative
therapy [3-6].
The worldwide incidence of urolithiasis is quite high,
and more than 80% of urinary calculi are calcium
oxalate (CaOx) stones alone or CaOx mixed with
calcium phosphate.2 Epidemiological studies revealed
that the nephrolithiasis is more prevalent in men
(12%) than in women (6%) and is more prevalent
between the ages of 20–40 in both sexes [7].
Urinary supersaturation of various stone-forming
elements is commonly considered to be one of the
causative factors in the stone formation [8]. Renal
calcium oxalate (CaOx) crystal deposition induced by
ethylene glycol is the most appropriate animal model
that is frequently used to mimic the stone formation in
humans. Previously reported studies showed that after
the 28 days period of ethylene glycol (0.75% v/v)
administration in the drinking water of laboratory
animals significantly cause renal stone formation that
mainly consist CaOx by increasing the urinary
concentration of oxalate [9-13].
In the traditional systems like Siddha medicine, most
of the remedies were formulated from plants and
minerals that were proved to be useful in various
disease conditions. Noteworthy, traditional Siddha
medicines are efficacious and have lesser side effects
compared to chemical drugs and also reduce the
recurrence rate of the renal stone. The vast literature
indicate a number of formulations to be useful in the
treatment of urinary stones. Many formulations need
to be explored for their pharmacological actions [14].
In the indigenous system of medicine, the Seenakara
Parpam (SKP) is reported to be useful in the treatment
of urinary stones. However, so far no systematic study
has been reported with respect to the anti-urolithiatic
property of SKP. Hence the main aim of the present
study is to evaluate the anti-urolithiatic property of
SKP using zinc disc implantation induced
experimental model of urolithiasis.
Materials and Methods
Evaluation of Anti-urolithiatic activity by zinc disc
implantation induced urolithiasis in rats
Animals
Healthy adult albino wistar male rats weighing
between 200-220gm were used for the study. The
animals were housed in poly propylene cages and
were kept in well ventilated with 100 % fresh air by
air conditioning. A 12h light/dark cycle was
maintained. Room temperature was maintained
between 22+2º C and relative humidity 40–65%. They
were provided with food and water ad libitum. All the
animals were acclimatized to the laboratory about 7
days prior to experimentation.
Experimental Protocol
Before day of implantation Zinc disc were prepared
having weight 20±2 mg. Prior to surgery, rats were
fasted for 8–10 hours. Just before anesthesia, they
were orally administered with 4mL of water to dilate
their urinary bladders. Zinc disc implantations in
urinary bladders were carried out by an earlier
reported method by Vermeulen et al [15]. The rats
were operated in sterile conditions under Ketamine
(80mg/kg/i.p.) and diazepam (4mg/kg/i.m.) anesthesia.
The urinary bladders were exposed through a
suprapubic incision and a small cut was taken to open
the lumen of the bladder. In zinc disc implanted
groups, discs of average weight of 20 ± 2 mg were
inserted and the incision was closed by 1 or 2 stitches
of absorbable sterile surgical sutures (Centennial
CNW 2670 6-0 USP). The abdominal incisions were
sutured with sterile silk suture. The rats in sham
operated groups were similarly operated except
implantation of zinc disc in the bladder [16].
All the operated rats were treated topically with
antibiotic dusting powder and allowed to recover for
three days without any interventions. Treatment was
started after the three days of recovery [17].  Rats were
divided into six groups of six animals each as normal
control group, sham operated group (the same surgical
procedure but without implantation of zinc disc), zinc
disc implanted group, zinc disc implanted group after
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recovery treated with Cystone 500mg/kg/day for seven
days, Similarly zinc disc implanted rats treated with
SKP at the dose of 200 and 400 mg/kg, p.o for seven
days.
Grouping
Group I: Control group rats received normal saline
Group II: Sham operated group without implantation
Group III: Disease control group surgically implanted
with zinc disc.
Group IV: Implanted with zinc disc and treated with
cystone 500 mg/kg, p.o
Group V: Implanted with zinc disc and treated with
SKP at 200 mg/kg, p.o
Group VI: Implanted with zinc disc and treated with
SKP at 400 mg/kg, p.o
Urine Collection
At the end of the treatment period, individual animal
was placed in the metabolic cage for collection of 24-
hour urine samples. Initially a drop of
chlorhexidinegluconate was added to the test tubes as
a preservative.
Radio Graphic Examination
Radio graphic examination was done before
sacrificing the animals to confirm the formation of
stones. The animals were kept under light ether
anaesthesia in anteroposterior position on the X-ray
board to expose the pelvic region, with digital X-ray
instrument (GE-525DX, USA) by Fuji computerized
radiographic system Japan.Thefilmfocus distance was
60 inches and machine was operated at 43 kVpeak,
2mA [19].
Calculi Weight
The weight of urinary calculi determined by
sacrificing the animals at the end of study. The urinary
bladders were exposed and zinc disc along with the
adhered crystals was removed and wrapped in
separated polyethylene bags.
Results
Effect of Seenakara Parpam on Urine volume,
Calcium and Calculi weight.
Zinc discs were implanted in the urinary bladder of
experimental rats. The zinc discs initiate and fasten the
nucleation process which is the rate limiting step in the
formation of urinary calculi. It was observed that there
was a significant decrease in urine volume of rats
belongs to zinc disc implanted group (1.5 ± 0.1 ml)
when compared to normal control (2.6± 0.2 ml).
Treatment with SKP at both the dose shown
significant increase in urine volume of about 2.3 ml in
200mg/kg treated group and 2.4 ml in 400mg/kg
treated rats. Similar type of results were observed in
standard drug cystone 500 mg/kg treated group (2.5 ±
0.2 ml). Rats treated with SKP showed dose dependent
increase in urine output.
Urolithiatic animals showed increase urinary calcium
excretion of about (23.8 ± 4.6 mg/dL). Treatment with
SKP at both the dose had shown significant decrease
in calcium excretion of about 11.6 ± 3.1 mg/dl in
200mg/kg treated group and 10.2 ± 2.5 mg/dl in
400mg/kg treated rats. Similar type of results were
observed in standard drug cystone 500 mg/kg treated
group (12.3 ± 3.9 mg/dl). Rats treated with SKP
showed dose dependent increase in urine output.
At the end of the study all the experimental animals
were sacrificed with excess dose of pentobarbitone
and the zinc discs were removed and weighed. The
average weight of zinc discs along with the deposited
crystals in the only disc implanted group without any
treatment was found to be 113.55 ± 7.90 mg. Group
that received Cystone 500 mg/kg, showed significant
reduction in the depositions hence there was
significant difference in the weight of bladder content
as compared to zinc disc implanted group ( < 0.001).
Similarly, the rats treated with SKP  200mg/kg/day,
and 400mg/kg/day showed reduced formation of
depositions around the zinc disc ( < 0.001) and the
corresponding results were tabulated in Table 1.
Table 1: Effect of Seenakara Parpam on Urine volume, Calcium and Calculi weight.
Groups Urine output
(mL)
Urinary calcium output
(mg/dL)
Weight of calculi (mg)
Normal control 2.6 ± 0.2 - -
Sham control 2.2 ± 0.1 10.4 ± 2.5** -
Disc implanted control 1.5 ± 0.1* 23.8 ± 4.6 113.55 ± 7.90
Cystone 500mg/kg 2.5 ± 0.2 12.3 ± 3.9** 6.90 ± 1.95***
SKP 200mg/kg 2.3 ± 0.2 11.6 ± 3.1** 11.6 ± 2.35***
SKP 400mg/kg 2.4 ± 0.2 10.2 ± 2.5** 10 .5± 1.93***
Value represents; mean ± SEM. Statistical analysis was performed by Newman-keuls multiple range tests. * < 0.05,
as compared with naive control, ** <0.01, and *** < 0.001 as compared with disc implanted group.
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The X-ray images of rats revealed presence of deposits
around the implanted zinc disc within 10 days after
implantation. Treatment with SKP at both the dose
level and Cystone at dose of 500mg/kg/day shown
significantly reduction in the formation of such
deposits within 10 days. These observations were
confirmed in actual weights of the bladder contents.
As shown in Figure 1 (A-E).
Figure 1 shows the results of effects of Seenakara
Parpam on zinc disc implantation model of
urolithiasis.
A. Sham operated group without implantation
B. Disease control group surgically implanted with zinc disc
C.Implanted with zinc disc and treated with cystone 500 mg/kg
Int. J. Adv. Res. Biol. Sci. (2016). 3(12): 7-13
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D. Implanted with zinc disc and treated with SKP 200 mg/kg
E. Implanted with zinc disc and treated with SKP 400 mg/kg
Figure 1: X-ray of image of rats in zinc disc implantation model of urolithiasis. (a) Sham operated (b) Zinc disc
implanted, (c) Cystone treated, (d) SKP 200mg/kg, (e) SKP400mg/kg,
Discussion
Renal calculi can be experimentally induced by either
administration of various chemicals such as sodium
oxalate or surgical implantation of foreign material
like zinc disc in the urinary bladder of rats. The
chemically-induced calculi model associated with high
incidence of nephrotoxicity, metabolic acidosis, and
occurrence of calculi in the renal cortex that is
situation opposite to that found in human
urolithiasis[20]. However, zinc disc model induces
renal calculi with minimal renal damage and mimic
the etiology of urinary stone formation in humans
[21]. Therefore, zinc disc implantation-induced
urolithiasis model was selected to induce urolithiasis
in rats. In this model, the implanted zinc disc act as a
nidus that subsequently leads to deposition of a urolith
minerals composed of magnesium ammonium
phosphate around the disc [22].
Hyperoxaluria and hypercalciuria are important risk
factors in the pathogenesis of urinary stone formation.
In zinc disc implantation model, the urine output was
decreased in disc implanted group as compared to
naıve control group. This suggests obstruction of
urinary bladder due to formation of large urinary
calculi. Partial obstruction of the urinary bladder outlet
leads to a compensatory growth of the detrusor smooth
muscle cells, and this occurs as a feedback response to
the increased intravesical pressure required to empty
the bladder. Partial obstruction of the urinary bladder
was also shown to induce a decrease in the density of
autonomic innervation and sensitivity to the
muscarinic agonist. In fact, increase of dieresis could
reduce super saturation of the urine with precipitating
substances which is normally associated with
formation of urinary calculi [23].
Urine output was decreased in disc implanted group
[24]. This suggests obstruction of urinary bladder due
to the formation of urinary calculi. In the present
investigation, treatment with SKP at the dose of 200
,400mg/kg and the standard drug cystone at the dose
of 500 mg/kg significantly increased urine output, and
this may be due to prevention of stone formation or
their direct diuretic effect which reduced super
saturation of urine with precipitating substances and
thereby stone formation.
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The increase in urine output by SKP might be via
activation of muscarinic receptor in the bladder
muscles along with other unrevealed mechanisms. On
the 10th day of post implantation, there was a
significant increase in the urine calcium  observed in
disc implanted animals [11]. Urinary calcium is a
factor that favours the process of nucleation and
precipitation of calcium oxalate or apatite (calcium
phosphate) from urine and subsequent crystal growth.
Treatments with Cystone significantly reduced the
increased calcium output. Similarly type SKP also
reduced such increased calcium output in dose
dependent manner. Treatment with SKP was found to
inhibit the formation of calculi which are mainly
composed of magnesium ammonium phosphate.
Treatment with Cystone (500mg/kg) also has similar
effects. Cystone has already been proved by Mitra et
al to possess Antiurolithiatic action; in our study we
found that SKP has potent Antiurolithiatic action at
comparatively very low dose range as compared to
Cystone.
The formation of calculus in urinary bladder was also
confirmed by X-ray (radiological) investigation.Drugs
treatment shows only zinc disc in radiographic studies.
Digital X-ray radiography provides a means to easily
monitor the crystal growth. As evident in this study,
within 10 days after implantation, depositions could be
visualized around the implants. Hence, use of this
technique can help the investigator to determine the
time at which study is to be terminated. Thus our data
indicates that while evaluating an Antiurolithiatic drug
by zinc disc implantation model, X-ray radiography
was used to monitor the growth of deposit around the
implants and as soon as sufficient deposition was
revealed in control groups, the study was terminated
so as to minimize undue stress to the animals.
Recently, instead of zinc disc other foreign bodies
which can be easily processed for evaluation have
been suggested to be implanted in the bladder.
From the results of the present investigation it was
concluded that the administration of SKP at both the
dose level showed significant Anti-urolithiatic activity
as indicated by increased urine output and related
parameters. The exact mechanism of action is not
established but attributed that SKP might act through
activation of muscarinic receptor in the bladder
muscles. Future studies needs to be carried out in
order to explore the exact mechanism of action of
SKP.
Various chemical constituents interacting toward
synergism. The possible mechanism underlying this
effect is mediated collectively through diuretic,
antioxidant and anti-inflammatory effects of the drug.
Further chemical analysis is required to establish the
exact mechanism of action.
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